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摘 要 本篇综述侧重于介绍美国本土的转基因作物安全评价的过程和进展。回顾了安全评价程序的建
立过程,从1975年阿西洛马(Asilomar)会议上关于重组DNA技术的问题,自1984-1994年间第一例转基因作
物进行田间试验到评估作为食物和饲料商业化生产时,美国政府、学术界和产业界科学家之间的讨论。此外,一
同回顾国际上的指南与美国的系统。整体过程还要考虑人类接触基因来源和表达蛋白是否有安全的或不安全
的历史。食用蛋白安全性首要考虑因素为某些消费者是否对其过敏或者拥有转基因编码蛋白的IgE抗体,或者
转基因食品会诱发乳糜泻,同时考虑表达蛋白的潜在毒性效果和对人或动物营养的影响。在美国,该过程与国
际食品法典委员会的建议是一致的,它是基于科学的并应用合理的假设。迄今为止,没有证据证明在美国获得
批准的转基因作物危害人或动物的健康。评价要考虑遗传和环境上的变化对植物新品种产物的影响,并坚持转
基因植物食品和非转基因相似物种同样安全的评价原则。
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  包括美国、中国等国际食品法典委员会(Codex
AlimentariusCommission,世界卫生组织及联合国
粮食和农业组织内部国际食品标准计划)(www.
codexalimentarius.org)成员国在内的大多数国家
对转基因生物或作物来源食品的安全性进行强制管
理。国际食品法典委员会拥有包括欧盟在内的185
个成员国和224个官方观察员(来自非成员国及非
政府机构),并形成了对于食品安全和国际贸易等许
多重要问题的指导意见。
仅有少数文献对转基因生物来源食品的安全评
价整体流程进行过描述。针对研发者和监管者关于
食品安全的主要指导意见出自食品法典委员会的联
合文件(第2版)“现代生物技术来源的食品”[1]。在
其第一章对基本原则进行了概述(CAC/GL44-
2003),包括现代生物技术或基因修饰生物的定义和
风险评价过程,该过程用于鉴定与新转基因生物相
关的新危害或营养方面或安全性的问题,以及适当
的风险管理程序。该文件随后的3个主要章节则明
确了转基因植物、转基因动物和转基因微生物的安
全性及营养品质方面的评价流程。这3类转基因生
物的评价策略是非常相似的。食品的致敏性评估在
每章的末尾以附件形式单独概述。潜在的毒性、乳
糜泻和营养等同性的评估在每个文档的前面部分
“实质等同性”章节讨论。法典为每一个国家建立自
己的管理办法提供了指导,其目的就是使所有的法
典成员国建立一个一致性的监管体系。除非有科学
的依据,各成员国的监管体系之间不能存在差异。
这些文件在2001至2003年间被制定,当前科学已
有新的发展,这些将与公众进行讨论。同时一些新
的评价步骤也将被讨论。本文着重探讨美国的评价
过程。为了解一些反对转基因人士和组织针对转基
因提出的问题和批评是否真正是目前没有被监管体
制和研发者解决的合理安全问题,这些反对意见也
将在本文中被探讨。
在美国、欧洲和中国,转基因食品的安全性问题
一直是一些非政府组织(NGO)如绿色和平组织、地
球之友、忧思科学家联盟以及电视和网络名人关注
的焦点。我们必须认识到,消费者对于食物安全性
的关心是很正常的,尤其是那些他们还没有完全了
解的新食品或新技术。大多数消费者不明白致敏原
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的科学原理,也不知道过敏反应、毒素、营养和抗营
养因子。他们也不明白作物的遗传多样性对于在不
同的环境条件下进行生产的重要性[2]。许多消费者
认为除非进行基因工程改造,所有的大豆都应该完
全一样。其他领域的科学家也不明白粮食作物中蛋
白质、油脂、碳水化合物以及各种代谢物的多样性和
复杂性。植物育种家的主要工作是引入变异。如果
我们考察基因工程的原理以及其带来的改变,显然
生物技术相对于育种家用于培养新品种的自然变异
或人工诱变,其引入的不确定性是最小的。我们是
否可以向消费者解释真实的风险以及目前的评估过
程是如何使风险最小化的吗?
转基因作物的反对者和制药业经常提到的一个
重要的意见是,转基因产品的研发公司自己检测其
安全性。这个意见看上去很合理,但涉及到了各个
国家的整体法律框架、政府和经济结构。美国政府
的科学家和其他许多国家一样,通常不会去检测大
多数产品的安全性。值得一提的是,世界上没有任
何一个政府拥有足够多的具有专业知识的科学家和
足够多的资金在合理的时间内对所有的潜在产品执
行相应的安全检测。许多重要产品的开发将会由于
研发者必须等待政府的安全检测而被迫终止。在目
前建立的监管体系内,大多数包括美国在内的国家
只需要在其监管部门建立一支有资质的科学家队
伍,他们可以根据相关的程序和指导进行严格的数
据审查并做出决定。许多政府如美国政府,可以通
过司法程序邀请学术专家进行咨询来协助进行评
价。监管者也可以有效地同研发者进行沟通来告诉
他们需要提供哪些额外的数据或检测,或者哪些问
题还需要被回答以获得批准。
我对于孟山都公司这个主要的转基因作物研发
者最为熟悉。他们拥有大约600名受过高等教育
(学士、硕士和博士)的员工在涉及转基因审批的部
门工作。这些科学家制定计划并开展安全和环境相
关的研究,归档并对测试对象(植株、种子、DNA载
体和蛋白)进行描述,开展测试,分析数据并提交报
告给监管机构。他们需要在不同的环境下,有时候
需在多个国家种植植物以完成田间测试和环境试
验。监管相关的程序非常复杂,一个产品获得审批
通常要花10~14年时间。类似孟山都这样的公司
拥有专门的质量保证单位(qualityassuranceunits,
QAU),它向一个不同于研发和销售部门的管理部
门进行汇报。QAU 在开展研究前审查其方案、在
向监管部门提交数据和报告前进行审阅,以确保研
究的充分性和准确性。在一个产品被商业化种植
前,公司的科学家们要评估海量数据并制作提交给
多个政府的各类文档。大多转基因产品的种子在释
放给农民前,需要获得主要贸易国家(澳大利亚、加
拿大、中国、日本、韩国、美国)的行政审批。大宗商
品或食品和饲料的国际贸易,只有在拥有材料和数
据的研发者有能力和意愿确保及时协调地通过相关
流程的情况下才能进行。在某些情况下,一些审批
所需的研究特别是毒理学研究,需要通过合同在其
他实验室进行。有些管理条例非常严格,要求这些
特定的研究需要遵循由美国环保署(EPA)制定的
良好实验室管理规范(goodlaboratorypractices,
GLP)。只有少数研发者的基础设施能够达到GLP
要求。这些通过合同开展毒理学研究的公司可以满
足审批的需要。相关研究可以由EPA审查。他们
拥有非常严格的关于记录保存、职业道德和数据完
整的规定。如果是政府来进行这些研究,谁又来审
查他们数据并对其负责? 谁又来保障这些研究可以
及时被完成?
有些研究由一些进行学术研究的实验室完成,
因为这些研究无论是研发者还是满足GLP的合同
实验室都没有足够的专业水平来实施。我在内布拉
斯加大学的实验室就为生物技术公司、非盈利农业
机构以及开发新食品原料的食品公司进行过大量的
致敏性研究(人血清IgE结合和生物信息学研究)。
我们与临床医生合作,他们提供从愿意提供血清样
本的过敏患者身上采集来的血清样本,以评价产品
的安全性。我们建立了操作指南,开展研究,评估数
据,撰写报告并保存相关研究记录。我们在与研发
者在合同约定下开展研究,并遵守内布拉斯加大学
和合作机构的道德标准。
我参与设计、开展和审查关于转基因作物和新
食品添加剂的致敏性、毒性和营养品质和表现的相
关研究已达17年。2001年,我参加加拿大温哥华
举行的食品法典工作组会议并达成致敏性的指
南[1]。我曾参与安全性研究,并审查过提交给美国、
加拿大、阿根廷、巴西、欧盟、印度、韩国和中国台湾
政府审查的转基因生物安全评价程序,我还对几百
篇关于致敏性、毒理学和潜在基因水平转移的发表
文献进行过审稿。在我的职业生涯内还未曾发现任
何案例能证实人或动物在食用被批准的转基因作物
后出现健康问题。我相信转基因生物的安全性审批
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过程是非常可靠的[2-3]。
当然,我必须经历一个学习的过程才能达到充
分了解转基因生物评价过程的水平,因为我天生是
一个怀疑论者。本人的科学研究始于农业生物技术
发展的初期。本文回顾了美国关于转基因作物的安
全评价及管理的发展历史,包括一些之前被证实的
食品安全相关的危害和风险,并介绍了在新转基因
作物商品化释放之前安全性评估的流程。本文包括
了一个典型案例,一个已被批准的转基因产品
(Starlink,玉米)由于安全性数据的不确定(并非有
危害性)而退出市场。
1 真实的与假想的食品风险
今天食用的很多食物我们在千百年前就开始食
用了。很多作物的基因和确切的营养成分由于常规
育种的改造,与原始品种相比已有很大的变化。很
大程度上,大宗商品作物如小麦、水稻、玉米和大豆,
还有很多的水果蔬菜与食物类似,人类安全地食用
它们已有几个世纪。利用这些作物的经验指导监管
者建立了一套安全评价流程,首先考虑人类是否有
认识、接触或食用宿主植物(基因受体)和供体生物
(被转化基因的来源)的经历。
在20世纪70年代中期,我刚刚取得生物学学
士学位时曾是绿色和平、地球之友和忧思科学家联
盟的积极成员。当时重组DNA技术的细节刚开始
在大学课堂上讲授,我们认识到这个技术具有创造
有用的重组细菌和植物的潜力。很多学生和教授对
DNA、RNA、核糖体和蛋白质合成的认识相对于20
世纪90年代而言显得非常浅显,更不用说2014年
的高校课堂所教授的知识。在20世纪70年代早
期,保罗·伯格、沃尔特·吉尔伯特和弗雷德里克·
桑格(后来都是诺贝尔化学奖的得主)开始讨论重组
生物体潜在的(假设)危险,如致病病毒的DNA序
列通过该技术导入细菌中。玛克辛·辛格等人在科
学界呼吁建立安全标准。许多关注都集中到科尔等
人提议的将构建到细菌质粒上的猿猴空泡病毒40
(SV40)的DNA片段转化到猴子的培养细胞中以研
究基因功能[4]。作为回应,在美国科学院的敦促下,
伯格等人组织的阿西洛马会议于1975年举行,讨论
建立指南以保证安全。伯格和桑格综述了这一过程
以及从那时起20年重组DNA工作的安全经验[5]。
在指南建立的前一年,美国所有的重组DNA工作
基本上都停止了。他们基于预期风险的周密考虑,
要求所有从事基因工程研究的研究机构或公司建立
各自的生物安全委员会,审查每一个新的重组DNA
实验。主要重点是潜在的风险或者新DNA元件的
安全性(基于DNA供体生物的行为模式和风险)。
指南有助于确保利用该技术不会产生真正的危险生
物。相对安全的克隆实验(生物安全等级1或2)可
以在一个典型的洁净实验室环境下进行,并对其的
限制较少。在非常严格限制的极少数地方(生物安
全等级3或4),可进行致命性和传染性病原体的重
组实验(http://en.wikipedia.org/wiki/Biosafety_
level)。
当然,转基因植物来源食物的安全性问题是不
一样的。转基因植物没有传染性,转基因植物的食
品安全性相对于微生物而言要低得多,与非转基因
植物的风险没有区别。当然食物也有特殊的风险需
要评估,如潜在的致敏原或者毒素从其他生物转移
到粮食作物。很多假设的风险成为目前讨论的热
点,而非基于我们已有的科学和安全知识去评估那
些有限并且明确的风险。对于在作物(其本身含有
10000到20000个内源基因,并且已被安全食用)
中,添加了一个或几个基因或蛋白或新的代谢物而
产生的新产品,其评估应重点放在基因来源、蛋白的
特性和代谢物(如果导入蛋白是一个酶)的安全性。
其他10000多个基因和蛋白与目前作物已有的风
险是一样的。而且,根据我们对其他食物的经验,新
的基因和蛋白质呈现的风险类别是可以确定的。目
前大多数非转基因作物食品都含有特定的致敏原的
蛋白,一些还含有毒素(龙葵碱)或抗营养因子(胰蛋
白酶抑制剂)。所以,对新蛋白的关注是评估其是否
含有潜在的致敏性、毒性和抗营养特性。
一些被广泛种植的转基因作物的生产和消费历
史已有近20年,比如含有苏云金芽胞杆菌来源的特
殊蛋白的抗虫玉米即Bt玉米、转土壤细菌来源基因
的耐除草剂大豆和抗病毒的木瓜。目前没有发现这
些转基因作物有害的证据。生物技术改良的作物已
经展现出很多优点,比如减少农药的施用或减少植
物病原菌的影响(霉菌毒素)。大量转基因作物正在
改善农业生产方式,如最大限度减少土壤退化以及
能源和水的消耗。
有些人可能会说,正是因为对于转基因生物强
烈的恐惧,引发了对适当监管研究的正常争论,从而
促进可靠评价过程的建立。其他人则认为,研发者
面对的监管要求已经过度,延缓了医学、工业和农业
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科学的进步。真实情况可能位于两种极端观点之
间。但是,同转基因研发者、贸易公司和食品公司的
交流,以及对欧盟和其他国家的监管制度的考察,可
以清楚发现过去10年(2004-2014)全球转基因的
评价和审批进程明显拖累了研发进度,并导致全球
性的贸易壁垒。由于贸易的国际化特性,农业公司
必须等待很多年才能通过审批获许新产品进入全球
主要市场。似乎所有国家的监管都变得越来越谨
慎,他们害怕由于批准一个转基因作物、而这个转基
因作物还没有在所有可能的情况下都被证明是绝对
安全的而受到指责。预防性原则违背了美国食品和
药物管理局(FDA)在1994年建立的政策。该政策
认为所有食物的风险都是可以评估和管理的,安全
的标准就是转基因作物来源的食物与传统作物来源
的类似食物一样安全。而预防性原则只能接受零
风险。
今天在科技文献中以“转基因”、“遗传修饰”、
“基因工程”、“毒理学”、“生殖”、“癌症”作为检索词
搜索,可找到很多针对转基因作物新的研究问题和
设计,但这些研究问题和设计应该是基于作物或者
是基因和基因产物信息的可检测的假设。极少有膳
食蛋白可以影响生殖健康、导致癌症或增加大量自
身免疫性疾病的发病率。那又为什么要对转基因作
物的这些特性进行检测?
如今,活动家们如吉尔-埃里克·塞拉利尼、塔
尔杰·特拉威克、范达娜·席娃、何美芸和杰弗里·
史密斯,知名人士如奥普拉·温弗瑞、奥兹博士和崔
永元,以及相信活动家们发表在网络、书籍、新闻媒
体和电视上的关于转基因生物健康风险不恰当言论
的消费者们,正在对监管者和政界人士施压。例如
杰弗里·史密斯的网站,具有欺骗性的“负责任的科
技研究所”(http://www.responsibletechnology.
org/),声称非常多的人类疾病,包括自闭症、乳糜
泻、食物过敏和癌症的发病率由于消费转基因作物
而显著提高。他从观察数量很少和控制条件很差且
未经验证的动物研究中得出结论,人类将会因食用
转基因食物而患上各种复杂的疾病。史密斯先生还
举办了一个要价150美元的“反转基因演讲家”的培
训会。他没有发表任何可靠的经同行评议的科学研
究论文以支持其说法,一般靠引用转基因产品增多
且疾病同样增多的相关性(这类疾病是高度多样化
和不明确原因引起的)。事实上这些相关性与转基
因食物引入食物链并没有关系。然而,许多受过高
等教育的人认同史密斯和其他的活动家的观点,并
拒绝深入了解那些已经公开和发表过的、具有良好
科学性的、证明批准的转基因生物已经经过安全评
价的科学研究。没有研究能够将食用抗虫玉米和乳
糜泻、食物过敏、自闭症或癌症联系起来。如果将我
们的生活和环境中的巧合描述为必然的因果关系,
我们就应该停止航空旅行,关闭互联网,丢掉手机和
电视,禁止加工食品、疫苗以及处方药。我们应该以
100年前的生活方式生活,那个时候世界人口不到
20亿,生活和现在完全不同,而且人均寿命更低。
考虑食物风险时,食物的遗传多样性会导致其
风险是非常值得怀疑的。人类是杂食性动物,依赖
高度多样性的食谱。我们现在食用的食品和1914
年时差异很大,更不用说1514年,那时马铃薯、辣椒
和番茄还没有由南美洲引入欧洲、印度和中国。如
果某种食用植物与我们平时食用的品种相比只因有
非常少的遗传差异而表现出显著不同的风险差异,
那么我们需要非常复杂的检测方法。然而,没有依
赖高度复杂的科学研究,我们人类几千年来在评估
食品安全性方面已经做得非常好。2014年,美国和
中国延长的人均寿命、相对低的新生儿的死亡率和
基础健康数据都有力地证明了目前的转基因生物不
太可能是有害的。我们应该把关注重点转向食品的
真正风险并建立相关流程保证转基因作物食品与非
转基因作物食品同样安全。
2 转基因生物安全评价的早期发展
20世纪80年代中期,我还没有意识到转基因
作物需要安全性评价以评估其食品安全性。我对于
利用农杆菌介导的将功能DNA片段插入植物内的
遗传转化过程知之甚少[6]。我在美国俄亥俄州立大
学读博士时期学到了更多的生物技术相关知识。我
克隆了牛乳铁蛋白基因的cDNA,并进行测序和表
达,在校期间我必须学习和遵循学校生物安全审查
委员会的评估。我必须回答基因来源、编码蛋白和
质粒载体,以及接受克隆DNA的宿主细胞和生物
体等相关问题。当进行老鼠和人类细胞因子的cD-
NA工作时,我在康奈尔大学以及随后的密歇根大
学学习了免疫学,我也因此得到了进一步的训练。
1997年,我作为一名监管转基因安全审查的科学家
加入孟山都时,我不再相信绿色和平组织以及其他
机构关于转基因作物的假想风险,以及他们声称的
没有任何安全评价。我退出了这些组织。加入孟山
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都2个月,我被安排建立一个动物模型,评估一个棉
花转基因事件种子的潜在致敏性风险。这些测试都
是新的和前所未有的,之前没有人证明啮齿类动物
模型可以预测人类的潜在致敏性。然而,印度政府
要求动物模型的致敏性测试。同一作物在美国被批
准近7年后才被印度批准。印度在2008年调整监
管方针与食品法典委员会指导意见(2003)保持一
致[1],不再要求用动物模型来评估潜在风险。我在
孟山都的工作使我熟悉美国和其他国家的监管流
程,并学习评估潜在致敏性、毒性和营养等同性的科
学知识。2004年我被内布拉斯加大学聘任后,继续
参与监管评估流程,在2014年我甚至更广泛地参与
其中。然而我仍在学习目前的评价相关过程。
一篇公开发表的综述显示,学术界、企业和政府
的科学家合作通过多次协商后制定一个有用的可预
知风险的转基因作物安全评价流程。美国政府在
1986年制定了一个包括FDA、EPA和美国农业部
(USDA)在内的协调监管框架,以评价和监管转基
因作物(科技政策办公室,1986;http://www.a-
phis.usda.gov/brs/fedregister/coordinated_frame-
work.pdf)。此时离第一例转基因作物获批还有8
年。一群学术界和企业界的科学家举办会议成立国
际食品生物技术委员会(IFBC)并与国际生命科学
学会(ILSI)合作,建立了一套风险评估指导意见并
发表在毒理学和药理学监管条例(1990)12卷的补
充材料中[7]。IFBC-ILSI卷由28个资深科学家和
法律专家完成,包含基因修饰的方法、传统食物中不
同的作物组分、微生物来源食品原料的安全评价、单
个化学体的安全评价、食物整体及复杂复合体的安
全评价,还有法律和监管方面的事宜。该卷的草稿
在发表前,经过了来自13个国家的150位企业、政
府和学术界专家的评审。其中的主要问题在一次公
开的会议中由120名专家提出并讨论。IFBC-ILSI
文档提出了许多关键的评价步骤和是否需要进一步
评价的决定,并讨论了美国的食品安全监管法律框
架。他们支持美国政府关于转基因作物来源食品能
够在现有的监管框架下有效监管的决定,因为他们
发现产生新品种的过程(如基因枪或农杆菌介导的
遗传转化)对潜在的安全性影响与传统育种方法并
无不同。该小组总结认为,重点应放在对导入转基
因生物的DNA、蛋白质或任何新酶导致的新代谢产
物的特征研究和安全评价。
3 美国关于转基因生物评价的监管
流程
  1992年FDA根据美国联邦食品、药品和化妆
品法案(FDA联邦登记第57卷,第104号,案卷编
号92N-0139)发布了植物新品种(包括通过重组
DNA技术获得的新品种)来源食品的安全评价流程
的政策声明。1994-1995年第一例获批的转基因
作物依据安全评价流程进行了安全评价,尽管现在
(2014)更复杂些,但是其流程是一致的。USDA动
植物卫生检疫局(APHIS)负责监管未获批的转基
因事件的田间试验,通过一个审批系统来控制包括
转基因生物、植物害虫和兽药产品。USDA另外一
个部门,食品安全检验局(FSIS)负责监管肉类和禽
类产品的安全性。FDA负责包括转基因作物安全
评价、牛奶和乳制品在内的其他食品安全问题。
EPA则主要负责评估转基因植物整合的杀虫性
(PIP)基因(例如携带编码苏云金芽胞杆菌晶体蛋
白基因的植物即Bt植物,携带抗病毒基因的植物如
抗李痘病毒的李子树),以及化学除草剂和杀虫剂。
EPA和FDA遵循相同的食品安全方针。对于PIP
审批的标准流程是与FDA进行咨商,并将完整的
文件档案提交给EPA。虽然与FDA咨商以及提交
数据在理论上是“自愿的”,但如果未与FDA咨商
且未提交完整的转基因作物潜在致敏性、毒性和营
养功效的评价数据,则有可能因出现疑似有害而被
强制召回和被采取法律行动。EPA和 USDA的要
求是明确强制性的。EPA和FDA都希望在产品进
入市场前接受相似的食品安全的评价和测试。
3.1 FDA针对转基因生物食品安全性的政策:与非
转基因生物的类似品种一样安全
  FDA及其他国家如澳大利亚、巴西、加拿大、日
本、荷兰和英国的政府监管机构是2003法典指南的
主要编写者[1]。中国和美国都接受其作为整个法典
系统的一部分。该流程包含评价的风险与非转基因
生物来源食品是一样的,即大家都熟知的对健康有
不良影响的因素:食物过敏性、食物毒素和不良的营
养因素包括潜在抗营养因子的增加或者潜在的乳糜
泻诱导蛋白(小麦及其近亲来源的麦麸)。研发者需
要提供人类安全使用(HOSU)或接触基因源和蛋白
或基因历史的文档信息,以及引起不良后果的信息。
这些信息必须包括基因产物(蛋白或RNA)的特征、
被引入酶的代谢物和基于新转基因生物来源食物的
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消费方式来确定转基因生物中的蛋白或代谢物的消
费量。如果有证据表明基因供体有潜在风险的历史
记录,那么还需要额外的测试。
FDA认为所有食物的一些内源组分对消费者
都可能存在某些风险。有些风险可通过食物的储
藏、加工(如烹饪)或食用限制来降低。如凝集素、蛋
白酶抑制剂和豆类的淀粉酶抑制剂,可以通过食用
前烹煮而失活。木薯在做成木薯粉食用前可通过浸
渍和挤压以除去氢氰酸防止氰化物中毒。马铃薯通
过品种选育确保它们只含有低浓度的龙葵素(一种
较温和的毒素)。幼嫩、绿色的马铃薯不能食用,因
为这个阶段的龙葵素含量很高。人类已经适应了这
些食物并通过加工以确保安全。这些危害如果不妥
善处理,将会对所有食用者产生影响。其他可能会
影响到每个人的威胁来自于细菌、真菌或化学试剂
的污染。
我们需要认识到摄取食物最常见也是最严重的
危险来自于外源物质的污染。这些污染可能发生在
农场里,也可能通过餐馆和家庭的储藏而产生。细
菌、病毒、真菌、寄生虫和化学物质包括真菌毒素、重
金属和杀虫剂都是常见的污染物。最严重的危险来
自于细菌,包括大肠杆菌O157和其他产毒菌株、单
增李斯特菌、沙门氏菌属、弯曲杆菌属和产气荚膜梭
菌。美国疾控中心(CDC)和 USDA食品安全检验
局估计,2014年美国3.1亿人口中有约3000例的
死亡案例和约128000的住院案例(www.foodsafe-
ty.gov/poisoning/causes)是微生物污染造成的。
一些寄生虫也通常通过食物传播。弓形虫病由弓形
虫引发,是美国最常见的食源性寄生虫病,导致人们
需住院治疗甚至死亡。有些病毒通常也通过食物传
播。诺如病毒在美国是诱发急性肠胃炎的最常见原
因,其因接触不卫生的加工食品而发生,但很少导致
死亡。甲型肝炎感染敏感个体如不经治疗可导致死
亡。霉菌的污染很少在人类的食源性疾病中记录,
偶尔会出现一些发霉谷类产生的霉菌毒素中毒事
件[8]。但是,通常会因喂食含高浓度霉菌毒素的谷
物,导致家禽或其他农业重要物种的严重疫情。霉
菌毒素是小分子到中等分子质量的有机化合物,通
常是多环化合物,不容易被部分人群或物种的肝脏
解毒。有些引发毒性反应的物质是蛋白质,如肉毒
杆菌产生的肉毒素,蓖麻籽里的蓖麻毒素。蓖麻毒
素是已知的极少数能够影响哺乳动物的植物蛋
白[9]。有趣的是,转基因玉米表达植物整合的杀虫
剂如Cry1A,能够减少烟曲霉素的水平(一种霉菌
毒素),从而减少了鸡、猪和牛的中毒风险。未来的
转基因产品很可能会表达出一些特异性抗真菌和抗
微生物的蛋白,从而进一步增强食品安全和粮食
安全。
毒素和抗营养因子几乎影响每一位消费者,但
一些危害只影响一小部分人群。特定的食物致敏原
可能只影响不到1%的人群,但是会引起剧烈反应
甚至死亡。小麦的麦麸(醇溶蛋白和谷蛋白)与乳糜
泻高度相关,这是一种患病人群不到1.5%的慢性
自身免疫性疾病。乳糜泻受遗传因素影响,总人口
的25%可能会受乳糜泻影响,而且还有其他很多未
知的诱发因素。食品安全评估的一个重点是评价和
保障将基因转入转基因植物时,不会转入一个致敏
原,或者是将乳糜泻的诱发谷蛋白从一个乳糜泻的
源头转化到另一个。
3.2 认识包括非转基因作物中包括乳糜泻在内的
食物过敏风险
  食用食物最常见的内源性风险是由IgE介导的
食物过敏[10]和细胞介导的乳糜泻[11-13]。食物过敏
可能会不同程度地影响2%到6%的美国人。一个
人通常会对1~5种食物过敏。致敏原对过敏者造
成显著风险,但不影响非过敏的消费者。食物过敏
性因疾病严重程度和食物组分的复杂性不同而复杂
多变,因而个体的致敏源并非总是很清楚[14-15]。诊
断食物过敏的方法在许多医疗机构都不一致,很少
医生受过良好训练可以精确诊断食物过敏[16-17]。食
物过敏是特异的,因为每个患者都产生结合食物某
个或多个蛋白质的IgE抗体。在过敏反应中,个体
合成的特异IgE抗体至少结合食物中一种含量相对
丰富蛋白质的2个表位(IgE结合位点)。他们的
IgE抗体结合粘膜肥大细胞和血液嗜碱性粒细胞表
面上FcεR1受体。如果摄取含过敏蛋白的食物后,
这种蛋白或蛋白片段被吸收并结合粘膜肥大细胞和
血液嗜碱性粒细胞上的IgE,刺激细胞内产生信号。
如果几分钟内有足够多的致敏原-IgE结合发生,将
诱发粘膜肥大细胞和血液嗜碱性粒细胞释放组织胺
和白三烯,从而导致血管渗漏和由血管神经性水肿
和神经刺激引起的相关症状。很多人经历过相对温
和的口腔瘙痒以及口腔和咽喉轻度肿胀(血管性水
肿),有人得过荨麻疹。一些人经历过哮喘引起的喘
息和呼吸困难,有人有过呕吐和腹泻。少数人有过
低血压(血压下降)。过敏性休克是一种严重的危及
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生命的全身性反应,包括低血压和呼吸困难,通常需
要立即就医,注射肾上腺素或其他药物并接受输氧。
在美国,每年约有150~200例因食物引发严重过敏
反应而死亡的案例[18]。大多数死亡案例都是因为没
有及时接受医治,包括立即注射肾上腺素。花生、一
些坚果、牛奶和鸡蛋都是一些常见的引起致命过敏反
应的食物[19]。一旦个体接触致敏原而诱发过敏,这
种过敏反应将可能伴随一生。然而,年幼的孩子可能
会在接触过敏食物产生初次反应后的5~10年形成
免疫耐受而能耐受致敏食物(牛奶、大豆或鸡蛋)。
食物过敏的发病率只能估算。美国、欧洲和日
本有最好的估算数据,这些国家中1%到2%,最多
10%的人群受食物过敏影响[20-21]。有些严重的危及
生命过敏案例的频率没有很好地统计。但是已经明
确的是,花生、一些坚果、牛奶和鸡蛋肯定比水果和
蔬菜更易诱发严重过敏反应。包括美国在内的大多
数国家都没有一套标准的食物过敏上报机制。流行
病学家在美国疾控中心审查医院1997-2007年的
各种来源的医院编号,估计大约每年有31.7万病例
与食品过敏有关(2003-2006年),其中超过9000
例有严重的反应[22]。这些过敏反应通常和花生、贝
类甲壳类(虾)、坚果、牛奶、鸡蛋和鱼有关。
乳糜泻是一种受由遗传因素影响的自身免疫性
疾病,其由特定小麦、大麦和黑麦麦麸(醇溶蛋白和
谷蛋白)激活辅助性T1型CD4+ T细胞导致的[23]。
这是一种慢性疾病,导致小肠上部绒毛萎缩,并且是
一种消耗性疾病,有时会导致特定的癌症和其他自
身免疫疾病。其遗传性主要是由于组织相容性复合
体(MHC)位点 HLA-DQ2.5或 HLADQ8的异常
蛋白序列造成[24]。25%以上的美国人有 HLA-
DQ2.5或HLADQ8两个位点中的一个,但估计只
有1%不到的美国消费者明确被诊断为乳糜泻,这
和欧洲的患病率相似[25]。中国乳糜泻患病率未知,
不过最近一个研究表明该病比以往认为的要普
遍[26]。患病率的不确定性是由精确诊断的复杂性
造成的,取食麦麸过敏反应以内窥镜多点活组织检
测作为黄金诊断标准,而子宫内膜或组织转谷氨酰
胺酶特异抗体 HLA分型测试中,近亲的诊断也会
被作为有效证据[27]。在有 MHC遗传性的乳糜泻
患者中已经鉴定到刺激Th1CD4+ T细胞克隆的谷
蛋白和麦醇溶蛋白的特定多肽[28-30]。乳糜泻患者控
制疾病的唯一途径就是避免食用含小麦、大麦、黑麦
和一些燕麦蛋白质的食品[31]。越来越多的消费者
认为他们并不对麦麸过敏,然而发病方式并不一致,
反应的机制也未知,在疾病的鉴定上肠胃科专家之
间还存在一些分歧[32]。
3.3 食物致敏原是特异蛋白,而不是整个食物
通常人们认为食物过敏就是对整个食物有过敏
反应(如牛奶、鸡蛋和花生)。但过去20多年的研究
已经确认食物中的特定蛋白才是导致过敏的原因。
国际免疫学协会联盟(IUIS)致敏原命名小组委员
会(www.alergen.org)列出12个常见的致敏原蛋
白家族。报告中最突出的以花生蛋白命名的主要致
敏原是小分子质量醇溶蛋白(14~18ku),包括2S
白蛋白(Arah2和Arah6)和较高分子质量的主要
种子存储蛋白cupin蛋白(50~75ku),Arah1和
Arah3。每种cupin蛋白都占种子总蛋白含量的
15%以上。若某人这4种蛋白任意一种对应的IgE
处于高浓度,在食用花生后会诱发最危险的剧烈反
应[33-34]。Arah2和6蛋白以4个链内二硫键形成
高度交联的小分子质量蛋白,可以抵抗胃蛋白酶的
消化[35-36]。还有其他的一些蛋白被鉴定为花生致敏
原,但是丰度都很低,并且/或者蛋白稳定性较低,被
认为是次要致敏原。大多数有明确IgE介导的花生
过敏反应患者一定拥有主要过敏蛋白的IgE,而次
要致敏原是否引起临床反应还不清楚。其他食物或
花粉中的一些被鉴定的与同源蛋白类似的蛋白被认
为是泛致敏原,这是因为一个物质的IgE抗体可能
会与很多物种的同源蛋白结合。泛致敏原一般不会
引起剧烈的过敏反应。花生中的泛致敏原包括抑丝
蛋白(Arah5),致病相关蛋白-10家族成员(Arah
8.0101和 Arah8.0201)和一个脂质转移蛋白
(LTP)Arah9。两个防御蛋白 Arah12和 Arah
13的序列被IUIS命名委员会认可,但还未发布,并
且其引发过敏反应的频率和程度都还未知。包括杏
仁、榛子、山核桃和核桃在内的坚果引发的过敏反应
通常与IgE抗体识别2S白蛋白和cupin种子贮藏
蛋白类似的蛋白有关。某些情况下,似乎坚果蛋白
之间甚至与花生蛋白之间存在交叉反应,但很难从
“从头敏化”(denovosensitization)分离IgE交叉反
应,这样的物质是共敏化和共反应的。当然,山核桃
和核桃有非常近的亲缘关系,它们的致敏蛋白几乎
一样,因此,无疑有交叉反应。
在过去的25年中,一些独立的与IgE结合过敏
源蛋白,如来自食物、吸入源(花粉,屋尘螨和霉菌孢
子)和皮肤接触(乳胶)或注射源(毒虫叮咬),已被研
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究和鉴定。利用合适的过敏者血清公开证明的IgE
结合蛋白序列发布于内布拉斯加-林肯大学食物过
敏研究和资源项目管理的数据库中(www.Al-
lergenOnline.org),以提供一个转基因生物安全评
价的生物信息学工具。该数据库中的一些蛋白已通
过过敏对象的皮肤点刺试验、嗜碱性粒细胞组织胺
释放或嗜碱性粒细胞活化证明,会引起生物反应,这
些蛋白被充分证明为致敏原。每个致敏原蛋白组被
分类罗列在数据库中(www.AlergenOnline.org),
并且对每个归类的过程进行说明。该数据库还提供
序列比对算法以评价新的转基因生物或新的食物蛋
白存在交叉反应的潜在风险。
尽管IgE介导的过敏反应存在遗传风险因素,
但是目前还不清楚为什么人们对特定蛋白和食物变
得过敏,而不是对这些基本上是无害的蛋白变得耐
受。发达国家食物过敏的发病率在升高,但这并不
能归咎于消费者发生了遗传学上的变化[37]。一些
机理被提出,其中包括“卫生”假说(在环境中或胃肠
道内缺乏某些类型的细菌),其解释了过敏(特异
IgE的诱导)和耐受(IgE和致敏原的抑制),但没有
哪个机理或假说适合解释每种情况[37]。很可能在
儿童期开始摄取食物时,食物加工方式,因久坐室内
的生活方式导致的维生素D缺乏和过少接触某些
微生物或寄生虫等多种因素相互作用,共同导致过
敏性疾病的增加。
乳糜泻是由一定量的来自小麦、大麦、黑麦和也
有可能的燕麦的麦谷蛋白和醇溶蛋白,以及所有
Pooideae亚家族成员引起的。为了提供一个食物风
险评估工具,我们收集了已发现会诱发乳糜泻T细
胞的1016个多肽和58个蛋白,建立了一个专门的
乳糜泻数据库以用于风险评估(www.alergenon-
line.org/celiachome.shtml)。我们也开发了生物
信息学工具通过比对以帮助评价新的食物蛋白,标
注出潜在的有可能对乳糜泻患者有风险的蛋白。
4 美国的转基因作物安全评价
4.1 安全使用历史(HOSU)
安全使用历史的评价范围涵盖基因来源、基因
受体和基因的特异产物,包括通过相关文献确定与
蛋白存在直接接触或与代谢物间接接触(如果该蛋
白为酶类)的情况。该领域的资深科学家已经描述
了如何进行适当的致敏性和毒性评价[38-39]。如果基
因来源本身是一种常见的致敏原或有毒性,则与没
有任何过敏和毒性记载的基因源比较,需要额外的
测试。例如,花生和一些坚果(核桃、山核桃、杏仁和
榛子)被认为是过敏的常见原因。如果一个基因来
自一个常见过敏源,特异性血清IgE测试就需要执
行,如同Nordlee等人对巴西坚果2S白蛋白的研究
一样[39]。如果基因源是蓖麻、Closteridiumbotunli-
num 细菌或黄蜂,监管者可能会要求额外的毒性测
试以确定该蛋白不是一种毒素。特异的测试需求由
该风险的天然属性确定。如果来源生物具有神经毒
性,神经毒性测试就需要执行。可识别的风险来源
一般可以通过搜索相关文献得到,谷歌搜索有时会
有用。如果来源物有非常明确的使用历史,并且该
蛋白被证明在来源物中表达(例如坚果、水果或草本
植物),来源物没有致敏性和毒性将帮助确定该蛋白
不太可能有风险。然而,在许多情况下没有这样的
安全使用历史,并不意味着额外的测试是必须的,只
是会稍微少些对安全性的肯定。
通常情况下,如果有明确的基因来源,风险会非
常明确和有限。苹果含有的2种蛋白,可能被认为
是显著的致敏原,一个会在极少人群中引起严重过
敏反应的非特异LTP和一个效应不大的常见交叉
反应蛋白 Mald1。Mald1蛋白同呼吸道致敏原
Betv1家族有序列相似性,Betv1在桦树和相关树
种的花粉中很常见。其他苹果蛋白被认为导致食物
过敏的风险很低或者没有。花生有4个烈性的致敏
原和一些额外的小致敏原。食品标签法根据致病率
和致敏程度以区分食物过敏的风险级别。在美国、
欧洲和日本,花生被认为是一种常见的且很重要的
食品过敏源,任何加工食物,只要含有花生成分就必
须标注。而苹果就不是常见的烈性过敏食物。来自
花生基因的蛋白要比来自苹果基因的蛋白接受更为
严格的风险评价。
杀虫晶体蛋白Cry1A、Cry2A和Cry3A来自苏
云金芽胞杆菌。该物种的孢子被用作微生物农药已
有70余年,并且没有任何证据证明它们在哺乳动物
中会导致过敏或毒性反应。作为有机农药的安全使
用史,尽管只是证明Bt毒素作为微生物杀虫剂在细
菌中表达而不是在所有物种表达是安全的,但仍然
为Bt毒素提供了保证。
研发人员需要提供基因来源生物或者是基因产
品(如果有)安全使用历史的文献资料。这些证据还
包括提供关于在该材料中的表达蛋白或其他基因产
物在食物中出现过,以及这种食物的加工过程。
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4.2 新蛋白和产品的特征鉴定
研发者必须对转基因过程中转化的 DNA 或
RNA进行说明。这些说明还包括其他遗传元件的
来源(启动子和终止子)。转化的方式也需要描述。
基因拷贝数、基因整合和DNA的遗传稳定性同样
需要确定。基因产物需要在受体植物通常使用的条
件下进行定量分析。某些情况下,mRNA在各个组
织中的大小和积累也需要检测以保证其转录产物与
预期相同。大多数情况下,一个基因编码一个蛋白。
如果蛋白是酶,任何预期的和测定的代谢产物都需
要说明。基因和产物的功能必须公开。DNA和蛋
白的序列也需要公布并且蛋白氨基酸序列必须与其
他毒素和致敏原比对以进行评估。
4.3 潜在致敏性
由于食物过敏的重要性,FDA重视阻止致敏原
转化到转基因作物新食品源中。对于花生过敏的消
费者而言,一个编码花生致敏原的基因转化到水稻
或者玉米中是一个很大风险。这个已被先锋公司
(PioneerHi-Bred)的经验证明,他们转化了巴西坚
果的2S白蛋白至大豆中,以改善动物饲料品质。大
豆含有丰富的蛋白质,但缺乏含硫氨基酸。巴西坚
果中的2S白蛋白是一种富含蛋氨酸和半胱氨酸的
小分子蛋白。先锋公司提交该产品的评审材料时曾
与内布拉斯加大学史蒂夫·泰勒博士交流,他建议
既然巴西坚果对许多消费者而言是一种致敏源,就
应该评估转基因表达蛋白的潜在致敏性。在1995
年,没有人知道巴西坚果中哪些是致敏原蛋白。直
到Nordlee等的研究成果公布才知道巴西坚果中的
2S白蛋白是一种很明显的重要致敏原[39]。这些结
果公布以后,先锋公司停止开发该产品,没有提交评
审材料。这些经验帮助验证了1992年FDA联邦注
册局发布的评价流程的正确性,并有助于 Metcalfe
等人发布的转基因蛋白潜在致敏性评价过程[40]的
成型,以及食品法典委员会于2003年发布的指
南[1]。
食物过敏通常限定于特异性抗原介导的IgE抗
体反应和任何免疫学课本上描述的机制。大多数的
膳食蛋白刺激免疫系统从而对这些蛋白耐受。然
而,对于那些容易过敏的人群,他们的T辅助细胞
和B细胞可能因为T辅助2型细胞提供了细胞因
子和细胞表面信号的混合物,建立起IgE免疫球蛋
白。B细胞分化为浆细胞或B记忆细胞,表达高水
平蛋白特异性IgE,结合粘膜或皮肤的肥大细胞和
血液中嗜碱性粒细胞的FcεRI高亲和受体。当抗原
被再次通过饮食吸收时,如果至少2个表位被结合,
它将偶联IgE抗体并启动信号级联反应。如果几分
钟之内发生足够量的偶联,肥大细胞或嗜碱性粒细
胞将释放组织胺、白三烯和蛋白酶并引起血管渗漏
和炎症。症状可能包括血管性水肿、荨麻疹、哮喘、
呕吐、低血压(血压下降),并在极少数情况下,因全
身性过敏反应而死亡。由于IgE抗体是特异性的肽
表位识别,症状是可以再现的,相同的抗原,相似的
反应。通常过敏反应的敏感性被认为是终生的。很
多膳食蛋白也会诱发IgG和IgA抗体,但这些都不
是剧烈食物过敏的风险因素。B细胞也需要T细
胞的帮助合成这些免疫球蛋白,但是响应和信号
都不同于IgE。因此,致敏性评估的重点是IgE
反应。
也存在T细胞介导对膳食蛋白的反应,主要的
一个就是前面提到的麸质敏感性肠病或称乳糜泻。
对转基因生物蛋白潜在诱发乳糜泻的评价是相对直
接的,这将在后文中讨论。很少有膳食蛋白诱发肠
炎综合征(FPIES)的案例,这种烈性反应主要与牛
奶和大豆中的蛋白有关,但很少在水稻和燕麦或其
他一些食物中出现[41]。如果没有特异蛋白被鉴定
为引起过敏的因子,个体通常在取食引起反应的食
物3到5年后变得耐受该食物。因此,此时不可能
将该蛋白评估为FPIES的可能诱因。
有可靠的证据表明,食物过敏和乳糜泻的发病
率在全球范围有增多的趋势,但是对发病率增多的
幅度和原因都未知。部分增多的案例可能是消费者
对于食物过敏的意识增加,以及医生对乳糜泻的意
识和诊断提高。有很多关于发病率的误导,并且人
们常常被误诊。很多报告的食物过敏病例经临床评
估后被证明并不是食物过敏。
食物过敏主要的风险是急性的,在摄食过敏源
食物几分钟到几个小时后就会发生。转基因作物的
首要食品过敏风险是潜在转化了的已经在特异消费
者中发生过敏反应的蛋白。如果受影响的个体食用
了含致敏原的转基因作物,将很可能像他们摄食天
然来源的致敏原一样发生剧烈反应。因此,对于转
基因作物而言,首要任务是避免转化这种能够导致
过敏的蛋白(任何种类的,接触、空气或食物)到作为
食物的植物的其他品种中。
国际生命科学学会(ILSI)-过敏和免疫学学会
和国际食品生物技术委员会组织了一些讨论,并发
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表一系列供同行评阅的文献讨论转基因作物潜在的
食品过敏风险。该文章发表于食品科学与营养特刊
(第36卷,增刊,1996)。该小组成员包括生物技术
发展和监管、或致敏原、过敏方面的资深专家。第一
章解释了过敏、食物过敏、植物蛋白的生物学、作物
遗传修饰的过程,并对当时已知的过敏食物进行了
综述;中间两章内容介绍了指导建立基于科学的新
蛋白过敏风险评估流程的基本背景信息[42-43];最后
一章概述了确定一个外源基因表达蛋白是否会对消
费者产生过敏风险的评估流程[40]。
Metcalfe等人提出的评价流程[40]与FDA的建
议(1992)一致,包含将基因来源的致敏性作为评价
起始的决策树流程图。然而,决策树与文字描述并
非完全一致,并且一些事情还没有描述清楚。图1
表示我根据文字[40]对于该决策树的理解。如果一
个基因明确来自于一个过敏源(食物、呼吸道或接
触),下一步则是获得14个过敏人类的血清并通过
标准实验室测试方法检测结合转基因蛋白的IgE。
如果发现的可供测试的过敏供体少于5个,则评估
该蛋白对胃蛋白酶的稳定性。所有的蛋白,无论何
种来源,都应该接受与已知致敏原、食物性致敏原和
呼吸性致敏原(1995年)的序列比对[40]。他们推荐
使用FASTA格式将蛋白和已知致敏原进行比对,
寻找连续8个氨基酸一致匹配的区域。在实际应用
中大多数生物信息学匹配只是简单的执行滑动的8
个氨基酸“文字”的匹配。如果一个蛋白质匹配上一
个致敏原,过敏患者的血清就需要用于结合测试。
如果在正确诊断的过敏患者血清中的IgE结合了该
蛋白,研发者就可能要终止其开发并取消审批材料
的提交。但是,如果他们打算继续,监管机构将可能
会要求转基因来源的食品加上标签以警告过敏消费
者避免食用。在不确定IgE结合的情况下,过敏受
体就需要接受该蛋白的皮肤点刺测试(SPT),如果
结果都是阴性,他们将被要求在伦理小组的批准下
进行一个双盲且有安慰剂作为对照的食物测试
(DBPCFC)。此外,该蛋白会被检测酸性环境和蛋
白酶稳定性,以其消失的时间进行评级来评价其消
化率。该蛋白对应作物可能根据其常规的食品加工
过程进行测试,以确定加工过程中是否会被变性。
然而,加工稳定性只是用于了解过敏或毒性风险能
否通过常规食物加工过程减轻,类似于通过烹煮,豆
科植物的天然凝集素和蛋白酶抑制剂可以失活。如
图1 对转基因蛋白的潜在致敏性评价
Fig.1 AssessmentofthealergenicpotentialofGMproteins,adaptedfromMetcalfeetal,
1996tomorecaauratelyreflectthedescriptioninthetext
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果蛋白对胃蛋白酶稳定,监管机构将可能要求额外
的测试。
美国批准的大多数转基因事件和新表达的蛋白
符合 Metcalfe等[40]和法典[1]提出的致敏性评估的
风险最小原则。文献检索发现只有一种转基因作物
产品不符合安全使用历史,并且在巴西坚果过敏症
高危人群血清接受IgE结合测试中发现该蛋白可以
结合IgE[39]。该产品未被提交给监管机构,并被研
发者(先锋公司)终止。据我所知,还没有接受来自
致敏生物基因的产品被批准。因此,巴西坚果2S白
蛋白是唯一一个可能对部分消费者具有较大过敏风
险的蛋白。
4.4 匹配致敏原的生物信息学分析
除了评价基因来源,利用生物信息学搜索转基
因蛋白与任何已知或可疑的致敏原之间的一致性匹
配可能已成为最重要的鉴定潜在风险的工具,以及
是否进行血清IgE检测的理由[38,44-45]。食品法典委
员会[1]文件呼吁使用FASTA或BLASTP来利用
转基因蛋白的氨基酸序列比对搜索一个已知的致敏
原数据库。www.alergenonline.org数据库是我知
道的最全面的经同行评审的致敏原数据库。最重要
的标准是与任何80个或以上的氨基酸的任何部分
有大于35%的一致性。致敏原在线数据库(www.
alergenonline.org)于2004年在内布拉斯加大学的
食物过敏研究和资源项目中建成,并进行了专家评
审。这个网站每年更新,提供一个准确的数据库,以
及使用生物信息学进行过敏风险评估的算法[44]。
2014年1月公布释放了第14版的数据库,包括来
自代表了290个物种的645种蛋白分类群体的
1706个序列。我认为,如许多已报道的文章所述,
任何一段80个氨基酸序列中大于35%的一致匹配
搜索是相当保守的。很少有证据表明整体序列相似
性不到45%的全长蛋白质在体外有交叉反应。就
由于交叉反应引起的过敏来说,很少有全长匹配小
于50%的蛋白质发生交叉反应[46]。自1996年以
来,已经有很多科学咨询者和建议者建议“改进”转
基因作物的致敏性评价。FAO/WHO[47]专家审查
小组提出了一些没有生效的改进建议。FAO/
WHO推荐使用FASTA或BLASTP去比对识别
匹配度大于35%的任何80个或以上的氨基酸片
段;搜索连续6个而不是 Metcalfe等人提出的8个
相邻的氨基酸短肽是否有匹配[40]。但这些预防原
则尚未生效。这些建议在已发表的文献中进行了综
述[3,38,45]。大量的研究表明,6个氨基酸的一致性匹
配搜索产生的假阳性比真实的阳性多得多。8个氨
基酸相似性比对较好,但仍没有一个高的预测价值。
其他人也表明80个氨基酸的搜索过于保守;尽管使
用这个标准我没发现很多假阳性的结果,也没有漏
过任何可能交叉反应的蛋白对[45]。正如一些生物
信息学家建议的,对于80个氨基酸的搜索,通过
FASTA 或BLASTP搜索最好的全长序列并且获
得最佳匹配分数作为一个更可信的选择,但对于这
个优化算法仍有一些分歧[48-50]。最近,欧洲食品安
全机构(EFSA)[51]不再推荐搜索短的连续的一致性
比对,并且鉴于EFSA和欧盟委员会[52]的关系,欧
盟委员会也接受了这个建议。有一些例子表明,短
的连续的匹配是偶然发生的(没有整体同源序列的
证据),这使得没必要的血清IgE检测变得必要[53]。
在体外进行IgE结合实验也是有风险的,结果可能
不明确,假阳性的结合结果会不准确地暗示一个蛋
白可能是致敏原[54]。虽然IgE结合到2个非同源
蛋白的一个单一小片段上,意味着在这种情况下有
过敏风险的可能性很小,而一些监管机构可能会希
望研发者继续研究,并可能要求进行人类的体内
试验。
4.5 血清 IgE检测
血清IgE的检测很少批准用于评价转基因蛋白
的潜在致敏性。然而,如果血清IgE的检测被批准,
则必须精心设计实验,并使用对于过敏性血清供体
已知的致敏原来证实,并且参加试验的个体应有合
适的过敏反应和IgE敏感。试验材料应包括纯化的
转基因蛋白、纯化的致敏性靶标(如致敏原有匹配的
序列)以及合适转基因材料的抽提物。此外,IgE检
测抗体的特异性需要验证,以及需要合适的封阻溶
液阻止非特异性的抗体结合。在某些情况下,可能
需要特定的抑制试验来检测其特异性。材料和方法
设计中的关键因子已存在于发表的大量文献
中[45,54-55]。如果蛋白质含有天冬酰胺连接的碳水化
合物,植物可能会通过在天冬酰胺链多聚糖主干上
添加α-1,3岩藻糖或者β-1,2木糖对蛋白进行修饰,
因而可以与IgE结合,但是相应的个体没有临床反
应[56-57]。这些结构现在已知为交叉反应的碳水化合
物决定物(CCD)。如果有一个信号肽和 N链接的
sequon(天冬酰胺-X-苏氨酸/丝氨酸),这种蛋白被
测试为存在CCD。需要抑制试验来评价体外IgE
结合的相关性。如果有体外IgE结合的证据,但又
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希望继续进行产品研发,可利用嗜碱性粒细胞的激
活或嗜碱性粒细胞组胺释放试验来检验结合作用的
生物学相关性[58]。或者,利用高度特征性试验材料
和愿意参加试验的知情受试者进行皮肤点刺试验
(SPT)或双盲、使用安慰剂对照的食物测试。
4.6 潜在的从头敏化作用:胃蛋白酶稳定性和蛋白
丰度
  如果没有证据说明蛋白质可能是致敏原和缺乏
生物信息学的匹配,那么就没有理由进行血清IgE
试验。风险的概率很低而且没有处于风险的群体。
关于致敏性唯一的问题是蛋白是否会重新致敏。
Metcalfe等人[40]建议,如果蛋白质在胃蛋白酶体外
消化实验中是稳定的,而且含量丰富,则这个蛋白质
很有可能是重要的食物致敏原。然而,这种相关性
也并非很高。因为虽然许多主要食品致敏原是稳定
的,或其部分片段是稳定的并且含量丰富[59],但是
也有很多稳定且含量丰富的蛋白质并不导致过敏。
胃蛋白酶稳定相关性的验证一般在pH值为1.2和
2.0条件下进行,2001年FAO/WHO建议使用这
2种pH 条件进行稳定性评价。不过,我们也没发
现这2种情况有何显著差异[59]。EFSA曾经建议
使用更“生理的”pH值(3.5)[57],但在这个条件下胃
蛋白酶活性明显降低而且其预测性的价值并未被证
实。FDA一直接受的pH条件为1.2或2。对于丰
度,仍然没有一致意见,但是很明显的是,在植物中
许多主要致敏性蛋白的丰度在食用部位大于蛋白含
量的1%[60]。
已发现大部分的转基因蛋白在pH为1.2或2
时被胃蛋白酶迅速消化。然而,Bt蛋白Cry9C最初
由在比利时根特的植物遗传系统(PGS)公司导入到
玉米中以抵抗玉米螟幼虫的危害,但被发现在胃蛋
白酶中稳定。其产品被称为“StarLink”玉米。PGS
公司被 AgrEvo购买,然后被 Aventis作物科学公
司收购,最后 Aventis作物科学公司又被拜耳作物
科学公司收购。作为食品应用的批准被暂停,因为
蛋白质在胃蛋白酶消化实验中是稳定的(稍后介
绍),而监管机构认为这有风险,最终可能会使某些
人过敏,导致对Cry9C有过敏反应。1999年,美国
约有12.2万hm2土地种植了StarLink玉米。由于
一些意外,StarLink玉米非法进入了一些人类的食
品(玉米片和玉米卷)。反对转基因的NGO通过测
试发现StarLink玉米进入了一些食品中,并通知了
美国政府和新闻媒体。有趣的是,关于人们是否可
能对这个蛋白质过敏的问题,使消费者过敏是需要
一定时间的。没有迹象表明,人们之前接触过
Cry9C,因此过敏反应只能从接触受污染的玉米卷
和玉米片开始。不过,在通告的2周内,有超过100
位消费者抱怨在消费玉米卷壳或玉米片后有食物过
敏反应。由于玉米是谷物中致敏原最少的作物之
一,玉米粒中Cry9C的含量大约为50μg/g,这些谷
粒的种植也仅仅只有1年,所以任何人对这种蛋白
过敏都是不太可能的。然而,美国疾控中心还是调
查了每一份消费者报告。那些声称有反应的个人可
能含有食物致敏原,当被问及是否愿意提供血液样
本,有18个人提供了[61]。这些人都没有Cry9C特
异性的IgE。由于谷物和玉米种子释放并未经批准
在食品中使用,美国政府要求召回和监测。食品、食
品原料和玉米种子被筛查,那些含Cry9C蛋白或基
因的材料从市场被召回。一共花了6年或更久才完
全剔除所有种子和粮食店中的Cry9C痕迹。粗略
地估计,“剔除”的成本可能超过5亿美元。但我们
应该记住,没有证据表明有人因接触Cry9C而受伤
害。显然,来自转基因作物食品如Starlink玉米的
过敏风险与诺如病毒、肝炎或大肠杆菌 O157爆发
的风险程度是不同的。我们可以得出这样的结论,
监管机构的反应相对于StarLink事件的风险,并不
相符。然而,对StarLink玉米的召回体现了能够从
产品中剔除转基因作物的能力。这也表明如果有足
够的理由,我们是可以从农业和食品系统中剔除转
基因作物的。只是需要花费时间和大量的金钱
而已。
另外一个产品是在其他的抗虫玉米中的2个蛋
白(Cry34Ab2/Cry35Ab1),它们不像 Cry1Ab(玉米
中)或者CP4EPSPS(耐除草剂大豆中)那样可以在
胃蛋白酶中快速消化。这2个蛋白如研发者陶氏益
农公司所报道的那样呈现一定的稳定性[62]。EPA
还是允许该产品进入市场,因为这2个蛋白在籽粒
中的丰度低而且只是相对稳定。
目前在已被批准的转基因作物中表达的新蛋白
在作物来源的食品原料中只是低水平的积累,通常
小于100μg/g。我所知道的表达量最高的蛋白,包
括耐除草剂大豆(孟山都公司)的某些品系中表达的
CP4EPSPS蛋白高达400μg/g,以及在转基因玉米
事件3272的种子中富集接近2000μg/g即2mg
每克种子干质量的淀粉酶AMY797E蛋白(先正达
公司)(CERA转基因作物数据库,2014;http://ce-
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ra-gmc.org/index.php/GMCropDatabase)。因
此,所有的转基因蛋白积累的水平显著低于最重要
的食物致敏原的浓度。
没有证据显示已获批的转基因作物会由于转基
因蛋白造成过敏反应。为了确定对大豆过敏者的
IgE是否可以结合CP4EPSPS酶,CP4EPSPS酶导
入大豆中使其具有草甘膦抗性。这不是一个监管审
批需要的研究,而是作为管理需要的研究,只是看看
是否有证据表明该产品进入市场多年后有没有过敏
性。从欧洲和韩国收集了大豆过敏者的血清样品,
使用了通用的检测方法和高度特异性的试验材料。
该研究没有发现IgE结合纯化的CP4EPSPS蛋白
或转基因大豆蛋白提取物的证据[55]。
4.7 对 IgE介导的致敏性评价的潜在改进
FAO/WHO机构推荐使用针对性人血清试验,
来尝试确定一个与任何已知致敏原都不相似的蛋白
可能存在的致敏或者交叉反应的风险。针对性的试
验是指,在体外使用50个对转基因来源有关材料过
敏个体的血清,来进行抗体IgE结合试验。如果基
因来源于双子叶植物,那么一种或多种双子叶植物
过敏者将被用于血清结合试验。对于细菌源蛋白一
般不需要该试验,几乎没有人对细菌过敏。针对性
血清试验的预测能力从来没有被证明过,它有违于
我们对交叉反应知识的直觉。相对比较近缘(分类
上“科”一级)的同源蛋白的体外试验,很少发生交叉
反应以及临床反应。在实验室实验中,唯一具有广
泛交叉反应的蛋白是抑丝蛋白(profilins)、PR-10蛋
白 (Betv1同源物)、脂质转移蛋白与甲壳类和其
他无脊椎动物来源的原肌球蛋白(tropomyosins)。
这些通过生物信息学很容易识别。美国不认为针对
性血清试验是新蛋白质评价的有用工具。
FAO/WHO也推荐使用2种动物模型进行致
敏试验,或者一种动物中的2种敏感途径来评估每
个新蛋白的致敏性潜力。Ladics等人的综述告诉我
们,许多实验室都尝试过不同动物模型测试预测蛋
白质的过敏性,没有一个试验可以预测各种程度的
有效致敏性(从没有或轻度到强烈的过敏)[63]。有
研究表明,评价过敏的机制和免疫疗法[64],以及对
过敏原进行初步评分还是有一些希望的[65-66]。几个
研究测试了纯化的或者部分纯化的蛋白[67],但是对
新蛋白的过敏潜力或发病率的评分没有在人群中进
行过验证[63]。美国不承认目前的动物模型对预测
新蛋白的致敏性是有用的。
法典委员会的指南确实推荐使用FASTA 或
BLASTP搜索比对以确定任何部分的80个或更多
的氨基酸序列一致性匹配大于35%的序列测试。
法典委员会[1]还保留建议使用短的6或8氨基酸的
匹配,但评价者必须科学地判断这一选择。美国监
管机构目前要求使用 www.alergenonline.org上
的比较工具,或者通过BLASTP进行全长比较,以
超过80个氨基酸大于35%的一致性作为标准,进
行比较。他们似乎不在乎短的8个氨基酸匹配,但
是大多数(或者所有)的研发者都提交了这一数据。
欧盟的管理条例[52],很大程度是基于EFSA专
家小组的评价过程,同时也包括一些未验证的试验
如:对新蛋白的潜在佐剂性的评价;使用蛋白质组学
考察常见致敏物种(如大豆、花生)的内源性致敏蛋
白表达的潜在变化;使用更多的生理学pH 条件
(3.5)进行胃蛋白酶消化实验。然而目前这些方法
均未证实会改进风险评价,且美国监管机构对其也
不作要求。除非有合理的理由支持一个新的蛋白质
可能是一种凝集素或有其他一些辅助性质,美国监
管机构不要求额外的检验,如潜在的免疫辅佐。
4.8 乳糜泻
已发现乳糜泻相关的风险涉及某些来自小麦和
近亲缘麦类的麦麸(醇溶蛋白和谷蛋白)。法典委员
会[1]建议且美国政府也要求,如果小麦、大麦、黑麦
或者燕麦来源的基因转入其他物种,比如玉米、大米
或高粱需要进行评价。据我所知,目前还没有开发
商向美国监管机构提交一个这样的潜在产品。虽然
法典要求对来源于小麦或近缘种的蛋白进行评估,
但他们没有对这一过程提供指导。我的实验室关注
的问题是对乳糜泻以及涉及麦麸的已有知识,并开
发一个乳糜泻数据库以提供一个快速鉴定潜在的危
险性蛋白的生物信息学工具。为了开发这个工具,
我们回顾了已发表的关于乳糜泻的科学信息,并描
述如下。
对食用面包引起的吸收不良和腹泻的症状在约
2000年以前的希腊医学著作中首次描述[68]。直到
1888年,英国的一个内科医生才将这种食用含有麦
类食品而遭受的肠道病痛命名为乳糜泻。现代医学
并没有注意到这种现象,直到1952年,英国内科医
生发表对这种由食用麦类引起消耗性的肠道疾病的
相关描述。在20世纪90年代,胃肠病学家发展出
了内窥镜检查和抗体检测的方法,证实乳糜泻患者
携带的抗体能与小肠内的结缔组织结合,麦麸来源
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的小麦多肽与主要组织相容性抗原受体结合激活患
者的T细胞。近年来的研究发现了许多小麦、大麦
和黑麦谷物中谷蛋白和醇溶蛋白的多肽,可以激活
遗传上敏感个体的T细胞[30,69]。小麦、大麦和黑麦
中蛋白是引起具有敏感性的 MHCII类(MHCDQ
2.5和 MHCDQ8)的少部分个体特异性T细胞反
应的原因。由于许多这样的发现发生在20世纪90
年代中期及以后,所以对小麦、大麦和黑麦中蛋白的
评价才出现不久。此后,很多的研究鉴定出了结合
正确的 MHC以及激活乳糜泻患者中T细胞效应
子的多肽序列。与此同时,Metcalfe等人[40]以及法
典[1]的建议没有认识到生物信息学是有评估来自小
麦亚家族蛋白的乳糜泻风险的预测能力。很明显的
是,大量蛋白都被数据库确定为“有风险的”蛋白。
2011年,我实验室的一个博士生PlaimeinAmnuay-
cheewa,综述了50多篇发表的文献,这些文献使用
来自乳糜泻患者的细胞样品鉴定涉及T细胞反应
的多肽。我们开发了一个多肽的数据库,从来源于
小麦或近缘种的蛋白中筛选出潜在危害性的多肽。
我们建立了一个来源于小麦、大麦和黑麦的多肽数
据库,这些多肽会引起T细胞应激反应或者肠道上
皮细胞病理(www.alergenonline.org/celiachome.
shtml)。这个数据库是 www.AlergenOnline.org
的一部分,它可以对转基因蛋白质引起的潜在IgE
介导的致敏原性进行生物信息学评估。目前,这个
数据库含的1016个多肽都有公开发表的T细胞反
应的证据,这些证据来源于与 MHCII类DQ2.5或
者DQ8相关的乳糜泻患者的细胞,或者对有乳糜泻
患者的肠道上皮组织毒理学效应,或者乳糜泻患者
肠绒毛组织的病理学。在数据库中,转基因作物中
被转入蛋白质的氨基酸序列可与数据库中的多肽进
行精确匹配的搜索,也可使用FASTA搜索比对已
知的68个乳糜泻致病的全长蛋白质,如果至少100
个氨基酸片段中有大于45%的一致性匹配则被认
为可以潜在刺激乳糜泻发生。数据库中可能导致敏
感个体发生乳糜泻的多肽和蛋白,总共参考了53篇
文献。与致敏性评价类似,生物信息学的方法可以
鉴定具有中等到明确风险的致病蛋白。如果需要将
一种小麦亚家族蛋白导入到另一种作物,如水稻或
者茄子,其氨基酸序列也应该利用这个数据库来筛
选考虑其风险。如果发现阳性的匹配,这个蛋白应
该使用细胞或乳糜泻患者进行试验来评估风险。这
个试验应该是基于细胞的检测或者至少10个愿意
测试的乳糜泻患者的食物检测,以确保其对乳糜泻
患者即“处于风险的”消费者的风险最小化。我们认
为生物信息学的标准是基于广泛的模拟来进行预测
的,要求对于1016多肽之一的任何100%一致性匹
配,或者FASTA一致性匹配大于45%的任意100
个或者更多氨基酸片段,或者E值小于1×10-15。
非早熟禾亚科的其他禾本科植物来源的基因引起乳
糜泻风险很小,即使与引起乳糜泻的谷蛋白是同源
的,它们导致疾病的可能性也不大。如果蛋白不超
过上述的标准,诱导乳糜泻的风险应该很小或者无
风险,不需要额外的检测。
4.9 潜在的毒性
少数蛋白被食用时是有毒性的,且大多表现为
急性毒性(如蓖麻毒素)[70]。除了用生物信息学方
法将任何一个新表达的蛋白比对关键词为“毒素”或
者“有毒”的NCBI蛋白数据库以外,安全使用历史
的评估也是重要的考虑因素。尽管似乎缺少发表数
据来说明如何对于转基因生物潜在毒性进行生物信
息学评估,但所有提交到FDA或EPA的转基因产
品都必须接受评估[71]。针对监管意见书,我也对一
些提交监管审批的潜在转基因作物和新的食品原料
进行过生物信息学搜索,在关键词为“毒素”或者“有
毒”的限定下BLASTP比对搜索NCBI蛋白质数据
库,将重点集中于潜在风险上。通常对于新蛋白的
搜索还需要额外的序列比对,在没有关键词的限制
条件利用新蛋白进行搜索比对,提供已知有安全使
用或者人类安全接触历史的蛋白质与查询蛋白质
(转基因蛋白质)序列或者新的食品添加剂的比对。
这个过程还需要一个对已发表的科学文献细致的评
估,这些文献应该与目的蛋白和搜索序列最接近序
列相关。虽然生物信息学家经常声称,序列一致性
大于25%的蛋白质具有同源性和相似的功能,但是
大部分具有如此低序列一致性的蛋白质,并不一定
具有相同的特异性毒性性质或者完全一致的酶学功
能。因此,相对其他蛋白质的生物信息学评估结果
也需要被评估。这个评估用于决定是否需要任何毒
理学测试,如果需要,需确定测试的靶器官,以及哪
些测试对于评估风险可能有用。到目前为止没有证
据表明在美国被批准的任何导入转基因作物的蛋白
对人或其他哺乳动物有毒性。
在美国的监管体系中,如果一个转基因作物中
被转入的蛋白质可能对昆虫、细菌、真菌有毒或者具
有抗病毒活性,比如植物整合的杀虫苏云金芽胞杆
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菌晶体蛋白,这样的蛋白必须通过小鼠的急性毒性
试验。OECD 对于急性毒性试 验 的 指 导 原 则
(E425,2001)是很多研究遵循的模式。成年小鼠被
灌胃的蛋白剂量通常为每千克体质量1mg蛋白量
的1000倍,(每千克体质量1mg蛋白量)是人类食
物摄取量的期望值。有时候超出剂量不会这么高,
但一般也可达到100倍的剂量。从剂量给予当天开
始,在有对照(给予模拟剂量)的条件下进行14d的
动物健康监测。进行体质量、血液样品观测和每日
临床观察的数据收集。对动物实施安乐死并进行整
体病理学检查,如果需要则进行组织学样品检查确
定是否有异常。通常每个处理组的每个性别有10
只动物。一般会有2个剂量的实验处理组以保证任
何异常有剂量效应。尽管在转基因组和对照动物组
之间,一些测量值可能会有统计学的差异,同一品种
老鼠的历史体质量和测量值可以用于对非期望差异
的评估。一些对批准的转基因产品进行小鼠急性毒
性试验的研究已经发表[72-74]。很少情况下,更长的
毒理学研究会被监管机构或者技术上的专家要求,
但是额外的毒理学测试对于增加科学上的判断依据
意义不大。非常重要的一点是,考虑到不同于许多
的有机物或者重金属,摄入的蛋白质不会在动物体
内富集,来自蛋白质的毒性效应应该是急性的而非
慢性的。
一些国家(如欧盟)要求进行急性小鼠试验,以
及亚慢性的大鼠90d全食物喂养研究,或使用高剂
量蛋白质的重复剂量试验。对于90d研究的试验
设计,OECD的指南有详细描述;一些已发表的研究
论文也进行过验证,但是没有很好的理由或者充分
的证据来证明这样的研究可以鉴定已知的危害[75]。
90d大鼠喂饲研究更多的是一种毒理学和营养学的
混合研究。一些监管者和建议者认为90d研究提
供了一个评价由于新基因的插入作物基因组而引起
“非期望效应”的工具。值得考虑的是,对于宿主(受
体)作物我们通常食用了几个世纪,具有安全食用历
史,并且通过自然繁种品种和品系的遗传变异导入
了很多非期望的遗传改变,但是并没有在食物中引
入有害的毒性。
有2个研究使用了重组水稻进行大鼠90d喂
饲试验检测一些预期值,得到了一些相互矛盾的结
果[76-77]。第 1 个试验喂饲了表 达 来 自 雪 花 莲
(GNA)凝集素的转基因水稻,作者的结论是该研究
未能发现雪花莲凝集素具有潜在毒性。第2个实验
是表达高水平菜豆凝集素PHA-E的转基因水稻,
当蛋白以原始状态高浓度喂食时表现出了毒性。我
理解的是当人们食用未加工的芸豆或者菜豆时,未
煮过的PHA具有明显毒性,这和预期是一样的。
对雪花莲凝集素的研究结果似乎是阴性的,可能是
因为蛋白的表达浓度太低或者在饲料制备过程中被
加热了。由于人类可以食用煮熟的芸豆和菜豆,而
不是生的豆子,这似乎使得实验结果预测了人类的
经验。试验应该设计未加工的和煮熟的2组单独的
处理,这样似乎更合适。这个测试也不是很灵敏,而
且相对于人类的饮食,喂食的剂量非常有限,远远小
于毒理学研究中通常使用的100倍安全系数。许多
毒理学家质疑90d的全食物喂饲研究是否真的有
用[9]。而另一些科学家则主张需要更详细、更复杂
和更昂贵的研究来充分检测潜在毒性[78]。然而,最
近对已发表的针对转基因作物安全性、毒理学以及
全谷粒的大鼠喂饲研究,进行一个同行评估对这种
评估方法作出了客观的评价,结论是大多数情况下
90d喂饲试验是没有必要的,而且结果也是一致性
的安全[79]。有趣的是,在动物人道主义协会和动物
保护和利用委员会呼吁减少动物实验的同时,一些
参与监管或者转基因生物检测的科学家们呼吁开展
更多的未证实的动物研究。
4.10 额外的毒理学研究
对于任何新建议的毒性测试和已存在的测试方
法有几个问题是需要考虑的。在已有的测试方法
中,什么类型的危害可以或已经被确定? 每个试验
的假阳性和假阴性率是多少? 最后,有没有更有效
的试验可用? 最近许多发表的文献讨论了使用替代
性的基于计算机、基于细胞或者基于组织的方法(包
括赞成和反对意见),主要针对的是药物的毒理学评
价[80-81]。讨论集中于科学上合理的假说、经过验证
的方法和历史参照数据作为基础标准。了解不同模
型的局限性和优点对于决定试验是否可用于评估潜
在毒性是至关重要的。在大多数国家,包括美国,动
物保护和利用委员会有一个基本要求,除非有理由
怀疑结果,否则不能在之前没有应用过的特定试验
材料上进行特定测试。因此,相同的转基因作物的
事件在多个国家重复相同的动物试验,被认为是不
道德的。
毒性评价的最终结果应该是相对于类似的非转
基因品种,转基因作物不会造成任何额外的显著毒
性风险,或者是构成实质性的新风险。如果研发者
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遵循标准的评价过程,对许多新转基因产品,FDA
和EPA就能够作出结论。不幸的是,欧洲(如EF-
SA和欧盟委员会)、印度以及中国的一些监管机
构,继续提出假设性的新问题,包括潜在的免疫辅
佐,导致消费者生育问题或诱发消费者癌症,即使只
有极少的例子,膳食蛋白质具有这样的效应。因此
这些监管机构不批准这些没有风险证据的产品。美
国监管机构强调需要使用经过验证的方法来评估
新的蛋白质和转基因产品的安全。他们没有要求
(到目前为止)还没有证实对安全评价有帮助的其
他研究。不过,如果研发者提供从新检测方法获
得的数据,他们也会进行考虑,虽然这样会使审批
延迟。
4.11 转基因产品的非预期效应评价
相对于通过突变或生殖等“自然过程”,产生抗
除草剂和抗虫性状(这些性状已经过监管审批并广
泛应用)所使用的遗传修饰的方法造成的宿主基因
组改变是很小的。有趣的是,这种“未知的”自然变
化只能通过表型变化来描述,并且这些方法已经被
接受,它们提供必要的遗传背景多样性,使得植物可
以在病虫害威胁、气候条件及土壤多样性的环境中
生存下来。相比之下,转基因生物却可以从插入位
点、拷贝数、基因序列和编码产物几个方面来精确地
描述其特性。如果引入了一个编码酶的基因,就必
须对这个酶的代谢产物进行评估。1948年,在芭芭
拉·麦克林托克的研究中描述了在玉米(Zea
mays)基因组中有相当一部分是由被称为“跳跃基
因”的转座子组成和改变的。由于她的这项发现,芭
芭拉·麦克林托克获得了1983年的诺贝尔生理学
奖[82]。最近的一项研究表明,在玉米的503个遗传
上不同的家系中,有大约16%的基因不存在于所有
的503个家系[83],表现出显著的遗传变异。人们今
天所食用的面包小麦(Triticumaestivum)是由3套
相对原始的禾本科物种的染色体(因此是进化上的
六倍体)组成的,所以,小麦中的大多数蛋白是由3
套相异的基因编码的,有些几乎相同,有些差异显
著。除此之外,在有性繁殖过程中的基因组复制可
以造成获得或缺失某些基因功能,改变植物在不同
环境下的生长能力或对营养物质(或抗营养因子)进
行选择。面包小麦和意大利面小麦(硬粒小麦和圆
锥小麦亚种,硬粒小麦是进化上的四倍体)都具有很
高的营养价值并且在人类食品中有着广泛的应用。
但它们可以导致一些人产生乳糜泻,这样的人口占
北美和欧洲总人口的1%,遗传上易感个体占总人
口的25%,有小部分群体(<0.4%)会产生IgE介
导的食物过敏反应。这2种小麦都属于非转基因作
物,目前相关部门还没有批准转基因小麦品种。这
说明,所有的食物对于一些消费者都存在某些风险,
通过遗传变异为每一位消费者生产可以食用的食物
是非常有用的。
我们应该退一步想想,为什么我们吃某些食物,
如大米、小麦、大豆、玉米和其他食物,却不仅仅只吃
谷物。人们选择了某些便于生产的特定食物来源,
但更多的是看重其营养价值。一般情况下,营养价
值可以从能量、氨基酸组成、脂质含量、碳水化合物、
维生素和矿物质几个方面来衡量。很久以前从这些
作物初次种植和消费到现在,在没有任何科学方法
测量其营养价值的情况下,作物通过育种与栽培已
经发生了很大的改变。在过去的100年里,我们已
经知道怎样去测量营养物质的组分,并且在很多情
况下知道什么样的饮食是“健康”和“营养”的。通常
就是食物多样化。尽管我们知道所有的信息,但我
们不会详细地测量每一批制成麦片或面包的作物的
所有组分,因为这样的花费是巨大的,同时,我们也
知道麦片和面包在安全和营养方面都是合格的。我
们已经知道了每种主要粮食作物的基本组成成分,
并且有农业营养学测试的典型数据以确保这些农业
上重要的物种可以做出最佳的饮食。每一种作物的
特定组分也已经进行过评估,营养学家也划定了可
以接受用作动物饲料的范围。
4.12 关键营养物质和抗营养因子
转基因宿主植物的关键营养物质和抗营养因子
都需要进行检测,并与非转基因品种或同等用途的
品系进行比较,期望转基因的关键营养物质不超过
遗传背景相似的非转基因品种的合理范围[84-85]。在
测定许多组分时,使用不同的统计学方法,会得到不
同的统计学显著性。统计上的差异不能作为评判转
基因作物不安全的标准,应该有一个基于科学的基
础理论来评判产品潜在危害性。为了给特定粮食作
物的组分性状提供指导,必须找到相同作物的不同
品种最近的历史数据或者在多次田间试验的临近小
区种植大量的商业化的品种。
动物营养学家知道选择不同的组分进行检测对
于油菜、玉米、棉花、马铃薯、大豆和小麦是非常重要
的。并不是所有的组分都需要进行检测,因为有些
组分的测定对于这些作物的典型用途是无关紧要
89
 第6期 RichardE.Goodman:生物安全:美国转基因作物的评价与管理  
的。然而一些转基因生物监管机构和建议者期望研
发者会检测转基因生物的每一个可能的组分,并将
其与最近缘的品种进行比较。如果有显著性差异,
一些人就认为这是由于DNA插入造成的并且该食
品是不安全的。我们还了解到,具有相同遗传学背
景的植物生长在附近或相距100英里外时,由于微
环境的差异会导致多种组分上的差异。基因型和环
境互作可能导致重要农作物的某些组分的表达产生
显著性差异,它们之间的复杂性没有根据生物学相
关性进行充分的评估,一些科学家正在呼吁增加使
用各种组学来进行高精度的测量。幸运的是,即使
组分分析被认为是转基因作物安全性评估的重要组
成部分,在美国和大多数国家的监管机构都没有因
为组分上的微小差异而阻止批准转基因食品或饲料
作物,因为很明显,非转基因的产品在组分上具有的
显著性差异不会对食品和饲料的安全评价产生实质
影响。最近,两个不同的研究团队发现转基因植物
与近等基因系之间的成分差别主要是由于回交和常
规育种造成的,与基因的插入无关[86-87]。了解变异
的来源是一个需要考虑的重要方面,因为一些作者
认为使用蛋白质组学分析转基因植物,内源性致敏
原水平的潜在差异也许是由于插入造成的,因此要
求额外的测试[88]。
因此,我们需要进一步的定义需要检测的重要
组成成分和以及这些组分变异具有生物学相关性的
指导。为了给组分提供一些参考,在生物技术产业
的支持下,国际生命科学学会(ILSI)建成了作物组
分资料库[89],这个数据库包含了玉米、棉花和大豆
种子组分数据 (https://www.cropcomposition.
org/query/index.html)。版本5的数据量是之前
数据库的7倍,之前这个数据库只包含了1995-
2005年的几个特定栽培国家的数据。在日本建立
的一个数据库 (http://afdb.dc.affrc.go.jp/afdb/
index_e.asp)中,可以查到水稻和大豆的信息。在
日本数据库中,可以获得这2种作物部分品种和有
限年限的数据[90]。这些数据库提供了相关的方法
和不同物种组分范围的一些信息。有趣的是,饲料
行业对于商品作物的组分变化最为敏感,因为饲料
质量轻微的变化对主要动物生产商来说可能意味着
盈利或亏损。比如具有4000多家禽养殖场生产鸡
肉的泰森(美国)公司和美国的第二大家禽生产商柏
杜农场(美国),会检测饲料中不同作物的重要营养
组分含量。为了给禽类的生长和安全制定最佳的饲
料配方,他们对每次交货的大量商品作物进行随机
抽样并做大致测量分析,测量总蛋白、脂类、碳水化
合物、灰分、纤维,常常也会测量氨基酸组成和作物
特定的维生素、脂肪酸和矿物质。他们同样测量作
物特定的毒性和抗营养因子。家禽业对营养品质的
变化是最敏感的。除此之外,由于玉米是最易被污
染的作物,每一批玉米粒或干酒糟都要检查霉菌毒
素水平。一项转基因作物复合性状在肉仔鸡中的研
究,描述了饲料原料组分的评估并提供了真实的数
据,这可能和泰森或柏杜的分析类似[91]。优化鸡饲
料的主要组分和方法是在饲料准备的过程中进行评
估的,并不包含代谢、RNA转录或蛋白组学检测。
相反,他们关注的是那些有助于提高小鸡生长率的
组分(在这些研究中,从孵化开始的42d后体质量
增长了大约35倍)。饲料效率和体质量增加与营养
特性是高度相关的,这种相关性比任何其他动物都
要多。商业化生产的饲养场规模和动物数量通常是
非常巨大的。给鸡喂食的是脱脂大豆粉,因为大豆
中的脂肪酸和脂质组分对于鸡饲料来说不像哺乳动
物如奶牛那样重要的。大多数的奶牛场、牛肉、猪
肉、山羊和绵羊农场除了检测玉米中的霉菌毒素,不
会监控每天运来的饲料,只是在一年当中偶尔取样,
如果主要组分的营养价值发生变化就重新制定饲料
配方。在美国,提供给监管机构的研究中,将新的转
基因家系和近缘非转基因家系及3到5个其他商业
化非转基因家系进行比较,将这些不同的品种或家
系种植在多个地理位置以提供多样化的生长环境,
对品种中近似和特有的作物组分进行检测和对比。
有些国家,一般的转基因生物研发者必须进行多年
多个地理位置种植重复试验,向监管机构提供转基
因作物与非转基因作物具体成分的统计分析结果。
但这与安全性的相关性通常不明确。
除了营养物质,特定的作物也有其特定的抗营
养因子需要检测,包括凝集素、胰蛋白酶抑制剂、毒
素如龙葵素和高致敏性作物(如大豆)的致敏原等。
目前,多数抗营养因子已经有了普遍可接受的范围
(如龙葵素的可接受范围是每千克鲜质量200mg,
Friedman,2006),但还没有致敏原可接受的限制
范围[92]。
4.13 检测内源致敏原水平的潜在变化
如果基因受体(宿主)是常见的食物过敏源,美
国要求和欧盟推荐考虑转基因插入是否增加内源性
致敏原的表达或积累。监管机构认识到,来自不同
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过敏源的食物过敏风险是不同的。加工的食品要在
标签上真实地进行标注以降低致敏风险。美国和欧
盟的食品标签法规要求,主要过敏源来源的所有成
分必须标明。这份名单包括了美国8种常见的致敏
食物:鸡蛋、牛奶、花生、多种坚果、甲壳贝类、鱼类、
大 豆 和 小 麦 (http://www.fda.gov/food/re-
sourcesforyou/consumers/ucm079311.htm)。 此
外,在美国除非麦麸含量小于20μg/g,含有小麦、
大麦和黑麦麦麸成分的食品都必须在标签上标明。
在欧盟,除了这8种食品还添加了6种食品到清单
中:含麸质的谷物(小麦、黑麦、大麦、燕麦、斯佩耳特
小麦、卡姆小麦以及这些谷物的杂交种),芹菜(根)、
芥末籽、芝麻、扇羽豆和软体动物以及二氧化硫,其
相对未分离的成分必须标明其来源(如小麦、蛋、牛
奶)。在美国和欧盟,除非加工的成分是免于标识的
(如正己烷炼制的大豆油),通常引起过敏的食物来
源成分也必须予以标明。小麦来源的淀粉需要标示
为小麦源淀粉,而来自玉米、大米或木薯的淀粉则可
以简单地标注为加工淀粉,无需标明来源。因此,在
美国和欧盟,研发人员必须对转基因花生、大豆和小
麦的内源性致敏原潜在变化进行评估。由于菜豆、
玉米、水稻不是常见的过敏源,所以无需对它们进行
内源性致敏原潜在变化评估。用于评估的方法一般
与诊断致敏原产物的致敏原测量方法一致[93-94]。药
用级的致敏原抽提物期望显示出与免疫印记相似的
定性结合和总IgE结合的变异(50%~150%的抽提
物标准平均血清IgE结合)[93,95]。IgE结合使用混
合的过敏者的血清进行以比较一批致敏原提取物与
上一批提取物。利用SDS-PAGE分离大豆提取物
蛋白并与3位独立的大豆过敏者的血清进行 West-
ern杂交,对首个耐除草剂大豆(孟山都40-3-2事
件)进行IgE结合试验[96]。Sten等进行了更广泛非
监管要求的体外IgE结合研究[97],利用10位大豆
过敏试验者血清与转基因事件(40-3-2)来源的10
个品种和8种遗传背景相似的非转基因品种进行比
较。他们利用RAST抑制和噬碱性粒细胞释放组
胺,发现虽然个体之间与品系之间明显不同,但转基
因大豆和非转基因大豆之间没有显著差异。我的实
验室也选取3个不同公司来源的5个转基因大豆事
件进行血清IgE结合研究。我们用到的研究方法包
括直接IgE结合实验,混合大豆过敏血清的ELISA
抑制或独立血清的直接ELISA,除了一个或多个非
转基因家系之间存在显著性差异,没有发现任何显
著性差异[92,94]。在某些非转基因大豆间被发现存
在某些差异,因为在IgE定性免疫印迹实验中缺少
或者多了1条IgE结合的带。由于EFSA[51]和欧
盟[52]的规定,除了这些评估致敏原丰度潜在变化的
标准方法以外,还需要利用2D免疫印迹的方法分
离单独个体的血清蛋白,并将每个转基因的与非转
基因蛋白家系相比较。一些个体的血清IgE结合位
点存在不同之处,但在转基因家系中没有表现出差
异[92,94]。显然,在类似的研究中,过敏个体之间的
差异会对结果产生影响。除非多个大型过敏中心参
与,在一项研究中寻找好几个(10个?)特异性的过
敏者是不切实际的。不同过敏者蛋白质和同工异型
体与IgE的结合总是存在一些不确定性。然而,对
于EFSA建议使用蛋白质组学(LC-MSMS)来评价
大豆和其他常见致敏粮食作物的各个“致敏原”的丰
度不像血清测试一样有效,因为EFSA希望使用的
“致敏原”列表[例如,在 OECD的大豆组分列表中
的致敏蛋白,包括致敏性证据很少或没有证据(甘氨
酸 m1、甘氨酸m2、甘氨酸m3(抑丝蛋白)、P34甘
氨酸 mBd30K、未知的天冬酰胺残基连接的糖蛋
白、凝集素、脂肪氧化酶、Kunitze胰蛋白酶抑制剂、
未知的39和50ku的蛋白质和P22-25]。已经确定
的大豆中重要的致敏原有甘氨酸 m5(β-伴大豆球蛋
白α-,α’-,和β-)、甘氨酸 m6(5-大豆球蛋白)和可
能的甘氨酸 m4,也被称为SAM22。由于对选择的
蛋白没有进行风险分级,且事实上有些致敏源没有
发表的证据或某些情况下蛋白序列没有确定,所以
EFSA 的 建 议 不 是 基 于 风 险 证 据 的。另 外,
LC-MSMS不能100%覆盖很多蛋白,因此也不太可
能鉴别出共同异型体,这些蛋白中的一些可能不与
IgE结合。血清IgE结合实验至少可以应用过敏个
体来源的血清比较转基因作物和非转基因作物品种
的生物学测量(IgE结合)结果。
但考虑这些对内源性致敏原的测量与安全性是
否有相关性是非常重要的。如果有差异,是否会导
致过敏的风险增加? 对大豆过敏的人应该避免食用
任何大豆。对大豆不过敏的人则想吃多少就可以吃
多少。在加工食品中,不同产品的总大豆蛋白含量
差异非常大,食品公司不会选择太多特殊的大豆品
种。相反,他们会大批量购进,并在料仓、运输、制粉
和加工、食品制造过程中将大豆混合。
有一个很重要的问题没有任何科学研究或监管
机构可以回答。什么程度的改变会导致内源性致敏
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原的累积,从而对敏感的、处于高风险、对特殊食物
过敏人群的健康产生负面影响。一个可能有用的评
估是,经过很好训练的临床过敏专科医师应用间隔
性剂量提高做双盲的、有安慰剂作对照的食物测试
(DBPCFC)。有一些发表的文献,描述了用已建立
剂量阈值的各种致敏原测试高风险患者的方法。
Crevel等人发表的一篇研究综述[98]中报道了对花
生过敏试验者增加3到10倍的花生测试剂量的实
验方法。在EuroPreval的DBPCFC研究中设计的
实验,首先使用3μg过敏源蛋白和增加10倍至30
mg蛋白,随后当用量超过30mg后只增加3倍的
用量,因为超过30mg的用量后感觉严重过敏反应
的风险会增加[99]。因此,在实验设计时用量至少要
成3倍地增加。如果世界级的临床过敏专科医师认
为使用3倍到10倍剂量没有问题的话,使用比这个
水平低的剂量就没有问题。
4.14 对潜在新的非预期蛋白的评价
在描述研究每一个转基因事件时,都需要对插
入的 DNA 进行分析,以确认插入序列以及侧翼
DNA序列。通常除了插入序列还要鉴定数百到一
千不等的碱基数。分析插入的序列是为了确保蛋白
被正确表达。如果发生非预期的改变,那就应该对
新蛋白的功能进行评估并利用生物信息学方法对新
蛋白质的过敏性和毒性风险进行评价。侧翼DNA
被评价以确定是否可能有新的融合蛋白在植物中表
达。DNA序列中所有的6个阅读框都将利用计算
机算法进行评估以识别潜在的开放阅读框。一些监
管者只要求符合从起始密码子(甲硫氨酸)到终止密
码子确定的潜在开放阅读框(ORF),而另外一些监
管者则要求所有假设的即从终止密码到终止密码的
开放阅读框。随后利用生物信息学对这些潜在的开
放阅读框进行评估分析,搜索匹配的致敏原和毒素
蛋白。最关键的部分在于融合位点。插入片段两端
的植物DNA是已经存在的,如果它编码致敏原或
毒素,则是已有的内源性风险。安全性评价主要关
注新的潜在危害和风险。如果与致敏原和毒素匹
配,则需进一步分析评价是否有以及哪个组织从该
DNA区域转录了 RNA。如果存在这种特定的
RNA,那么需要使用LC-MSMS或由该开放阅读框
编码的合成肽产生抗体来检测是否翻译出产物(蛋
白)。如果蛋白质水平可以忽略不计的,则风险
很小。
一些监管者要求更长的侧翼序列,直到清楚地
知道转基因没有打断内源植物基因的编码序列或间
隔序列(内含子)。通过地域重复的田间试验来评价
植物的农艺性状可以帮助识别转基因与非转基因品
种之间的各种生物学显著差异。这种类型的评估是
针对植物性状的,而不是安全性。美国的监管机构
非常注重收集食品和饲料类产品安全性的相关信
息,因此转基因的研发者和相关的种子公司必须向
农民们提供数据让他们相信转基因作物在产量和总
组分上有足够的产出,否则农民们不会购买他们的
种子。
4.15 对非预期效应评价的结论
组分分析的结论通常是指特定作物的总营养物
质和抗营养因子是否大体上和非转基因作物实质等
同。这些分析通常是通过转基因和非转基因品种在
真实的田间条件下进行不同地域重复的田间试验。
当然,在测量不同地区众多样本的各种组分时往往
会导致一些统计上的显著差异。大部分的变化是由
于整个植物基因组的实际遗传差异,回交及各种育
种方法对转基因插入没有影响[82-83]。此外,最近的
研究发现DNA甲基化模式可以遗传并且改变基因
的表达而不引起任何DNA的变化,这个发现帮我
们认识到我们不能期望控制或者了解DNA序列信
息上每一个可以测量的差异[100]。更重要的是,我
们知道并不是每一个可测量的差异都会对消费者构
成风险,事实上只有很小的一部分会。人类在几百
到几千年前选择并改良了大多数驯化的作物。我们
知道遗传多样性使得可以在各种环境条件下都能种
植同一物种,来生产食物和饲料。
在美国,对转基因事件和遗传背景相近的作物
(近等系或亲本品种)以及同一田间试验的商业种植
品种或者实际生产采集的样品的最近记录数据等来
源的不同测量数据进行比较。如果转基因作物的测
量结果落入偏差范围基准之内,那么这个转基因作
物和遗传背景相近的品种之间的差异就被认为是可
接受的。转基因作物因此也被认为在实质上等同于
这一作物的其他品种。同样的推论也适用于通过饲
喂实验测量动物反应所获得的数据,如一些监管者
要求的90d老鼠喂养试验;42d肉鸡研究或者大型
动物喂饲试验在许多国家是行业接受的研究,但一
些监管者也对其有要求(如印度)。
4.16 转基因生物审批现状
有多少转基因作物已经得到研发并且获得监管
部门的批准允许作为食品和饲料进行种植? 目前为
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止仍很难找到准确的信息。环境风险评估中心
(CERA)转基因作物数据库 www.cera-gmc.org/
GmCropDatabase中列举了总共153个作物事件,
但并不是所有的这些都是通过转基因技术完成的,
其中有一部分是通过突变或者传统育种的手段研发
的。此外,并不是所有作物在任何地方都被批准种
植,而且其中一些被批准了但没有被使用。国际农
业生物技术应用服务组织(ISAAA)还建立了一个
转基因作物数据库(www.isaaa.org/gmapprov-
aldatabase),其中列出了353个事件。通过快速查
询,ISAAA似乎有一些没有被CERA列出的作物
类型,包括豆类(菜豆)、茄子、杨树、甘蔗和胡椒,这
些还没有提交给美国或者加拿大的监管机构。很可
能每个这样的数据库会遗漏一些转基因事件,但不
太可能遗漏目前全球交易的转基因作物。另外美国
的3个监管机构都有各自独立的显示他们针对个别
转基因事件动态的数据库。USDA 的网址是:ht-
tp://www.aphis.usda.gov/biotechnology/peti-
tions_table_pending.shtml。FDA 的网址是:ht-
tp://www.accessdata.fda.gov/scripts/fdcc/? set
=Biocon。EPA的网址是:http://www.epa.gov/
oppbppd1/biopesticides/pips/pip_list.htm。
尽管许多不同特性的转基因事件被批准使用,
但是大多数的事件存在于少数大宗商品作物中比如
油菜、棉花、玉米和大豆等。通过在美国测量种植转
基因作物面积的百分比可以看出转基因作物的采用
率增长非常迅速,从1994年的零增长到了2014年
的大豆和玉米超过90%。在美国棉花产量中很大
一部分来自转基因作物,而在印度95%的棉花以及
中国90%的棉花是转基因棉花。现在许多来自不
同研发者的转基因作物都有相似的功能,比如对除
草剂的耐受性和特定的抗虫性。与此同时,许多以
前批准的转基因作物(1994年之前)已经从市场上
消失了。一些产品被撤销是由于受到了消费者和公
司方面的压力,比如孟山都公司研发的抗病毒、抗马
铃薯甲虫的转基因马铃薯。由于在马铃薯市场占据
主导地位的是炸薯条和快餐店,他们对于消费者的
偏好非常敏感。这些产品可以大幅度地减少马铃薯
杀虫剂的使用,由于来自快餐行业的压力于2002年
退出市场。孟山都公司向美国和加拿大提交了耐除
草剂小麦的申请,但在未获审批前就撤销了。这是
因为来自加拿大小麦协会的压力,他们担心这些小
麦出口亚洲会有贸易障碍。延熟番茄没有被商业化
应用就退出了(有4个公司包括捷利康和孟山都公
司的获批转基因事件),因为鲜食的质量没有非转基
因的品种好。陶氏益农公司开发的抗病毒瓠瓜仍然
在市场上,但是已转让给圣尼斯公司。抗病毒的木
瓜由康奈尔大学的研究者研发,目前批准在美国使
用,因为夏威夷的木瓜树受环斑病毒危害严重。转
基因载体可以阻止病毒复制,引入这个性状拯救了
夏威夷的木瓜产业。
4.17 小 结
一些专家预测会有严峻的全球粮食危机,而另
一些专家认为是由部分地区的干旱、疾病、人为政策
或者经济问题而引发持续性的区域化危机[101-102]。
生物技术及现在和将来的转基因作物可以作为改善
全球可持续农业的部分解决方案。但其进展受到过
于专注且有资金支持的少数非政府组织和知名人士
的压制,虽然这些知名人士并没有很好地理解农业、
粮食生产、饥饿和成本问题,却依然激起了民众的疑
虑。在这场争论中我们能找到共同点吗? 少数食品
生产、农业和人类健康的学生可能否认,虽然在过去
的一个世纪生产效率显著增加,但世界日益增长的
全球人口将超过长期维持粮食生产的能力[103]。然
而,目前我们提高生产的能力是通过使用开采的矿
质作为肥料,在耕作中增加化石燃料的使用,用机器
代替人力劳动,和在劳动密集的区域使用牲畜而实
现的。那我们可以保持目前的扩张速度吗? 通过美
国农业系统的经验,可以为中国及其他亚洲国家利
用转基因作物的益处并对建立新开发产品的食品安
全标准,提供有用的参考实例。
考虑到美国在安全评价过程及转基因作物法规
方面的经验,有必要看一下全球粮食供应的性质、各
种食品安全监管机构的担忧以及各种粮食作物的悠
久种植历史。没有一个国家是自给自足的,任何一
个国家大多数食用的食物都起源于其他国家,或者
在一定程度上依赖其他国家的输入。我们今天食用
的小麦、大米、马铃薯、番茄、辣椒及各种豆类和特定
的动物,都是由自然出现的原始生物从不同的地理
区域进化而来,而不是像现在这样生产出来的,并通
过数百年甚至数千年的育种过程筛选和改良。这些
食物是基于食物的实用性(营养和抗营养)、易于生
产和食用安全等特性而选择出来的。当然也存在人
们对食物过敏及乳糜泻的风险。对某些人也有烹饪
或储存不当导致没有抑制微生物和腐败和灭活抗营
养因子的风险。而新蛋白质的主要潜在风险通过当
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前法典的评价框架是相对容易避免的。
还有一些不确定性使美国的监管机构仍然不能
理解。首先,如果蛋白质对胃蛋白酶测试是稳定的,
那这个蛋白质可能使人们对其变得敏感而成为致敏
原。低丰度的稳定蛋白质有低风险,但应该找到一
个可以接受的标准。我们还需要继续努力以一个更
好的方式来预测致敏原。当前计算机程序预测建议
的抗原性远不完美,并且会有过度预测的风险。到
目前为止,动物模型没能很好地提供有效精准的预
测。基于人体抗原呈递细胞为基础的细胞检测,T
细胞和B细胞没有显示出精准的预测。在当前法
典指南和美国的评价过程没有显示安全结果的一些
困难蛋白,需要额外的研究。但现在转基因产品很
容易通过生物信息学避免过敏、乳糜泻和毒性的问
题。在一些情况下,血清IgE检测或者简单、预测性
的毒性测试也是必要的。
食品标识是一个全世界的主要问题。一些国家
像中国一样要求含有转基因成分的食物进行标识。
在美国一些州,标识制度已经通过了法律(可能在不
久的将来生效),还有一些州将在2014年11月就标
识问题进行投票。食品生产经济上和实际上的障碍
使得标识制度难以执行。作物种植和交易跨越州界
和国界,食品公司的产品通常销往50个州甚至出
口。有个别的材料可能含有转基因成分,但是不同
批次的情况不同。例如,图2显示了在美国生产的
黑色素食豆类汉堡的标识成分。来自大豆、玉米、油
菜、棉花的组分都可能是转基因的。CERA转基因
作物数据库(http://cera-gmc.org/index.php/GM-
CropDatabase)列出12种被批准的转基因大豆,代
表了8种转基因蛋白,57种被批准的玉米代表至少
15种不同的蛋白。如果这些法律通过,并且商品、
原料和最终食品的供应商不想被贴上“转基因食品”
标签的话,他们必须控制和检测所有的这些材料。
这样将增加费用,并且对安全性没有益处。对于食
品,那些已经杂乱的标签信息,使得关键的安全信息
如致敏原成分都丢失了。
 IngredientsthatmaycontainacurrentlyapprovedGMOarelistedinboldandunderlined.ThoseingredientsmaybesubjecttoGMOla-
belinglawsifmandatorylabelinglawsarepassed.TheAlergeninformationisasafetylabelasitshowsmajorelergenicingredientsthat
havetobeavoidedbysomeconsumerswithspecificfoodalergiessotheywouldknowtoavoidthisproductforsafetyreasonsiftheyare
alergictosoybean,wheat,eggsormili.
图2 2014年美国生产的商业黑豆汉堡的成分标签
Fig.2 IngredientlabelofacommercialblackbeanburgerproducedintheUSin2014
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  人类消费的食物在组成和营养品质上极其多样
化,这本来就有危险。我们是杂食动物,我们的祖先
适应了不同的气候和条件,遍及大陆各处,从迁徙的
狩猎者到游牧民族,最后成为相对稳定的农耕
者[104-106]。从人类的可以合作和接受由于帮助他人
生存(而不仅仅是保护自己的家庭)而增加成本的能
力来看,这种适应似乎已经变为可能。但这种适应
有时对直系亲属没有益处,但对社会是有益的[106]。
在后工业时代,人类个体已经变得高度机动。然而,
由于种种原因,在每个社会维持人口所需的基本食
品生产基础设施变化缓慢,这些原因中包括设备投
资巨大、商品及食品加工设备的复杂性、用于生产的
植物及动物基因资源的限制。但是适应发生了,生
产效率也增加了,尤其是在20世纪。随着人口远离
粮食作物生产而集中在城市,可用耕地增加了[107]。
世界人口现在估计超过72.5亿,总生物量超过了所
有其他的陆地脊椎动物生物量的总和,我们需要认
真考虑如何改善食物和饲料生产。人类花了数百或
数千年才学会如何管理和接受许多食品生产的新方
法。在过去的100年里,食品生产已经明显地转变
为工业化的方式,来适应食品的需求。一些人试图
阻止新技术,限制将新改良引入粮食作物的工具,因
为他们声称这将生产出不安全的食品。但是当我寻
找转基因危害的证据时,发现并不存在。
现在我们生产及消费的植物食品没有一个是完
全自然的。虽然从遗传学上讲它们与一些本土植物
非常相似,但谷物(小麦、大麦、黑麦、水稻、玉米、高
粱)已经被选育了数百年。番茄、马铃薯、茄子、辣椒
的许多品种经过不同的烹饪过程后食用是安全的。
但它们与其他茄科包括有毒的茄属植物如不能食用
的烟草及矮牵牛关系密切。可食用的茄属植物同属
一种的野生近缘种中产生足够水平的配糖生物碱
(茄碱、番茄苷及其他)和凝集素,如果食用则会对人
及家畜相当有害。我们仅能食用这些作物中的当前
这些品种,因为我们的祖先经过育种和筛选,这些植
物的可食用部分含有低水平毒素和抗营养因子。他
们完成这些工作,并没有我们今天使用的复杂科学
测试和仪器来检测引起伤害的特定物质,也没有标
准化的动物喂饲试验。虽然我们是杂食动物,可以
食用不同的植物和动物,但我们必须知道我们能够
食用的限制是什么。我们今天吃的马铃薯是安全
的,但我们已经了解到一些野生近缘种能产生足够
高浓度的茄碱、番茄苷和其他配糖生物碱,足以引起
危害甚至死亡。
超越历史的角度来看,同样重要的是要记住,我
们生活在一个频繁且无意识影响错误信息传播急剧
增加的时代。许多人声称各种食物中真实或者潜在
的危害是几个世纪或者几十年前根本没有引起注意
的,但引发恐惧的往往是假设的危险。然而即时通
讯和互联网使时间变短。16世纪,当欧洲探险家把
番茄和马铃薯从南美带入意大利和英国,他们在南
美被引入并且种植和安全食用了1000多年。但是
欧洲人没有足够的知识种植和安全食用这些植物。
一些人由于不正确的食物烹饪,或者食用植物的绿
色部分而生病,生病之后,人们认为整个植物包括果
实和块茎都是有毒的。南美洲的原住民知道避免食
用绿色的植物材料。在欧洲的这些极少数的食物中
毒事件导致了人们广泛的恐惧,拒绝现在这些主粮
进入人们的餐桌。现在关于转基因的虚假报道俯拾
皆是,并产生持久的影响。最近奥兹博士、杰弗里·
史密斯、奥普拉·温弗瑞和崔永元声称转基因作物
不安全或未经检验,导致消费者对声称转基因作物
安全的生物技术公司和政府产生怀疑。然而这些媒
体名人并没有阅读文献或者美国监管部门为确保像
MON810(抗欧洲玉米螟)这样的产品是安全的而开
展的安全性研究。当那些“可信的”知名人士告诉消
费者政府是多么的腐败,像孟山都这样的大型生物
公司并没有做足够的测试和安全评价工作时,我们
该怎样向消费者陈述事实呢?
5 结 论
美国监管机构评价转基因作物安全性涉及3个
联邦机构:USDA、FDA和EPA。这个评价程序始
于20世纪80年代末和20世纪90年代初,由学者、
企业科学家、政府监管的科学家及政策制定者磋商
而来。在20世纪末到2003年,通过与食品法典委
员会关于转基因作物安全评价指南相结合而得到完
善。对转基因作物来源食物中潜在的过敏性风险的
评价须使用科学上可以接受的方法进行。这对于鉴
定可能出现食物过敏风险的蛋白很有效。这个蛋白
可能是一个经转移的已知的致敏原或是一个交叉反
应的蛋白。但仍然有一点不确定:如何预测一个没
有明显风险的新蛋白是否会导致新的过敏呢? 不
过,如果这个蛋白在胃蛋白酶体外测试中会被迅速
降解,或者该蛋白在食品中的含量比较低,这种风险
是比较低的。与非转基因品种相比,转基因植物显
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著提高内源致敏原表达水平的可能性是相当低的,
但对于原本就要避免食用寄主植物的那些消费者存
在风险。因此,即使内源致敏原含量增加了,其风险
也没有实质性地增加。基于非转基因生物确立的食
物毒性评价原则可用于转基因生物。少数蛋白是有
毒的,将转基因的蛋白序列与已知有毒蛋白的序列
比对,同时评价基因来源及该蛋白的作用机制,将鉴
定出高风险的蛋白。美国已经评价并批准了大约
100种转基因新事件或新品种的商业化。目前还没
有关于人或动物因食用转基因植物可食用部分而中
毒的记录。然而监管过程花费昂贵并且消耗时间。
粮食作物的交易是国际化的,但遗憾的是,目前没有
一个标准的、各个国家都可以接受的安全评价程序
来避免重复研究。
致谢 感谢美国科学院和中国科学院,为我参加在
武汉召开的讨论安全评价的联席会议提供资金支
持。我的实验室也很幸运得到EPA关于转基因作
物致敏性评价改进的3个研究的经费支持。如同盖
茨基金会通过丹弗斯植物科学中心,美国农业部
FASBorlaug计划资助我们就转基因作物致敏性评
价培训了大批国际学者。我不但有幸能够帮助非
洲、澳大利亚、印度和美国一些科学家,评价大量重
要转基因产品潜在的致敏性和毒性,而且受到8个
农业生物公司提供资金来维护 AlergenOnline数
据库,并对转基因大豆内源性致敏原的潜在变化进
行研究。最后,能和一群有天赋且工作努力的研究
生、技术人员以及过敏方面的专家工作,并探讨数据
库和其他致敏原的问题是非常美妙的。
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Abstract Thisreviewofthesafetyassessmentofgeneticalymodified(GM)cropsisfocusedpri-
marilyontheprocessandprogressintheUnitedStates(US).Itreviewsthedevelopmentofthesafety
evaluationprocessfromtheAsilomarconferencein1975consideringissuesrelevanttorecombinantDNA
technology,todiscussionsbetweentheUSgovernment,academicandindustrialscientistsbetween1984
and1994whenthefirstGMcropswerebeingfieldtestedandevaluatedcommercialreleaseforfoodand
feedproduction.InternationalguidelineswerealsoreviewedforconsistencywiththeUSsystem.Theo-
veralprocessincludesconsiderationofinformationrelatingtohistoryofsafeorunsafehumanandexpo-
suretothegenesourceandexpressedproteins.Theprimaryconsiderationsofsafetyfordietaryproteins
arewhetherornotsomeconsumersaresensitizedandhaveIgEantibodiesagainsttheproteinencodedby
thetransgeneorwhetherthetransgenerepresentsariskofelicitingceliacdisease.Theprocessconsiders
potentialtoxiceffectsofexpressedproteinsaswelaspotentialimpactsonhumanandanimalnutrition.
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basedprocessbasedonjustifiablehypotheses.TodatethereisnoevidencethatGMcropsapprovedin
theUShaveharmedhumanoranimalconsumers.Theevaluationtakesintoaccountgeneticandenviron-
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Abstract  This review of the safety assessment of genetically modified (GM) crops is focused primarily on the 
process and progress in the United States (US).  It reviews the development of the safety evaluation process from the 
Asilomar conference in 1975 considering issues relevant to recombinant DNA technology, to discussions between the 
US government, academic and industrial scientists between 1984 and 1994 when the first GM crops were being field 
tested and evaluated commercial release for food and feed production.   International guidelines were also reviewed 
for consistency with the US system.  The overall process includes consideration of information relating to history of 
safe or unsafe human and exposure to the gene source and expressed proteins.  The primary considerations of safety for 
dietary proteins are whether or not some consumers are sensitized and have IgE antibodies against the protein encoded 
by the transgene or whether the transgene represents a risk of eliciting celiac disease.  The process considers potential 
toxic effects of expressed proteins as well as potential impacts on human and animal nutrition.  The process in the US is 
consistent with Codex Alimentarius recommendations. It follows a science based process based on justifiable hypotheses. 
To date there is no evidence that GM crops approved in the US have harmed human or animal consumers. The evaluation 
takes into account genetic and environmental variation in products produced by plant varieties and is intended to maintain 
the standard that foods developed from GM plants are intended to be as safe as non-GM genetically similar varieties.
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1  Introduction
The safety of foods produced from genetically modified 
(GM) organisms, GMOs or GM crops is mandated 
by most countries including the US, China and 
countries who are members of the Codex Alimentarius 
Commission, an international food standards program 
within the World Health Organization and the Food 
and Agricultural Organization of the United Nations 
(www.codexalimentarius.org). The Codex includes 185 
member countries plus the European Union (EU) and 
has 224 official observers (non-member countries plus 
non-governmental organizations (NGOs) and outlines 
guidelines for many important questions regarding food 
safety and international trade.
The overall process of evaluating the safety of foods 
produced from GMOs has been described in only a 
few documents.  The primary food safety guidance for 
developers and regulators of GMOs is the combined 
documents of the Codex Alimentarius Commission, 
Second edition, “Foods Derived from Modern 
Biotechnology”[1]. The principles are outlined in the 
first chapter (CAC/GL 44-2003) and include definitions 
of organisms derived from “Modern biotechnology”, 
or genetic modification and the risk assessment 
process that is intended to identify any new hazard 
or nutritional or safety concern presented by the new 
GM organism as well as risk management procedures 
if appropriate. Three major sections follow that are 
intended to define processes to evaluate the safety and 
nutritional properties of GM plants, GM animals and 
GM microbes.  The assessment strategies are quite 
similar for all three. The food allergy assessment is 
outlined as a separate annex at the end of the chapters. 
Evaluation of potential risks of toxicity, celiac disease 
and nutritional equivalence are discussed in the section 
on substantial equivalence toward the front of each of 
the documents. The Codex[1] document is a guideline 
for individual countries that have to develop their own 
regulations.  The intent of Codex is the signatory parties 
should develop regulations that are consistent with 
these guidelines unless differences are scientifically 
justified.  Since the documents were written from 2001-
2003, there have been some advances in the science 
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and those will be discussed along with commonalities. 
Newer evaluation steps will be discussed here.  This 
paper will focus primarily on the assessment as 
performed in the US.  However a review of some of 
the concerns and criticisms of people and organizations 
who opposed GMOs will also be discussed as it is 
important to understand whether there are legitimate 
safety issues that are not being addressed by regulatory 
bodies and developers.
The safety of foods derived from GMOs is a focus 
of some NGOs including Greenpeace, Friends of 
the Earth, Union of Concerned Scientists as well as 
personalities on popular television and the internet 
in the United States (US), European Union (EU) 
and China.  We must recognize that it is natural for 
consumers to be concerned about food safety, especially 
regarding new foods or technologies that many 
individuals do not fully understand.  Most consumers 
do not understand the scientific basis of allergens 
and allergies, toxins, nutrients and anti-nutrients in 
foods.  Most consumers also do not understand the 
importance of genetic diversity in food crops to enable 
production in diverse environmental conditions[2]. 
Many consumers believe that all soybeans are identical 
unless they have been modified by genetic engineering. 
Scientists in other disciplines also do not understand 
the tremendous variation and complexity in the normal 
composition of proteins, oils, carbohydrates and 
metabolites of all food crops.  A major focus of plant 
breeders is to introduce variation and if we consider 
the principles of genetic engineering and look closely 
at the changes, it is clear biotechnology introduces 
minimal uncertainty compared to the natural or induced 
mutations that breeders have relied upon to develop 
useful new varieties[2].  Can we explain realistic risks 
to consumers and also explain how the current safety 
assessment process minimizes risk? 
An important concern that is often voiced by the 
opponents of GM crops and of the pharmaceutical 
industry is that the companies developing the products 
are the ones who test for safety. That concern seems 
reasonable, but needs to be considered in the context 
the entire legal framework, governmental and economic 
structure of each country. Scientists in the government 
of the US and many other countries do not perform 
safety testing for most products.  It is worth noting 
that no government in the world has enough scientists 
with the right expertise or enough money to perform 
the appropriate safety tests for all potential products 
in a reasonable amount of time. Development of many 
important products would stop if developers had to wait 
for safety testing by their governments.  The regulatory 
systems established by most, including the US is to 
have a number of quality scientists in the regulatory 
departments who can review safety data critically and 
make decisions based on protocols and guidelines. 
Governments like the US have legal mechanisms for 
consultations with academic experts to assist in the 
evaluations.  The regulators also should have the ability 
to efficiently communicate with developers to ask for 
additional data or tell them what additional tests or 
questions must be answered to gain approvals. 
I am most familiar with Monsanto as a major GM 
crop developer.  They have approximately 600 college 
educated (BS, MS and PhD) individuals working 
in the regulatory division of the company. These 
scientists plan and conduct safety and environmental 
studies, archive and characterize test substances 
(plants, seeds, DNA constructs and proteins), perform 
tests, analyze data and write reports for submission 
to regulatory agencies. They have to grow plants 
in different environments and sometimes multiple 
countries in order to perform field and environmental 
tests. The regulatory process is extremely complex 
even for one product and development and regulatory 
approvals for each product often takes ten to fourteen 
years.  Companies like Monsanto also have separate 
quality assurance units (QAU) that report to a different 
management team from the development and sales 
divisions.  The QAU reviews protocols prior to study 
conduct and audit data and reports before they are 
submitted to regulators to ensure study adequacy and 
accuracy. Their scientists evaluate mountains of data 
and develop the dossiers that are submitted to multiple 
governments before a product is allowed to be grown 
commercially. Most will gain approvals in major 
trading countries (Australia, Canada, China, Japan, 
Korea, the US and Taiwan) before releasing seeds of 
a new GM product to farmers. International trade of 
commodities and foods and feed will only work if 
the developer is managing materials and data as they 
have the capacity and incentive to ensure timely and 
coordinated processes.  In some cases regulatory studies 
are performed by contract laboratories, especially 
toxicology studies as there are regulations that are 
very strict that require specific tests to be performed 
following “Good Laboratory Practices” (GLP) as 
defined by the Environmental Protection Agency 
(EPA) of the US government. Few developers have 
the infrastructure to meet all GLP requirements.  The 
toxicology contract companies specialize in meeting 
regulatory demands. Those studies can be audited by 
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EPA.  There are strict rules about record keeping, ethics 
and integrity of data.  It might be important to consider 
that if the government were to perform those studies, 
who would audit them and hold them accountable?  
Some s tud ies  a re  pe r fo rmed  by  academic 
laboratories because neither the developer nor any 
contract GLP laboratory has the right expertise to 
perform the study.  My laboratory at the University 
of Nebraska has performed a number of allergenicity 
studies (human serum IgE binding and bioinformatics 
studies) for biotech companies and non-profit 
agricultural organizations as well as food companies 
developing novel ingredients.  We have collaborations 
with clinicians who arrange samples from specifically 
allergic patients who are willing to contribute serum 
samples to evaluate product safety.  We develop 
protocols, perform the studies, evaluate data, write 
reports and maintain records related to the studies.  We 
do those studies under contract with the developers 
under ethical standards managed by the University 
of Nebraska as well as ethical standards of any 
collaborator’s institution.   
I have been involved in designing, performing or 
reviewing safety studies on allergenicity, toxicology 
and nutritional qualities and performance of GM 
crops and novel food ingredients for 17 years.  I 
was at the Codex Alimentarius Task Force Working 
Group meeting that was held in Vancouver Canada in 
2001 that developed the allergenicity guideline[1].  I 
have been involved in safety studies and reviewing 
procedures for GMO safety for submission to 
governments of the US, Canada, Argentina, Brazil, 
the EU, India, South Korea and Taiwan and reviewed 
hundreds of publications on allergenicity, toxicity 
and potential horizontal gene transfer.  In my career I 
have not seen any documented cases of adverse health 
problems in humans or agricultural animals caused by 
consuming approved GM crops and I believe that the 
safety assessment of GMOs is quite robust[2-3]. 
Of course I had to go through a learning process 
to gain an understanding and comfort level with the 
assessment process for GMOs because I am a born 
skeptic.  My scientific career began during the early 
years of development of agricultural biotechnology. 
This paper reviews some of the history of development 
of the safety assessment and regulation of GM crops 
in the US.  It includes the primary proven food 
safety hazards and risks and describes the process of 
evaluating safety of new GM crops prior to commercial 
release.  It includes a description of the most significant 
case of a GM product that was approved and then 
withdrawn from the market because of uncertainties of 
safety data, not because of harm.
1.1  Real risks of foods vs. hypothetical risks
Many of the foods we eat today were initially 
consumed hundreds to thousands of years ago.  The 
genes and exact nutritional composition of many crops 
have been changed from the earliest varieties using 
conventional breeding techniques.  However, to a great 
extent commodity crops including wheat, rice, corn and 
soybeans as well as many of the fruits and vegetables 
are quite similar to the food materials humans have 
consumed safely from these plants for centuries.  The 
experiences of using those crops have guided regulators 
in establishing a safety evaluation process that begins 
with considering whether humans have had experience 
and contact or consumption of the host plant (the gene 
recipient) and the donor organism (source of the gene 
to be transferred). 
In the mid-1970s as I was earning a bachelor’s 
degree in biology I  was an active member of 
Greenpeace, Friends of the Earth and Union of 
Concerned Scientists.  Details of techniques of 
recombinant DNA methods were first being described 
in college classrooms as we learned about potentially 
useful recombinant bacteria and plants that might come 
from the technology.  At that time most students and 
many professors had a very superficial understanding of 
DNA, RNA, ribosomes and protein synthesis compared 
to our knowledge in the 1990s and certainly compared 
to information available even in high school classes 
in 2014.  In the early 1970s Paul Berg, Walter Gilbert 
and Frederick Sanger (all future Nobel Laureates in 
chemistry) began discussing potential (hypothetical) 
risks that recombinant organisms might pose if certain 
viral DNA sequences from pathogens were introduced 
into bacteria using this technology.  Maxine Singer 
and others called on the community of scientists to 
develop safety standards. Much of the concern was 
on the proposed use of the simian virus 40 (SV40) 
DNA elements in recombinant bacterial plasmids that 
were being transferred in culture into monkey cells to 
understand gene function as described by Cole et al[4]. 
In response Berg and others organized the Asilomar 
Conference in 1975 at the urging of the National 
Academy of Science (US) to establish guidelines 
for ensuring safety. The process and twenty years of 
experience of safety of recombinant DNA work since 
then were reviewed by Berg and Singer[5].  Essentially 
all recombinant DNA work was halted in the US for 
one year while the guidelines were developed.  They 
detailed considerations based on perceived risks and 
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called for the establishment of institutional biosafety 
committees to review each new rDNA experiment 
in any institution or company that was performing 
genetic engineering research.  The primary focus was 
the potential risk or safety of the new DNA elements 
based on mode of action and risk of the DNA donor 
organism.  The guidelines have helped ensure that 
really hazardous organisms were not created using the 
technology.  Relatively safe cloning experiments can 
be performed in a typical clean laboratory environment 
with few restrictions (Biosafety level 1 or 2). There 
are few places with extremely tight controls (Biosafety 
level 3 or 4) where recombinant experiments can be 
performed on highly lethal and infectious agents (http://
en.wikipedia.org/wiki/Biosafety_level).  
The safety issues related to foods derived from GM 
plants are of course different.  Genetically modified 
plants are not infectious, potential risks of food 
safety for GMO are quite low compared to risks from 
microbes and risks are not different from those posed 
by non-GMO plants.  There are of course specific risks 
from foods that must be evaluated such as the potential 
transfer of an allergen or a toxin from another organism 
into a food crop. Many hypothetical risks are the focus 
of discussion today rather than the finite and definable 
risks that should be evaluated based on our extensive 
knowledge of science and safety.  The evaluation of a 
new product that has added one or a few new gene(s), 
new protein(s), or new metabolites to a crop that has 
10 000 to 20 000 endogenous genes and has already 
been safely consumed should focus on the safety of the 
gene source, protein characteristics and metabolites if 
the protein is an enzyme. The risks would be presented 
by the other 10 000 plus genes and proteins would be 
the same risks that already occur from that crop.  In 
addition, the types of risks the new gene and protein 
could present are definable based on our experiences 
with other foods. Most current non-GM food crops 
have specific allergenic proteins; a few may have toxins 
(solanine) or anti-nutrients (trypsin inhibitors). So the 
focus on the new proteins should be on evaluating 
potential allergenicity, toxicity and any anti-nutritional 
properties.  
There is now a history of nearly 20 years of 
production and consumption of a few commonly 
grown GM crops, for example insect protected 
corn containing a specific protein from Bacillus 
thuringiensis or Bt-corn; herbicide tolerant soybeans 
with a gene from a soil bacterium and virus resistant 
papaya, without evidence of harm.  Crops improved 
through biotechnology have shown benefits due of 
reduced pesticide applications or in some cases reduced 
plant pathogen impacts.  A number of GM crops have 
improved agricultural practices in ways that minimize 
soil erosion, energy or water consumption. 
Some might argue that the strong fears voiced 
against GMOs stimulate healthy debates about proper 
regulatory studies that have helped ensure a robust 
assessment process. Others suggest that many of the 
new regulatory demands developers face today are 
excessive and delay scientific progress in medicine, 
industrial development and agriculture. The truth 
probably lies between the extremes, but based on 
conversations with GM developers, commodity 
companies and food companies as well as review of 
regulatory guidelines of the EU and other countries 
it is clear that the global process of GM evaluation 
and approvals are slowing development and leading 
to global trade barriers over the past 10 (2004 to 
2014) years.  Because of the international nature 
of trade, agricultural companies have to wait many 
years before new products can be released in order 
to obtain approvals in the major world markets.  It 
seems that regulators in all countries are becoming 
more precautionary as they are afraid of being 
blamed for approval of a GM crop that is not proven 
to be absolutely safe under all possible uses.  The 
precautionary principle is counter to the policy of the 
Food and Drug Administration (FDA) of the US as 
outlined in 1994, which recognized that all foods pose 
some risks that can be evaluated and managed and that 
the standard of safety is that foods from GM crops 
must be as safe as conventional crops of similar types.  
A searching of scientific literature today identifies 
many new study questions and designs that are being 
performed on potential GM crops using a variety of 
search terms (transgenic, GM,  genetically engineered, 
toxicology, reproductive, cancer) that should only 
be performed if there is as testable hypothesis based 
on information about the crop or the gene and 
gene products. Few (if any) dietary proteins alter 
reproductive fitness, cause cancer, act as adjuvants or 
increase the prevalence of a broad range of autoimmune 
diseases.  
Today regulators and politicians are being pressured 
by activists like Eric-Gilles Seralini, Terje Traavik, 
Vandana Shiva, Mae-Wan Ho and Jeffrey Smith as 
well as celebrities like Oprah Winfrey, Dr. Oz and Cui 
Yongyuan or by consumers who listen to these activists 
make unsubstantiated claims of health risks of GMOs 
on websites in books, in the news media and television. 
For example, Jeffrey Smith’s website, the deceptive 
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“Institute for Responsible Technology (http://www.
responsibletechnology.org/) claims that very diverse 
human diseases including autism, celiac disease, food 
allergies and cancers are dramatically increasing due 
to increased consumption of foods produced from GM 
crops.  He takes small observations from a few poorly 
controlled animal studies that have not been validated 
to predict human disease and implies that humans will 
experience many complicated diseases from eating 
foods derived from GMOs. Mr. Smith offers a training 
program for “anti-GMO speakers” for a fee of $150 
USD.  Mr. Smith does not post credible peer-reviewed 
scientific studies to support his claims and generally 
cites correlations of increased GMO production and 
increases in these diseases that have highly diverse 
and uncertain causes. In fact the correlations usually 
do not match the introduction of most of the GMOs 
in the food chain. Yet many highly educated people 
take statements by Smith and other activists to be 
factual and they refuse to look more deeply for the 
many public and published studies that are available to 
demonstrate the approved GMOs have been evaluated 
for safety by scientifically sound studies. There are 
no studies that link consumption of insect-protected 
corn to celiac disease or food allergies, nor autism 
nor cancers.  If coincidental changes in our lives and 
environment demonstrated causality; we should stop 
air-travel, shut off the internet, discard cell phones 
and television; ban processed foods, vaccines and 
prescription medications.  We would need to live our 
lives as they were in 1914 when the world population 
was less than two billion, life was very different and 
the average life-expectancy less.     
In considering risks from foods, it is highly doubtful 
that genetic diversity of our foods represents a food 
safety risk.  We are omnivores and subsist on highly 
diverse diets.  We consume foods that are markedly 
different in 2014 compared to those consumed in 
1914 and certainly compared to 1514 before tomatoes, 
potatoes and peppers were transferred from South 
America to Europe, India and China.  If there are 
significantly different risks associated with eating plants 
that have only minor genetic differences compared to 
the varieties we eat every day, then maybe we need 
very complicated testing methods.  However, humans 
have been pretty good at evaluating food safety over 
thousands of years without highly complex scientific 
studies.  One could argue the extended life-expectancy, 
relatively low infant mortality rates and general health 
status of humans in the US and China in 2014 provides 
pretty convincing evidence that the current GMOs 
are not likely to be harmful. It is important to focus 
on realistic risks of foods and the development of 
processes that help ensure that foods produced from 
GM crops are as safe as foods produced from similar 
non-GM crops.
1.2  Early development of the safety evaluation of 
GMOs
In the mid-1980s I had not considered the safety 
assessment process that might be performed on GM 
crops to evaluate food safety.  I knew little about the 
process of using agrobacterium mediated transformation 
system to insert functional segments of DNA into 
plants[6]. As I learned more about biotechnology during 
training as a PhD student at the Ohio State University, 
cloning a cDNA of bovine lactoferrin for sequencing 
and expression I had to learn and comply with 
evaluations by institutional review committees at the 
university.  I had to answer questions about the source 
of the gene, the encoded protein, the plasmid vectors 
and the host cells and organism that was to receive 
the cloned DNA.  The training was reinforced during 
my work developing cDNA clones for rodent and 
human cytokines as I studied immunology at Cornell 
University and later at the University of Michigan.  By 
the time I joined Monsanto as a regulatory scientist 
working on the safety assessment of GM plants in 
1997, I stopped believing the statements by Greenpeace 
and others about many hypothetical risks of GM crops 
and statements that there were no safety evaluations 
and resigned my memberships in those organizations. 
Within two months of joining Monsanto I was thrust 
into the role of developing an animal model to evaluate 
the potential impact of a GM event to evaluate potential 
impacts on allergenicity.  The tests were novel and 
unprecedented as no one had demonstrated that a rodent 
model could predict potential sensitization in humans. 
However the government of India demanded an animal 
model test for allergenicity.  The approval process took 
nearly 7 years after the US had approved the same 
crop.  India dropped the requirement to use animal 
models to evaluate potential risks of food allergy after 
bringing their guidelines into alignment of the Codex 
Alimentarius Commission (2003) guideline[1] in 2008. 
My work at Monsanto involved becoming familiar with 
the regulatory process in the US and other countries 
and learning the science of risk evaluation for potential 
allergenicity, toxicity and nutritional equivalence. I 
continued being involved in the regulatory evaluation 
process when I was hired at the University of Nebraska 
in 2004 and have become even more broadly involved 
through 2014. But I am still learning about the process 
90 Journal of Huazhong Agricultural University Vol. 33
that led to the current assessment.
A review of publically available information shows 
that academic, industrial and government scientists 
have collaborated in many consultations to develop 
a useful and predictive safety assessment process for 
GM crops.  The US government outlined a coordinated 
regulatory framework in 1986 that includes the Food 
and Drug Administration (FDA) the Environmental 
Protection Agency (EPA) and the US Department of 
Agriculture to evaluate and regulate GM crops (Office 
of Science and Technology Policy, 1986; http://www.
aphis.usda.gov/brs/fedregister/coordinated_framework.
pdf).  That was eight years before the first GM crop 
approval.  A group of academic and industrial scientists 
held meetings as the International Food Biotechnology 
Council (IFBC) in collaboration with the International 
Life Sciences Institute (ILSI) and developed a 
risk assessment guideline that was published as a 
supplement to volume 12 of Regulatory Toxicology and 
Pharmacology (1990)[7].  The IFBC-ILSI volume was 
prepared by 28 highly experienced scientists and legal 
experts.  The volume presented methods of genetic 
modification, variable crop composition of traditional 
foods, safety evaluation of food ingredients derived 
from microorganisms, safety evaluation of single 
chemical entities, safety evaluation of whole foods 
and complex mixtures and legal and regulatory issues. 
The draft reports were reviewed by 150 experts in 
industry, government and academia from 13 countries 
prior to publication. The major issues were presented 
and discussed by 120 experts in an open symposium. 
The IFBC-ILSI document presented a number of key 
evaluation steps and decisions for whether further 
evaluations were necessary and also discussed the legal 
food safety regulatory framework in the US.  They 
supported the decision by the US government that 
foods derived from GM products could be efficiently 
regulated within the existing regulatory framework 
as they found that generating the new varieties (e.g., 
transformation through biolistics or Agrobacterium 
constructs) were not different in terms of potential 
impacts on safety compared to traditional breeding 
methods.  The panel concluded the focus should be 
on questions related to characterizing and evaluating 
the safety of the introduced DNA, proteins and any 
metabolic products of any new enzyme in the GMO.
1.3  US regulatory process for GMO evaluations
In 1992 the FDA issued a policy statement on the 
safety and evaluation process for foods derived from 
new plant varieties including those derived from 
recombinant DNA techniques under the Federal Food, 
Drug and Cosmetic act (FDA Federal Register vol. 
57, No. 104, docket No. 92N-0139).  The evaluation 
process was followed for the safety assessment of the 
first GM crop approvals in 1994-1995 and although 
more complex now, are consistent with the process 
followed in 2014.  Under the unified regulatory system 
the US Department of Agriculture (USDA) Agricultural 
and Plant Health Inspection Service (APHIS) is 
responsible for oversight of regulated field trials of 
unapproved GM events, control through a permit 
system of GM organisms, plant pests and veterinary 
products.  A different section of USDA, the Food 
Safety and Inspection Service (FSIS) is responsible 
for regulating the safety of meat and some poultry 
products.  The FDA has authority of other food safety 
issues including evaluating the safety of GM crops 
and all milk and dairy ingredients. The Environmental 
Protection Agency (EPA) is the lead agency involved in 
evaluating GM plant incorporate pesticidal (PIP) genes 
(e.g. plants containing genes encoding crystal proteins 
from Bacillus thuringiensis, or Bt plants; plants 
including genes for viral resistance such as the Plum 
Pox Virus resistant plum tree) as well as regulating 
chemical herbicides and chemical insecticides. The 
EPA and FDA follow the same food safety guidelines 
and the normal process for a PIP includes consultations 
with the FDA and a full dossier submission to the EPA. 
Although the FDA consultation and data submission 
is in theory “voluntary”, failure to consult with FDA 
and provide data to complete evaluation of potential 
allergenicity, toxicity and nutritional effects of a GM 
crop is likely to lead to mandatory recall and legal 
action if there is any suspicion of harm. Requirements 
by EPA and USDA are clearly mandatory.  Both the 
EPA and the FDA expect similar evaluation processes 
and tests for food safety before a product goes to 
market.
1.4  FDA policy on food safety of GMOs: as safe 
as similar varieties of non-GMOs
The FDA and regulatory agencies from Australia, 
Brazil, Canada, Japan, the Netherlands and the United 
Kingdom governments were significant contributors 
to the Codex 2003 guidelines[1] that were established 
as part of the Codex system that is agreed to by the 
US and China.  The process includes evaluation of the 
same types of risks presented by non-GMO sourced 
foods that are known to cause adverse health effects: 
food allergy, food toxicity and adverse nutritional 
effects including potential increases in anti-nutrients or 
inclusion of potential celiac eliciting proteins (glutens 
from wheat and near-wheat relatives). Developers 
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are expected to present documented information 
evaluating the history of safe human use (HOSU) or 
exposure of the gene source and protein or gene, as 
well as information showing adverse effects.  The 
information must include characterization of the gene 
products (protein or RNA) and any metabolites of 
any introduced enzyme, dose of consumption of the 
protein or metabolites that will be expressed in the 
new GM plant food material based on consumption 
patterns of foods made from the host organism.  If 
there is historical evidence showing potential risk from 
consumption of the gene donor, additional testing may 
be required.  
The FDA recognized that a few endogenous 
ingredients of all foods pose some risks for consumers. 
Some risks are normally mitigated by food storage, 
preparation (cooking) or limiting consumption. For 
instance lectins, protease inhibitors and amylase 
inhibitors of legumes (beans) are inactivated by 
cooking prior to consumption.  Cassava is soaked and 
pressed to remove hydrocyanic acid to prevent cyanide 
poisoning before manioc is made and consumed. 
Potato varieties are selected in breeding to ensure they 
have low concentrations of the glycoalkyloid solanine 
as it is a mild toxicant. Young, green potatoes are not 
consumed as the content of solanine is high at that 
stage. Humans have adapted the foods and processing 
to ensure safety.  Those hazards affect essentially 
all consumers if not handled appropriately. Other 
hazards that affect everyone are from contamination by 
bacteria, fungi or chemicals.  
I t  i s  impor tant  to  recognize  tha t  the  most 
common and severe risks of food ingestion are from 
contamination of food with exogenous materials. 
Contamination can occur on the farm, or during 
storage in restaurants or homes. Bacteria, viruses, 
fungi, parasites and chemicals including mycotoxins, 
heavy metals and pesticides are relatively common 
food contaminants.  The most significant acute risks 
are presented by bacteria including Escherichia coli 
O157 and other toxin producing strains; Listeria 
monocytogenes, Salmonella sp., Campylobacter sp, 
and Clostridium perfringens.  The Center for Disease 
Control (CDC) and USDA FSIS estimate that there 
will be approximately 3 000 deaths in 2014 in the 
US population of 310 million, and approximately 
128 000 hospitalizations (www.foodsafety.gov/
poisoning/causes). Some parasites are also commonly 
spread through food. Toxoplasmosis is caused by 
Toxoplasma gondii, the most common food borne 
parasite in the US causing hospitalization and some 
deaths.   Some viruses are commonly spread through 
foods. Norovirus is the most common cause of acute 
gastroenteritis in the US.  It is spread through contact 
with many foods due to unsanitary food handling in a 
given outbreak, but rarely causes fatalities.  Hepatitis 
A can lead to death in susceptible individuals who go 
untreated.  Mold contamination is rarely documented 
as a cause of significant food borne illness in humans 
with the exception occasional outbreaks of mycotoxin 
poisoning caused by moldy grains[8].  However, 
mycotoxins more commonly cause severe outbreaks 
in poultry and other agriculturally important species 
as they are often fed grain at high concentrations[8]. 
Mycotoxins are small to moderate molecular weight 
organic compounds that are typically polycyclic and are 
not easily detoxified by the liver of some individuals 
or species. A few of the substances that cause toxic 
reactions are proteins, such as botulinum which is 
produced by the bacteria Clostridium botulinum along 
with some other toxins while ricin from castor beans 
is one of the rare plant protein toxins known to affect 
mammals[9].  Interestingly GM plants expressing plant 
incorporated protectants such as Cry1A in corn can 
reduce fumonisin (a mycotoxin) levels, thus reducing 
the potential for toxicity in chickens, pigs and cattle. 
Future GM products are likely to include specific anti-
fungal and anti-microbial proteins that will further 
enhance food safety.  
While toxins and anti-nutrients often affect nearly 
every consumer, a few hazards in foods only affect 
a small percentage of the population.  Specific food 
allergens affect less than 1% of the population, but can 
cause severe reactions or death in a very small percent 
of the population.  Glutens (gliadins and glutenins) of 
wheat and closely related grains cause celiac disease 
(CD), a chronic autoimmune disease in less than 1.5% 
of the population.  Celiac disease affects a genetically 
restricted subset of the population that includes over 
25% of the total population and there are many other 
factors that are not completely understood.  A major 
focus of the food safety assessment then is to evaluate 
and ensure that the transfer of a gene into a GM plant 
does not transfer an allergen or a CD eliciting gluten 
from the allergenic or CD eliciting source into another 
source.
1.5 Recognized risks of food allergy including 
celiac disease in non-GM crops
The most  common endogenous r isks  of  food 
consumption are IgE mediated food allergies[10] and 
cell-mediated celiac disease[11-13].  Food allergy to all 
sources may affect 2% to 6% of the population in the 
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US, with varied degrees of severity.  Individuals are 
usually sensitive to between one and five allergenic 
foods.  Allergens pose a significant risk to those who 
are already allergic to the specific proteins while they 
do not pose a risk for non-allergic consumers.  Because 
food allergy is highly variable between subjects in 
terms of severity of disease and the complexity of food 
composition, the sources of allergy for an individual 
are not always obvious[14-15]. The methods used for 
diagnosing food allergy are not standardized in many 
medical facilities and few doctors are well trained to 
accurately diagnose food allergy[16-17].  Food allergies 
are specific because the patient has been sensitized 
and produces IgE antibodies that bind specifically to 
one or more proteins in the food.  In IgE mediated 
food allergy, reactions occur because the individual 
has developed specific IgE antibodies to at least two 
epitopes (IgE binding sites) on a relatively abundant 
protein in the food.  Their IgE antibodies are bound to 
FcεR1 receptors on the surface of mucosal mast cells 
and blood basophils. Upon subsequent ingestion of the 
food containing the allergenic protein, the protein or 
fragments of the protein are absorbed and bind IgE on 
the mast cells or basophils, stimulating signals within 
the cell.  If a sufficient number of allergen-IgE binding 
events occur within a few minutes it triggers the release 
of histamine and leukotrienes from the mast cells and 
basophils, inducing vascular leakage and symptoms 
due to angioedema and nerve stimulation.  Some 
individuals experience relatively mild oral itching and 
mild swelling (angioedema) in the mouth and throat, 
others get hives or urticaria.  Some experience asthma 
with wheeze and shortness of breath. Others may vomit 
or have diarrhea. A few will experience hypotension 
(drop in blood pressure). Anaphylaxis is a severe, life-
threatening systemic reaction that includes hypotension 
and breathing difficulty that usually requires immediate 
medical attention including injection of epinephrine, 
other medications and oxygen.  Perhaps 150 to 200 
highly allergic individuals in the US die each year due 
from anaphylaxis triggered by food allergy[18].  Most 
who died because they did not receive immediate 
medical treatment including an injection of epinephrine. 
Peanuts, a few tree nut species, milk and eggs are the 
most common causes of fatal anaphylaxis from food[19]. 
Although exposure to the allergen triggers an acute 
reaction in the allergic individual, once sensitized, the 
individual may remain allergic throughout their life. 
However, young children often become tolerant to their 
allergenic food (milk, soybeans or egg) five or more 
years after initial reactions through a process leading to 
immune tolerance. 
Estimates of the prevalence of food allergy are 
approximations.  The best estimates available for the 
US, Europe and Japan indicate that food allergy affects 
from between 1% and 2%, up to 10% of the general 
population in those countries[20-21].  The frequency of 
cases of severe, life-threatening reactions is not well 
established, but clearly some allergenic foods such as 
peanuts, some tree nuts, cow’s milk and eggs account 
for more severe reactions than fruits and vegetables. In 
most countries including the US there has not been a 
standard reporting system for food allergy anaphylaxis. 
Epidemiologists at the US Centers for Disease Control 
reviewed hospital coding within the US system for 
a period of 1997-2007 using various resources and 
estimated that there are approximately 317 000 food 
allergy related hospital visits per year in the US (years 
2003-2006), with more than 9 000 admissions due to 
severe reactions[22].  Anaphylaxis was usually attributed 
to peanuts, crustacean shellfish (shrimp), tree nuts, 
milk, eggs and fish. 
Celiac disease is a genetically restricted autoimmune 
disease initiated by sensitization to specific wheat, 
barley and rye glutens (gliadins and glutenins) by 
activation of T helper 1 type CD4+  T cells[23].  The 
disease is chronic and lead to flattening of the villi 
in the upper small intestine, wasting disease and 
sometimes to specific cancers and other autoinmmune 
diseases. The genetic restriction is due to unusual 
protein sequences that are presented most effectively 
by those with Major Histocompatability Complex loci 
HLA-DQ2.5 or HLA DQ8[24].  However, while more 
than 25% of the US population has either HLA-DQ 2.5 
or DQ-8, only an estimated 1% of US consumers are 
clearly diagnosed with CD, which is similar to the rate 
in Europe[25]. The rate of CD in China is not known, but 
one recent study suggests that it is more common than 
once believed[26]. There are uncertainties in prevalence 
due to the complexity of accurately diagnosing affected 
individuals as endoscopy with multiple biopsies are 
taken as the gold standard following consumption 
of  glutens,  but  endomesial-specif ic  or  t issue 
transglutaminase-specific antibody tests in conjunction 
with HLA typing or associations with diagnosed near 
relatives are often used as sufficient evidence for 
diagnosis[27].  Specific peptides of glutens and gliadins 
have been identified as stimulating Th1 CD4+ T cell 
clones from MHC-restricted CD patients[28-30]. The 
only way CD patients manage their disease is through 
avoiding consumption of foods containing proteins 
from wheat, barley, rye and for some, oats[31].  There is 
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also a growing number of consumers who believe they 
have non-celiac gluten sensitivity, however the specific 
disease pattern is not uniform, the mechanism of 
reactions are not known and there is some disagreement 
between Gastroenterologists as to the authenticity of 
the disease[32]. 
1.6 Food allergens are specific proteins, not whole 
foods
Generally people describe food allergy as being a 
reaction to a whole food (e.g. milk, eggs or peanuts). 
But research over the past two decades has identified 
specific proteins in the foods as the causes of allergy. 
The International Union of Immunological Societies 
(IUIS) Allergen Nomenclature Subcommittee (www.
allergen.org) lists 12 protein families as commonly 
allergenic.  The most prominently named peanut 
proteins reported as the dominant allergens are the 
small molecular weight prolamins (14 to 18 kDa) 
including the abundant 2S albumins (Ara h 2 and 
Ara h 6) and higher molecular weight cupins (50 to 
75 kDa) major seed storage proteins, Ara h 1 and Ara 
h 3. The cupins each account for more than 15% of 
the total protein content of the seeds.  Subjects with 
substantial IgE concentrations to any of these four 
proteins are most at risk for severe reactions following 
ingestion of peanut[33-34].  The Ara h 2 and 6 proteins 
are highly cross-linked small molecular weight proteins 
with four intra-chain disulfide bonds making them 
relatively resistant to digestion by the stomach protease 
pepsin[35-36].  A few other proteins have been identified 
as allergens in peanuts but represent low abundance 
and/or low stability proteins which are considered to be 
minor allergens.   Most people with clear IgE mediated 
allergy to peanut have IgE to the major allergenic 
proteins, it is not clear that IgE to the minor allergens 
cause significant clinical reactivity.  A few proteins in 
some foods are nearly identical to homologous proteins 
in other foods or in pollen and are considered pan-
allergens since the IgE of one subject may bind the 
homologous proteins from a wide variety of species. 
The pan-allergens do not cause serious reactions in 
most allergic subjects.  Pan-allergens in peanuts include 
profilin (Ara h 5), pathogenesis related protein-10 
family members (Ara h 8.0101 and Ara h 8.0201) and a 
lipid transfer protein (LTP), Ara h 9.  The sequences of 
two defensin proteins Ara h 12 and Ara h 13 recognized 
by the IUIS nomenclature committee has not yet been 
published and the frequency and severity of induced 
allergic reactions are unknown.  Individuals allergic 
to tree nuts including almonds, hazelnuts, pecans and 
walnuts usually have IgE antibodies that recognize 
similar 2S albumins and cupin seed storage proteins. 
In some cases there seems to be cross-reactivity 
among the tree nut proteins and even to peanut, but 
it is difficult to separate IgE cross-reactivity from de 
novo sensitization, where a subject is co-sensitized and 
co-reactive. Certainly though pecans and walnuts are 
very closely related and their allergenic proteins nearly 
identical. 
A number of individual IgE-binding allergenic 
proteins from foods, inhalation sources (pollen, house 
dust mites and mold spores) and dermal (latex) or 
injection (venom, saliva of biting insects) sources have 
been characterized and studied in the past 25 years. 
The sequences of the proteins with published proof 
of IgE binding using sera from appropriately allergic 
subjects have been included in the AllergenOnline.
org database managed by the Food Allergy Research 
and Resource Program at the University of Nebraska-
Lincoln (www.AllergenOnline.org) to provide a 
bioinformatics tool for the GM safety assessment 
process.  A number of the proteins included in the 
Allergen Online database have also been demonstrated 
to cause biological reactivity by skin prick tests of 
allergic subjects, basophil histamine release or basophil 
activation and those proteins are more reliably defined 
as allergens. The references used to categorize each 
allergenic protein group are listed in the database (www.
AllergenOnline.org) along with an explanation of the 
process of classification. The database also provides 
sequence comparison algorithms to evaluate potential 
new GM or novel food proteins for potential risks of 
cross-reactivity. 
It is not clear why people become allergic to certain 
proteins and foods rather than becoming tolerant to 
these generally innocuous proteins although there 
are genetic risk factors for IgE mediated allergy.  It 
is clear that the prevalence of food allergy is rising 
in industrialized countries and it cannot be explained 
by changes in the genetics of consumers[37].  There 
are a number of proposed mechanisms including the 
“hygiene” hypothesis (lack of certain bacterial types 
from the environment or within the gastrointestinal 
tract) for sensitization (induction of specific IgE) 
and tolerance (suppression of IgE and allergy), but 
no single markers or hypothesis fits everyone[37]. 
Very likely multiple factors interact at the time of 
introduction of foods in the developing child, food 
processing methods, reduced vitamin D levels due to 
sedentary indoor lifestyles and reduced exposure to 
certain microorganisms or reduced parasite burden 
that together are contributing to increases in allergic 
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disease. 
Celiac disease is elicited by a limited number of 
glutenins and gliadins from wheat, barley, rye and 
possibly oats, all members of the Pooideae subfamily 
of grasses. In order to provide a possible risk 
assessment tool for food safety assessment, we have 
gathered 1 016 peptides and 58 proteins f that have 
been found to stimulate CD restricted T cells into a 
CD-specific database for use in risk assessment (www.
allergenonline.org/celiachome.shtml). We have also 
developed bioinformatics tools that help evaluate novel 
food proteins for identity matches to be able to flag 
potentially important proteins as possible risky proteins 
for those with CD to consume.
2  Assessment of GM crop safety 
in the US 
2.1  History of safe use (HOSU)
The scope of the HOSU evaluation of the gene source, 
the gene recipient and the specific products of the gene 
includes determining whether there is documentation of 
direct contact with the protein or indirect contact with 
metabolites if the protein is an enzyme. Descriptions 
of appropriate allergenicity and toxicity assessments 
have been published by experienced scientists who 
have expertise in those areas[9,38].  In cases where the 
gene source is a common cause of allergy or toxicity, 
additional tests are likely to be required compared 
to sources without any history of allergy or toxicity. 
For example, peanuts and certain tree nuts (walnut, 
pecan, almond and hazelnut) are considered common 
causes of allergy.  If a gene is transferred from one 
of the commonly allergenic sources, specific serum 
IgE testing is likely to be required similar to the study 
performed by Nordlee et al., for the Brazil nut 2S 
albumin[39]. If the gene source is castor bean (Ricinus 
communis), the Closteridium botunlinum bacterium or 
a wasp (Vespula germanica), regulators are likely to 
ask for additional specific toxicity tests to verify that 
the protein is not a toxin.  Specific testing requirements 
will be dictated by the nature of the risk. If the source 
has neurotoxicity, then neurotoxicity tests are likely 
to be called for.  The identifiable risks of the source 
would normally be discovered by searching published 
peer reviewed literature, although sometimes sources 
including searching Google may be useful.  If there is 
a clear history of consumption of the source material, 
and the protein in question is proven to be expressed 
in the material that is consumed (e.g. the nut, fruit 
or herbaceous material), the lack of allergenicity or 
toxicity would aid in determining the protein is unlikely 
to present a risk. However, in many cases there will 
not be a history of safe consumption, which does not 
automatically mean additional tests are required, only 
that there may be slightly less certainty of safety.  
Often there are clear, restricted risks associated with 
a given gene source.  Apples contains two proteins 
that might be considered significant allergens, a non-
specific LTP that is known to cause severe allergy in 
a very small number of consumers and a less potent, 
common cross-reactive protein Mal d 1. The Mal 
d 1 protein is a sequence similar homologue of an 
airway allergen Bet v 1 that is common in pollen of 
birch and related tree species.  Other proteins from 
apple are expected to represent low or no risks of food 
allergy.  Peanuts contain four potent allergens and a 
few additional minor allergens. Food labeling laws are 
written to differentiate risks of food allergy based on 
the prevalence and severity of allergy to the sources. 
In the US, Europe and Japan, peanuts are considered 
common and important sources of food allergy and any 
processed food that contains an ingredient from peanut 
must be labeled as to source.  Apples are not considered 
to be common, potent sources of food allergy.  The 
safety of proteins derived from a peanut gene would be 
more thoroughly evaluated than a protein from apples 
for potential risks of allergy.  
The source of the insecticidal crystal proteins 
Cry1A, Cry2A and Cry3A is the bacterium Bacillus 
thuringiensis.  Spores of this species have been used as 
microbial pesticides for 70 years without demonstration 
that they cause allergies or toxicity in mammals. The 
historical safe use of the organic pesticides provides 
assurance of HOSU for some Bt toxins, although that 
is true only for proteins that are demonstrated to be 
expressed by the bacteria used as microbial pesticides 
and not from all varieties of the species.  
The developer is expected to provide documentation 
of the history of safe use of the gene source organism 
and if possible of the gene products.  The description 
should also include evidence that the protein or 
other gene products are expressed in the materials 
encountered in food as well as a description of 
preparation of the food. 
2.2 Characterizing the new protein and product 
attributes
The developer must describe the DNA or RNA 
sequence transferred in making the GMO.  The source 
of other genetic elements (promoter and terminator) in 
the construct must be included.  The method of transfer 
must be defined.  Confirmation of copy number, 
Richard E. Goodman: Biosafety: evaluation and regulation of Genetically Modified (GM) ... 95
gene integrity and stability of the DNA through 
reproductive cycles of the organism must be verified. 
Any gene product should be quantitatively measured 
under conditions of normal use of the plant.  In some 
cases mRNA size and accumulation in various plant 
tissues are also necessary to ensure the transcript is as 
expected.  In most cases the gene encodes a protein. If 
the protein is an enzyme, any expected and measured 
metabolites must be described. The function of the gene 
and products must be disclosed.  The sequence of the 
DNA and the protein are disclosed and data comparing 
the protein amino acid sequence to known toxins and 
allergens must be evaluated. 
2.3 Potential allergenicity
Due to the importance of food allergies, the FDA has 
focused on preventing the transfer of allergens into a 
new food source as a primary concern for GM crops. 
A major risk for consumers with allergy to peanuts 
would be the transfer of a gene encoding a major 
peanut allergen into rice or corn.  That possibility was 
demonstrated by the experience of Pioneer Hi-Bred 
when they transferred a gene encoding the 2S albumin 
from Brazil nut into soybean to improve feed quality 
for animals.  Soybeans have a high concentration of 
protein, but are deficient in sulfur containing amino 
acids. The 2S albumin of Brazil nut is a small protein 
with a high concentration of methionine and cysteine 
amino acids.  Pioneer Hi-Bred was preparing a dossier 
for submission for regulatory review for this potential 
product when they consulted with Dr. Steve Taylor at 
the University of Nebraska who suggested that since 
Brazil nut is known to cause food allergy in some 
consumers, the protein expressed by the transferred 
gene should be evaluated for potential allergenicity. In 
1995 no one knew what the allergenic proteins were 
in Brazil nuts, but during studies described by Nordlee 
et al.[39], it became apparent that the 2S albumin is an 
important allergen.  The results were published and 
Pioneer Hi-Bred stopped development of that potential 
product without submitting it to regulators.  The 
experience helped validate the evaluation process that 
had been outlined in the FDA Federal Register in 1992. 
The experience also helped crystalize the evaluation 
process outlined by Metcalfe et al.[40], for evaluating 
potential allergenicity of GM proteins and eventually 
the Codex Alimentarius Commission guideline first 
published in 2003[1].  
Food allergy is usually restricted to reactions 
mediated by antigen specific IgE antibodies and the 
mechanisms described can be found in any immunology 
text book. Most dietary proteins stimulate the immune 
system to become tolerant to contact with the protein. 
However, for those prone to allergies, their T helper 
cells and B cells may become educated to develop IgE 
immunoglobulin production because of the mixture of 
cytokines and cell surface signals provided by T-helper 
type 2 cells.  The B cells differentiate into plasma cells 
or B memory cells expressing high levels of protein-
specific IgE that becomes bound to the FcεRI high 
affinity receptors on mucosal or dermal mast cells and 
blood basophils.  When the antigen is absorbed again in 
subsequent meals, it cross-links IgE antibodies on the 
receptors if at least two epitopes are bound and initiates 
a signal cascade.  If a sufficient number of cross-links 
occur within a few minutes the mast-cells or basophils 
releases histamine, leukotrienes and proteases that elicit 
vascular leakage and inflammation.  Symptoms may 
include angioedema, urticarial, asthma, emesis (vomit), 
hypotension (drop in blood-pressure) and in rare cases 
death due to systemic anaphylaxis.  Since the IgE 
antibodies are specific in peptide epitope recognition, 
the symptoms are reproducible; same antigen, similar 
reactions.  Generally allergic sensitivity is assumed to 
be life-long. Many dietary proteins also induce IgG and 
IgA antibodies, but those are not risk factors for acute 
food allergy.  Production of these immunoglobulins by 
B cells also requires T cell help, but the responses and 
signals differ from those leading to IgE responses.  The 
focus of the allergenicity evaluation is therefore on 
measuring IgE responses.  
There are also T-cell mediated reactions to some 
dietary proteins, the major one being gluten-sensitive 
enteropathy or CD as discussed previously.  Evaluating 
GM proteins for potentially eliciting CD is relatively 
straight-forward and will be discussed later.  There 
are rare cases of T cell mediated food protein induced 
enterocolitis syndrome (FPIES), which is a severe 
reaction primarily to proteins in cow’s milk or soybean 
but occasionally to proteins in rice or oats and a few 
other foods[41]. Individuals usually become tolerant to 
the responsible food within three to five years and no 
specific proteins have been identified as the causative 
agents.  Therefore it is not possible to evaluate proteins 
as a possible cause of FPIES at this time.
There is credible evidence that the prevalence 
of food allergies and celiac disease are on the rise 
globally, although there is great uncertainty about the 
magnitude of the rate of increase and the cause.  Part 
of the increase is likely due to increased consumer 
awareness of allergy and CD as well as more awareness 
and testing by doctors.  There is much misinformation 
about prevalence and people are often incorrectly 
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diagnosed.  Many individuals reported being food 
allergic, but a clinical evaluation demonstrates they are 
not food allergic in many cases.  
The major risk for food allergy is acute, within 
minutes to hours after consumption of the allergenic 
food.  The primary risk of food allergy from GM crops 
is the potential transfer of a protein that already causes 
allergy in specific consumers.  If affected individuals 
consume a biotech crop that includes their allergen, 
reactions would likely be as severe as they would 
be to the natural source of the allergen.  Thus the 
primary concern for GM crops is to avoid the transfer 
of a protein that already causes allergy (of any kind, 
contact, airway or food) into a food grade plant of 
another species.  
The International Life Sciences Institute (ILSI)-
Allergy and Immunology Institute and the International 
Food Biotechnology Council organized discussions 
and a series of scientific peer-reviewed publications to 
consider potential risks of food allergy from GM crops. 
The publications were presented in a special issue of 
Critical Reviews in Food Science and Nutrition (Vol. 
36, Supplement, 1996).  Panelists included scientists 
with expertise in biotechnology development and 
regulation or allergens and allergy. The first chapters 
explain allergy, food allergy, the biology of plant 
proteins the process of genetic modification of food 
plants and review allergenic foods known at the time. 
Two chapters provide the basis much of the background 
information that guided development of a science 
based assessment process to evaluate potential risks of 
food allergy for novel proteins[42-43].  The last chapter 
outlines an evaluation process to determine whether 
a protein expressed by a transgene would potentially 
present a risk of food allergy to consumers[40].  
The evaluation process outlined by Metcalfe et al.[40] 
was consistent with the FDA recommendations of 
1992, and included decision tree flow-chart beginning 
with evaluating the allergenicity of the source of the 
gene.  However, the decision tree did not exactly match 
the description in the text and some things were not 
clear.  Fig.1 represents my interpretation of the tree 
from the text[40]. If the gene is from a clearly defined 
allergenic source (food, airway or contact allergen), 
the next step would be to obtain sera from 14 humans 
allergic to the source and test for IgE binding to the 
GM protein using standard laboratory test methods. 
If fewer than 5 allergic donors are found for the test, 
then the protein is evaluated for stability to digestion 
by pepsin. All proteins regardless or source should be 
evaluated by sequence comparison to known allergens 
and a list of known food and respiratory allergens 
known in 1995 was included[40]. They recommended 
using FASTA to align the protein to known allergens 
and search for any contiguous 8 amino acid segment 
having an identical match to any allergen.  In practice 
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most bioinformatics matches were simply performed 
by a sliding “WORD” match of 8 amino acids.  If the 
protein matches an allergen, sera from humans allergic 
to the source of the matched allergen would be tested 
for binding. If IgE from appropriately diagnosed 
allergic serum donors clearly binds to the protein, the 
developer is likely to stop development and not submit 
the dossier to regulators.  However, if they would try 
to continue, the regulator would likely demand foods 
made from that GM event would have to be labeled 
as to the source to alert allergic subjects to avoid the 
food.  In the case of inconclusive IgE binding, subjects 
allergic to the source would be tested by skin prick 
tests (SPT) with the protein and if all are negative, they 
would be asked to undergo a double-blind, placebo-
controlled food challenge (DBPCFC), under ethical 
panel approval.  In addition, the protein would be 
tested for stability in acid with pepsin (protease) and 
the time of disappearance would be graded to evaluate 
digestibility.  The protein might be tested following 
typical food processing methods for that specific crop 
to determine if it denatures.  However, processing 
stability is really only useful to understand if a risk of 
allergy or toxicity can be mitigated by normal food 
processing, similar to the inactivation of natural lectins 
and protease inhibitors in legumes during cooking. 
If the protein is stable to digestion by pepsin, the 
regulatory agency would be consulted for any requests 
for additional tests. 
Most GM events and newly expressed proteins 
approved in the US meet the criteria for minimum risks 
regarding the allergenicity evaluation presented by 
Metcalfe et al.[40] and the Codex[1].  A literature search 
finds only one potential GM crop product that did not 
fit the history of safe use and upon testing for serum 
IgE binding using samples from the at-risk population 
of Brazil nut allergic subjects was found to bind 
IgE[39].  That potential product was not submitted to 
regulators and was terminated by the developer (Pioneer 
Hi-Bred).  No currently approved product that I am 
aware of received a gene from a commonly allergenic 
organism.  Thus the Brazil nut 2S albumin is the only 
one that would have presented a major risk of food 
allergy to a subset of consumers.  
2.4 Bioinformatics for matches to allergens
In addition to evaluating the source of the gene the 
bioinformatics search for identity matches between 
the GM protein and any known or suspected allergen 
has become probably the most important tool to 
identify possible risk and a reason to do serum IgE 
testing[38,44-45]. The Codex[1] document calls for a FASTA 
or BLASTP search with the amino acid sequence of 
the GM protein against a database known allergens. 
The www.Allergenonline.org database is the most 
comprehensive peer-reviewed allergen database that 
I am aware of.  The criteria of greatest emphasis is 
any match >35% identity over any segment of 80 or 
more amino acids.  The Allergen Online database 
(www.AllergenOnline.org) was established in the 
Food Allergy Research and Resource Program at the 
University of Nebraska in 2004 and implemented 
an expert review process.  It is updated annually to 
provide a curated database and search algorithms for 
risk assessment of allergenicity using bioinformatics 
tools[44].Version 14 of the database was released in 
January, 2014 and includes 1 706 sequences from 645 
protein-taxonomic groups representing 290 species. 
In my opinion the search for >35% identity over any 
segment of 80 amino acids is quite conservative as 
described in a number of publications.  There is little 
evidence of in vitro cross-reactivity for proteins sharing 
less than 45% identity by overall alignment (full-
length). And in terms of shared allergic reactions due 
to cross-reactivity, very few proteins sharing less than 
50% overall identity matches are cross-reactive[46]. 
Since 1996 there have been a number of scientific 
consultations and recommendations for “improving” 
the allergenicity assessment of GM crops. The FAO/
WHO expert panel review[47] suggested including a 
number of changes that were not validated. The FAO/
WHO recommendation was to use FASTA or BLASTP 
to identify any segment of 80 or more amino acids 
with an identity match of >35%; and to search for short 
identity matches of six contiguous amino acids (aa) 
rather than eight aa suggested by Metcalfe et al.[40].  But 
those precautionary criteria have not been validated. 
They were reviewed in previous publications[3,38,45].  A 
number of studies demonstrated that searches for six 
aa identity matches produce far more false positive 
matches than true positives. The eight aa matches 
are better, but still do not have a high predictive 
value.  Others have also described the 80 amino acid 
searches as being overly conservative; however I have 
not identified many probable false positives using 
that criterion, but also did not miss any likely cross-
reactive protein pairs[45].  There is some disagreement 
about the optimum algorithm for the 80 amino acid 
search as some bioinformaticians suggest searching 
for the best overall alignment by FASTA or BLASTP 
and then scoring the best match as a more reliable 
alternative[48-50].   Recently the European Food Safety 
Authority (EFSA)[51] dropped the recommendation 
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to search for short, contiguous identity matches and 
the European Commission[52] accepted that advice 
in dropping it from their regulations.  There have 
been a few instances where short contiguous identity 
matches that occur by chance (no evidence of overall 
sequence homology), have led to requirements for 
serum IgE tests that were not needed[53].  There is a 
risk in performing such tests as in vitro IgE binding 
results can be ambiguous, with false positive binding 
that may inappropriately implicate a protein as a 
possible allergen[54]. Although there is little relevance 
of IgE binding to a single short segment of two non-
homologous proteins means a risk of allergy in that 
situation is unlikely, some regulatory bodies would 
want the developer to continue the investigation and 
possibly demand in vivo testing in humans.  
2.5  Serum IgE testing
Serum IgE tests are rarely warranted for evaluating the 
potential allergenicity of GM proteins.  However, if 
serum IgE testing is warranted the assays must be well 
designed, the methods should be validated with known 
allergens for the allergic serum donors and the test 
subjects should be demonstrated to have the appropriate 
IgE sensitivities. Test materials should include 
purified GM protein, purified allergenic target (e.g. the 
sequence matched allergen), and the specificity of any 
IgE detection antibody must be verified, appropriate 
blocking solutions are needed. In some cases specific 
inhibition assays may be required.  Critical factors in 
materials and assay design are presented in a number 
of publications[45,54-55]. If the protein may contain 
asparagine-linked carbohydrates, there is the possibility 
the plant might modify the protein with the addition 
of alpha-1,3 fucose or beta-1,2 xylose on the stem of 
the asparagine-linked glycan may bind IgE from many 
subjects, but there is little or no evidence for clinical 
reactivity[56-57].  Those structures are known now as 
cross-reactive carbohydrate determinants (CCD). If 
there is a signal peptide and an N-linked sequon (Asn-
x-Thr/Ser), the protein should be tested for the presence 
of CCD. Inhibition studies may need to be performed 
to evaluate the relevance of any in vitro IgE binding. 
If there is evidence of IgE binding in vitro and there is 
a desire to continue with development of the product, 
the biological relevance of binding may be tested using 
basophil activation or basophil histamine release[58]. 
Alternatively, skin prick tests (SPT) or double-blind, 
placebo-controlled food challenges may be required 
using highly characterized test materials and subjects 
who are well informed and have consented to the 
challenge.
2.6  Potential de novo sensitization: stability in 
pepsin and abundance
If there is no evidence the protein is likely to be an 
allergen based on source and a lack of bioinformatics 
match, there is no justification for performing serum 
IgE tests.  There is a low probability of risk and there 
is no at-risk population.  The only other questions 
regarding allergenicity are whether the protein 
might sensitize de novo.  As suggested by Metcalfe 
et al.[40], proteins that are stabile in pepsin in an in 
vitro digestion assay and are abundant, have a higher 
probability of being an important food allergen. 
However, the correlation is modest even though many 
major food allergens are stable or fractions of the 
protein are stable and abundant[59].  The correlation of 
stability in pepsin has been performed at pH 1.2 and 
2.0 and the FAO/WHO, 2001 recommendation was 
to use both conditions to evaluate stability.  We did 
not find any significant difference[59].  The EFSA[57] 
recommendation was to use more “physiological” 
pH (3.5), but that has the effect of markedly reducing 
pepsin activity and has not been investigated in terms 
of predictive value.  The FDA continues to accept the 
use of either pH 1.2 or 2.  There is also not a consensus 
on abundance although it is clear that the abundance 
of a number major allergenic proteins in plants used 
for foods is greater than 1% of the protein in the food 
fraction[60].
Most of the GM proteins have been found to be 
digested rapidly in pepsin at pH 1.2 or 2.  However, 
the Bt protein Cry9C that was originally introduced 
into corn to protect against the European corn borer 
moth larvae by Plant Genetic Systems (PGS) in Ghent, 
Belgium was found to be quite stable in pepsin. The 
product was called StarLink corn. The company was 
purchased by AgrEvo, then Aventis CropScience which 
was finally acquired by Bayer CropScience.  Food 
approval was withheld because the protein was stable 
in the pepsin digestion assay (described later) and 
regulators felt there was some risk the protein might 
eventually sensitize someone, predisposing them to 
allergic responses to Cry9C. StarLink corn was grown 
on ~ 122 000 hectares in the US in 1999, and some 
grain from the corn was accidentally, but illegally 
included in some human food products (corn chips and 
taco shells).  Tests by an anti-GM NGO discovered the 
inclusion of StarLink corn event in some food products 
and notified the US government and news media. 
Interestingly the question was whether people might 
become allergic to the protein, which would take time 
to sensitize people.  There is no indication that people 
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were pre-exposed to Cry9C, so sensitization would 
have been from exposure in the contaminated taco 
shells and chips. However, within two weeks of the 
announcement more than 100 consumers complained 
they had experience food allergic reactions following 
consumption of taco shells or corn chips.  Since corn 
is one of the least allergenic of grains and the quantity 
of Cry9C was quite low in corn grain and the grain 
was grown for only one year, it is highly unlikely that 
anyone was sensitized to the protein.  However, the 
Center for Disease Control of the US investigated 
each consumer report.  Those individuals who claimed 
reactions that might be consistent with food allergy 
were asked if they would provide blood samples and 18 
did[61].  None of those individuals had IgE specific for 
Cry9C[61].  Since the grain and corn seeds were released 
and in food without approval, the US government 
demanded recalls and monitoring.  Foods, ingredients 
and corn seed were screened and those containing 
the Cry9C protein or the transgene were pulled from 
the market.  It took six or more years to completely 
remove all traces of Cry9C from seed and grain stores. 
There have been rough estimates that total costs for 
removal may have exceeded $500 million.  Yet we 
should remember that there is no proof that anyone 
was harmed by consuming Cry9C.  There is clearly a 
different level of risk of allergy that might be present 
from a GM food crop such as StarLink than would be 
associated with an outbreak of Norovirus, hepatitis or 
E. coli O157. We might conclude that the regulatory 
response was not in proportion to the risk in the case of 
StarLink. However, the ability to remove a GMO from 
production was demonstrated by the recall of StarLink 
corn and it shows that you can remove a GMO from 
the agricultural and food system if there is a reason to 
do so.  It just takes time and an enormous amount of 
money.  
Another product that is not as rapidly digested in 
pepsin as Cry1Ab (in corn) or CP4 EPSPS (in herbicide 
tolerant soybeans) are the two proteins (Cry34Ab2/
Cry35Ab1) in another insect protected corn event. 
The proteins have intermediate stability as reported by 
Dow, the developer[62]. The EPA did allow this product 
into the market as the abundance of the proteins is low 
in grain and the stability intermediate.  
New proteins expressed in the GM crops approved 
so far have been expressed and accumulate at low 
levels in the food materials of the crop, often in the 
range of or less than a few micrograms per gram dry 
weight of seed (CERA GM Crop database, 2014; http://
cera-gmc.org/index.php/GMCropDatabase). Thus all of 
the GM proteins accumulate at levels markedly below 
the concentration of most of the important dietary 
allergens (typically >1% of total protein). 
There is no published evidence that an approved 
GM crop has caused allergies due to the presence 
of the transgenic protein.  A study was performed to 
determine whether soybean allergic subjects might 
have IgE binding to the CP4 EPSPS enzyme that was 
introduced into soybean to provide tolerance to the 
herbicide glyphosate[55]. This was not a regulatory 
study, but was performed as a stewardship study to see 
if there was any evidence of sensitization years after 
the product entered the market.  Serum samples were 
collected from soybean allergic subjects in Europe and 
South Korea and tested using common protocols and 
highly characterized test materials. The study did not 
find evidence of IgE binding to purified CP4EPSPS or 
to the protein in extracts of GM soybeans[55].  
2.7  Potential improvements for evaluating IgE 
mediated allergenicity
The FAO/WHO panel[47] recommended using targeted 
human serum testing in an attempt to determine 
whether a protein that is not similar to any known 
allergen might pose a risk due to existing sensitization 
or cross-reactivity.  Targeted testing was defined as 
in vitro IgE binding tests using sera from 50 subjects 
with allergy to sources that are broadly related to 
the source of the transferred gene.  For genes from a 
dicotyledonous plant, individuals allergic to one or 
more other dicot species would be used for serum 
testing.  There was an exemption for proteins from 
bacteria since there are almost no allergies to bacteria. 
The targeted serum testing has never been tested in a 
way that would demonstrate its predictive power and it 
is counter-intuitive based on our knowledge of cross-
reactivity.  Homologous proteins from even moderately 
related sources (family level) are rarely cross-reactive 
by in vitro tests and clinical reactivity is rarely shared. 
The only proteins that are so broadly cross-reactive in 
laboratory tests are profilins, PR-10 proteins (Bet v 1 
homologues), lipid transfer proteins and tropomyosins 
from crustaceans and other invertebrates. Those are all 
easily identified by bioinformatics.   The US does not 
recognize targeted serum testing as a useful tool for the 
assessment of novel proteins.
The FAO/WHO[47] also recommended performing 
sensitization tests using two species of animal models, 
or two routes of sensitization in one species to evaluate 
the allergenic potential of each new protein.  While 
many laboratories have tested various animal models in 
an attempt to predict the allergenicity of proteins, there 
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are none that have proven predictive over a wide range 
of effective allergenicity (from mild or non- to strongly 
allergenic), as reviewed by Ladics et al.[63]. There has 
been research that shows some promise for evaluating 
mechanisms of allergy and immunotherapy[64] and for 
preliminary ranking of allergenic sources[65-66].  A few 
have tested purified or partially purified proteins[67], 
but have not been validated to rank new proteins in 
the context of potency or prevalence of allergens in 
the human population[63].  The US does not recognize 
animal models as being useful at this time for 
predicting the allergenicity of novel proteins.
The  Codex  gu ide l ine  d id  inco rpora t e  t he 
recommendation for testing the sequences using the 
FASTA or BLASTP search alignments to identify 
matches of >35% identity over any segment of 80 or 
more amino acids.  Codex[1] also retained the language 
suggesting the use of a short identity match of 6 or 8, 
but suggested the evaluator must justify that choice. 
The US regulators now expect a comparison for 
identifying matches with >35% identity over 80 amino 
acids using a comparison like that available on www.
AllergenOnline.org or a full-length comparison by 
BLASTP with evaluation of alignments to meet the 
same criterion.  They do not seem focused on short-8 
amino acid matches, but most (all?) developers have 
supplied that data. 
The EC regulation[52], which was based to a large 
extent on recommendations from another expert 
panel review process by the EFSA[51] also includes a 
number of suggestions for unproven tests including: 
evaluation of potential adjuvanticity of the new protein; 
the use of proteomics to consider possible changes in 
the expression of endogenous allergenic proteins for 
commonly allergenic species (e.g. soybean, peanut); 
and the use of more physiological pH (3.5) for the 
pepsin digestion assay.  Yet those test methods have not 
been validated to demonstrate they would improve the 
risk assessment and are not asked for by US regulators. 
The US regulators do not ask for additional tests such 
as potential adjuvanticity unless there is information 
that would reasonably support the hypothesis that 
a new protein may be a lectin or have some other 
adjuvant-like properties.
2.8  Celiac disease
Risks related to CD have only been found to involve 
certain glutens (gliadins and glutenins) from wheat 
and near wheat grain relatives.  Codex[1] recommends 
and the US government would require an evaluation 
if a gene from wheat, barley, rye or possibly oats, 
is transferred into another species, such as corn, 
rice, or sorghum.  As far as I know, no developer 
has submitted a potential product to US regulators 
using such a construct.  While the Codex demands an 
evaluation for proteins from wheat or wheat relatives, 
they have not provided guidance on the process.  My 
laboratory considered the problem in the context of 
what is currently known about CD and the glutens 
involved in and developed a celiac database to provide 
a bioinformatics tool to allow rapid identification of 
potential hazardous proteins.  In order to develop the 
tool we reviewed published scientific information on 
CD. 
Symptoms of malabsorption and diarrhea associated 
with diet of bread were first described nearly 2 000 
years ago in medical writings from Greece[68].  But 
it wasn’t until 1888 that a physician in the United 
Kingdom (UK) gave the name coeliac (or celiac) to 
those suffering intestinal distress associated with eating 
foods containing wheat.  Those observations were lost 
on modern medicine until 1952 that physicians in the 
UK published descriptions associating the wasting 
and intestinal pathology with the consumption of 
wheat.  In the 1990’s gastroenterologists developed 
methods for endoscopy and developed antibody tests 
that demonstrated patients with CD were developing 
antibodies that bound to connective tissue in the 
intestine and had T cells that were activated upon 
binding wheat peptides from glutens in the context 
of specific major histocompatibility antigen resenting 
receptors. Recent studies have identified many peptides 
from glutenins and gliadins of wheat, barley and rye 
grains that are responsible for activating T cells in 
genetically susceptible individuals[30, 69]. As many of 
these discoveries were occurring in the mid-1990’s 
and beyond, the evaluation of proteins in wheat, barley 
and rye that might be responsible for causing the T 
cell specific responses in the fraction of subjects with 
the correct MHC Class II for susceptibility (MHC 
DQ 2.5 and MHC DQ 8) were just emerging.  Since 
then many studies have been published that identified 
peptide sequences that are responsible for binding to 
the right MHC and activating effector T cells in those 
with CD have emerged.  While the Metcalfe et al.[40] 
and the Codex[1] recommendations do not recognize 
the predictive capabilities of bioinformatics to evaluate 
risks of celiac disease from wheat subfamily proteins, 
it is clear that a substantial number of proteins were 
being identified that might serve as a database of 
“risky” proteins. Metcalfe et al.[40] and the Codex[1] 
both suggest that genes taken from wheat or wheat 
relatives that encode proteins should be evaluated for 
Richard E. Goodman: Biosafety: evaluation and regulation of Genetically Modified (GM) ... 101
their potential to cause CD, they did not specify how. 
In 2011, Plaimein Amnuaycheewa, a PhD graduate 
student in my laboratory reviewed more than 50 
available publications identifying peptides involved 
in T cell reactivity using cell samples from celiac 
patients and we developed a database of peptides that 
can be used to screen potentially hazardous peptides 
from proteins from the wheat and wheat relatives. 
We have constructed a database of peptides from 
wheat, barley and rye that cause T cell stimulation or 
intestinal epithelial pathology (www.allergenonline.
org/celiachome.shtml). The database is part of the 
www.AllergenOnline.org database for bioinformatics 
evaluation of potential IgE mediated allergenicity for 
GM proteins.  Currently it includes 1 016 peptides with 
published evidence of T cell reactivity using cells from 
CD patients in the context of MHC Class II DQ 2.5 
or DQ8, or toxic effects in intestinal epithelial cells or 
pathology in intestinal villi from those with CD.  The 
amino acids of proteins introduced into GM crops may 
be searched for exact matches to the peptides in the 
database, or the proteins can be searched by FASTA 
for meaningful matches to 68 whole proteins known 
to stimulate CD, using criteria of >45% identity over 
alignments of at least 100 amino acids as potentially 
stimulating CD. A total of 53 references are included 
to explain the selection of peptides and proteins that 
might cause CD in susceptible individuals.  Similar to 
the allergenicity assessment, bioinformatics methods 
should are able to identify proteins that might represent 
a modest to clear risk of causing disease. If there is 
a desire to introduce a wheat sub-family protein into 
another crop e.g. rice or eggplant (brinjal), the amino 
acid sequences there should be screened using this 
database to consider risk.  If a positive match is found, 
the protein should be tested using cells or challenges in 
CD subjects to evaluate risks using cell based assays or 
possibly food challenges in at least 10 consenting CD 
subjects to ensure minimal risk to the CD population as 
the “at-risk” group of consumers. The bioinformatics 
criteria we believe is predictive based on extensive 
simulations is any 100% identity match to one of the 
1 016 peptides or a FASTA match of >45% identity 
with any segment of 100 aa or more having an E 
score of < 1x 10-15.  Genes taken from plants outside 
of the Pooideae subfamily of grasses represent little 
risk of causing CD and therefore even if they are 
homologues of glutens that cause CD, they are highly 
unlikely to result in disease.  Proteins that do not 
exceed these criteria should present little or no risk of 
inducing CD.
2.9  Potential toxicity
Few proteins are toxic when consumed and most of 
those act acutely (e.g. ricin)[70].  The HOSU evaluation 
is a key consideration in addition to a bioinformatics 
comparison of the amino acid sequence of any newly 
expressed protein to the NCBI protein database using a 
keyword limit of “toxin” or “toxic”. Although it seems 
there is a lack of published data on how to perform a 
bioinformatics evaluation for potential toxicity for a 
GMO, all GM products submitted to the US FDA or 
EPA must undergo an evaluation[71].  I have performed 
the bioinformatics searches for a few potential GM 
crops and novel food ingredients for regulatory 
submissions using the general NCBI protein database 
using BLASTP with keyword limits of toxin or toxic to 
focus on potential risks.  Usually additional sequence 
comparisons are needed using the new protein in the 
search but without keyword limits to provide a relative 
comparison of other proteins with a known history 
of safe use or safe human exposure and the query 
protein (GM protein) or novel food ingredient.  The 
process also requires a careful evaluation of published 
scientific literature related to the closest sequence 
matched proteins as well as the protein of interest. 
While bioinformaticians often claim that proteins 
sharing greater than 25% identity over their full-length 
are homologues and often have similar functions, most 
proteins with such relatively low identities do not share 
specific toxic properties or exact enzymatic functions. 
Therefore bioinformatics evaluations must be evaluated 
relative to other proteins.  The results should guide 
decisions regarding a need for any toxicology testing, 
and if needed, the target organs and tests that might be 
useful to evaluate risks.  So far there is no evidence that 
any protein introduced into a GM plant approved in the 
US has had a toxic effect of humans or other mammals.
In the US regulatory system, if a protein introduced 
into a GM crop is intended to have toxic activity to 
insects, bacteria, a fungus or have anti-viral activity, 
such as the plant incorporated pesticidal Bacillus 
thuringiensis crystal proteins, the proteins must be 
tested by an acute mouse toxicity test.  The OECD 
guideline for acute toxicity testing (E425, 2001) is 
the model followed in many studies.  The protein is 
gavaged into adult mice using a dose that is typically 
1 000 fold higher on a mg protein per kg body weight, 
expected for human food consumption.  Sometimes 
the excess dose is not quite so high, but normally 
at least 100 fold higher.  The dose is given on day 0 
and the health of the animals is monitored along with 
control (mock-dosed) animals for 14 days.  At that time 
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body weights, blood samples appearances and clinical 
observations are collected. The animals are euthanized 
and gross pathology and if needed histology samples 
are examined for abnormalities.  Usually there are 10 
animals per sex per treatment group. Quite often two 
doses are used as separate treatment groups to ensure 
that any abnormality has a dose-effect.  While there 
may be some statistically different findings for a few 
measurements between groups for the GM and control 
animals, historical weights and measures of the same 
strain of mice should be available for that specific 
toxicology facility to be able to evaluate unexpected 
differences.  Some studies describing the acute mouse 
toxicity tests for approval of some GM products have 
been published[72-74]. In rare circumstances longer term 
toxicology studies are called for by regulators or critics 
of the technology, but the scientific justification for 
extra testing is usually quite weak. It is important to 
consider that unlike a number of organic compounds or 
heavy metals, consumed proteins do not accumulate in 
the body of mammals and toxic effects are expected to 
be acute rather than chronic.  
Some countries (e.g. within the European Union) 
require an acute mouse test as well as a subchronic, 90-
day whole-food feeding study in rats, or repeat dose 
testing with high doses of whole protein. While the 90-
day study design is detailed in the OECD guidelines 
and a few published studies have been performed, there 
is not a good justification and little proof that such a 
study will identify known hazards[75].  The 90-day rat 
feeding study is more of a hybrid toxicology-nutritional 
study. Some regulators and critics suggest that the 
90-day study provides a tool to evaluate “unintended 
effects” that might arise due to the insertion site of the 
new gene into the genome of the crop.  It should be 
worth considering that the host (recipient) crops are 
normally species that have been consumed for centuries 
with good history of safety and that genetic variation 
in naturally bred varieties and lines have introduced 
many unintended genetic changes without introducing 
adverse toxic properties in the food.
Two studies designed to test the predictive value 
of the 90-day rat whole food feeding study using 
experimentally designed recombinant rice gave 
somewhat conflicting results[76-77].  The first tested a GM 
rice expressing the snow-drop lectin from Galanthus 
nivalis (GNA) and the authors conclude that the study 
failed to show the potential toxicity of the lectin.  The 
second experimental GM expressed high levels of 
the common bean phytohemagglutinin lectin PHA-E, 
which did show toxicity when the protein was fed in 
raw form at high concentration.  My interpretation is 
that the raw, uncooked PHA gave significant toxicity as 
would be expected to occur in humans consuming raw 
kidney or navy bean.  The GNA study seems to have 
had negative results because the protein expression was 
too low in concentration or the protein was heated in 
feed preparation.  Since humans can consume cooked 
kidney and navy beans, but not raw beans, it seems the 
test results were predictive of the human experience. 
It might have been more appropriate to test raw and 
cooked samples as two separate treatments. The assay 
is not very sensitive and there are severe limitations 
to the dose that can be feed compared to the human 
diet, typically much less than the 100 fold safety factor 
typically used in toxicity studies.  Many toxicologists 
have questioned the usefulness of the 90-day whole 
food feeding study[9].  While others claim even more 
detailed, complex and expensive studies are needed to 
fully test potential toxicity[78].  However, a recent peer 
reviewed evaluation of published safety, toxicology and 
whole grain rat feeding studies on current GM crops 
provides objective evaluation of the overall approach 
and concludes that in most cases a 90-day feeding 
trial is not needed to evaluate safety, but results are 
certainly consistent with safety[79]. Interesting at a time 
when animal welfare groups and even the institutional 
animal care and use committees in many institutions 
are calling for reduced animal testing, some scientists 
involved in regulation or testing are calling for more 
unproven animal studies.  
2.10  Additional toxicology studies
Questions should be asked about any new proposed 
toxicity test, as well as existing testing methods.  What 
types of hazard can be or has been identified with a 
given test protocol? What is the rate of false positive 
and false negative results for each test? And finally, 
are there more effective tests that could be used?   A 
number of recent publications have discussed the 
pros and cons of using alternative computer based, 
cell-based, or tissue based methods, primarily for 
pharmaceutical toxicology evaluation[80-81]. They focus 
on having a scientifically sound hypothesis, validated 
methods and historical control data as essential criteria. 
Understanding the limitations and benefits of the 
different models are essential in making a determination 
about tests that might be useful for evaluating potential 
toxicity. In most countries including the US, there is a 
general requirement by animal care and use committees 
to show that the specific test on the specific test 
material has not been performed previously unless there 
is a reason to doubt the results. Therefore repeating 
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the same animal tests on the same GM crop event in 
multiple countries is deemed unethical. 
The final conclusion of toxicity evaluations should 
be either the GM crop does not pose any additional 
significant risk of toxicity compared to similar non-
GM varieties, or that it does pose a substantial new 
risk. The FDA and EPA have been able to reach 
those conclusions for many new GM products if the 
developer followed the standard assessment process. 
Unfortunately some regulatory bodies (e.g. EFSA and 
the European Commission) in Europe and regulators in 
India and China continue to raise new questions about 
hypothetical concerns including potential adjuvanticity, 
alteration of fertility or the potential to induce cancers 
even though there are very few examples that any 
dietary protein could have such an effect.  Those 
regulators then fail to approve products for which there 
is no evidence of risk. The US regulatory agencies have 
emphasized the need to use proven methods to evaluate 
safety of novel proteins and GM products.  They have 
not asked (so far) for additional studies that are not 
already demonstrated to help assess safety. However, if 
a developer provides data from a new evaluation, they 
will consider it, although it may delay approvals or 
acceptance.
3   Evaluting   GM  products for 
unintended   effects 
The methods and genetic modifications used to generate 
the herbicide tolerant or insect protected traits that have 
been widely adopted following regulatory approvals 
introduce relatively minor variations in the host 
plant genomes compared to those introduced through 
“natural processes” of mutations and reproduction. 
Interestingly those “unknown” natural changes are not 
characterized except by phenotypic variation and they 
have evolved to provide the diverse genetic background 
needed to allow plant survival with challenges of 
plant diseases and pests, and diversity of climactic 
conditions and soils. The GMOs on the other hand have 
been characterized in insertion site, copy number, gene 
sequence and encoded products.  If the introduced gene 
encoded an enzyme, metabolites of the enzyme would 
have to be evaluated.   Interestingly, a good portion of 
the maize (Zea mays) genome is made and modified by 
transposons that were described as “jumping genes” by 
Barbara McClintock from her studies in 1948.  She was 
awarded the Nobel Prize in Physiology in 1983 for that 
discovery[82]. A recent study identifying genes in 503 
genetically diverse lines of maize found ~ 16% of the 
genes are not present in all 503 lines, showing marked 
genetic variation[83].  The bread wheat we consume 
today (Triticum aestivum) is encoded by three sets of 
chromosomes (thus is an evolutionary hexaploid) of 
relatively primitive grass species so that most proteins 
in wheat are encoded by three sets of divergent genes 
that are nearly identical in some cases, or very different. 
In addition, the replication of genomes through 
sexual reproduction allows gain or loss of function 
and extension of the capacity of the plant to grow in 
different environments or have multiple options for 
nutrients (or anti-nutrients).  Bread wheat and pasta 
wheat (Triticum durum or Triticum turgidum subsp. 
durum, an evolutionary tetraploid) are both nutritious 
and used extensively in human food. But both cause 
celiac disease in about 1% of the general population 
in North America and Europe, genetically susceptible 
individuals (25% of the population) and IgE mediated 
food allergy in a much smaller number of people (<0.4% 
of the public).  Those are non-GM crops as there are 
no approved GM wheat varieties (yet).  That illustrates 
that all foods represent some risks for some consumers 
and that it is necessary to have genetic variation to 
produce the foods we eat.     
We should step back and consider why we eat 
certain foods like rice, wheat, soybeans and maize and 
other foods, but as humans we do not eat grain alone. 
Humans have selected certain food sources for ease of 
production but mostly for nutritional value, measured 
by average energy, amino acid composition, lipid 
content, carbohydrates, vitamins and minerals.  Those 
crops were initially grown and consumed long ago 
and dramatically changed by breeding and cultivation 
without any scientific measure of specific amino acids, 
caloric density, vitamins or fatty acid profiles.  In the 
past 100 years we have learned how to measure those 
components and also in many cases believe we know 
what a “healthy” and “nutritious” diet is made up 
of.  Typically it is a mixture of different foods.  Even 
though we have all that information today we do not 
make detailed measurements of the composition of 
every shipment of grain that goes into a box of cereal 
or a loaf of bread because would cost too much and 
we also know that on the average safety and nutrition 
of the cereal or bread is fine. We have learned the 
primary components of each major food crop and have 
typical measurements that are tested by agricultural 
nutritionists to ensure they formulate optimal diets for 
agriculturally important species. Each crop has specific 
components that are evaluated, and nutritionists have 
ranges that they deem acceptable for animal feed.  
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3.1  Key nutrients and anti-nutrients
Key nutrients and anti-nutrients expressed in the 
host plant (gene recipient) are to be measured and 
evaluated relative to non-GM varieties or lines 
intended for the same uses.  There is an expectation 
that the key components will fall within the range 
the same components in non-GM events of similar 
genetic background[84-85].  But as with all statistical 
measures, statistically significantly different values are 
expected when measuring many components. However, 
statistical differences alone are not a reason to reject a 
product as unsafe; there should be a scientifically based 
rationale to suggest potential harm. In order to provide 
guidance on appropriate compositional traits for given 
food crops recent historical records for varieties of the 
same crop must be found or a number of commercial 
varieties must be planted in adjacent plots in multiple 
field trials.  
Animal nutritionists understand the differences in 
compositional measurements that are important for 
canola, corn, cotton, potatoes, soybeans and wheat. 
And many possible compositional measurements are 
irrelevant to the typical use of these crops. However, 
some GMO regulators and cri t ics expect that 
developers will measure every possible component 
of the GMO and compare it to the nearest genetic 
relative.  If there are statistically significant differences 
some would argue it is due to the insertion of the DNA 
and that the food is unsafe. Yet we have also learned 
that plants from genetically identical plants grown in 
close proximity or 100 miles apart can differ in many 
components due to micro-environmental differences. 
The complexity of the genotype and environmental 
interactions that can lead to significant differences 
in expression of some components of agriculturally 
important crops has not been sufficiently evaluated 
in terms of biological relevance, yet some scientists 
are calling for increasing the use of various omics-
techniques to measure variation with high precision 
(Doerrer et al., 2010).  Fortunately, even though the 
compositional analysis is considered an important part 
of the safety assessment of a GM crop, in the US and 
most countries regulators have not blocked an approval 
of a GM food or feed crop due to minor statistical 
variations in composition as it is clear that non-
GM products often have fairly marked differences in 
components without measurable effects on food or feed 
safety (Privalle et al., 2013).  An important recent finding 
by two different groups is that compositional differences 
between GM and near-isogenic lines are primarily due 
to back-crosses and conventional breeding and are not 
caused by insertion of the gene[86-87].  Understanding the 
source of variation is an essential consideration as some 
authors are suggesting complex proteomics analysis 
of potential differences in endogenous allergen levels 
in GM plants might be due to insertion and require 
additional tests[88]. 
Thus we need further definition of the important 
components to measure and guidance on the variation 
of those components that may have biological 
relevance.  In order to provide some references for 
composition, the biotechnology industry supports 
the International Life Sciences Institute (ILSI) Crop 
Composition Database[89] that contains compositional 
data for seed of corn, cotton and soybeans (https://
www.cropcomposition.org/query/index.html). The data 
is limited to years 1995-2005 and specific countries 
of cultivation. The ILSI database is scheduled to a 
new version released by the end of 2014 that will 
include many more data-points and expand to include 
sweet corn, canola and rice. Additional information 
is available for rice and soybeans from a Japanese 
composition database (http://afdb.dc.affrc.go.jp/afdb/
index_e.asp). The data is available for a limited set 
of varieties of these two crops and limited years of 
cultivation from Japan[90].  These databases provide 
some information about methods and ranges of 
components specific for the species. Interestingly the 
animal feed industry is most sensitive to changes in 
composition of commodity crops as slight variation in 
feed quality can mean profit or loss to major animal 
producers.  Companies like Tyson (USA), with more 
than 4 000 poultry farms in chicken production 
and Perdue Farms (USA), second leading poultry 
producer in the US measure composition of feed 
based on nutritionally important ingredients that 
are crop-specific.  In order to formulate optimum 
feed for growth and safety they measure proximate 
analysis of every delivery of commodity crop getting 
random representative samples from their extremely 
large shipments, measuring total protein, lipid, 
carbohydrates, moisture, ash, fiber and often the amino 
acid composition as well as crop specific vitamins, fatty 
acids and minerals.  They also measure crop specific 
toxicants and anti-nutrients. The poultry industry is 
the most sensitive to nutritional quality changes.  In 
addition, every shipment of corn grain or dry distiller’s 
grain is checked for mycotoxin levels as corn is the 
most likely crop to have contamination. An example 
of a chicken broiler study on a GM stacked-trait event 
describes the feed ingredient evaluations and provides 
real data that would be similar to the analysis performed 
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by Tyson or Perdue[91].  The major components and 
measures essential to optimum chicken growth that are 
evaluated in feed preparation do not include a long list 
of metabolites, RNA transcripts or proteomic measures. 
Instead they focus on components that are known to 
contribute to the substantial growth rate (approximately 
a 35-fold increase in body weight from hatching 
through day 42 of the studies) for the chickens. The 
feed efficiency and weight gain are highly correlated 
to nutritional properties, more so than any other 
animal species.  The production of feed lot size and the 
number of animals in commercial production units is 
normally quite large.  Since chickens are fed defatted 
soybean meal, the composition of fatty acids and lipids 
is not as critical for soybean ingredients as it is for 
mammalian species, such as dairy cows.  Most dairy 
farms, beef, pork, goat and sheep operations do not 
monitor every shipment of feed, except for mycotoxins 
in corn, but instead sample occasionally throughout 
the year to re-formulate diets if the typical component 
nutritional values are changing. In the US studies 
supplied to regulatory agencies include proximate and 
specific ingredient measures comparing the new GM 
line ingredients (seeds, grain or forage) and ingredients 
from a nearest genetic comparator of non-GM line and 
ingredients from three to five other commercial non-
GM lines, all grown at multiple geographical sites 
to provide environmental diversity for plant growth. 
Some countries But in general a GMO developer 
must provide specific composition to regulators from 
multiple years of multiple geographical replicates of 
the GMO and a number of non-GM comparators to 
allow statistical comparison.  The relevance for safety 
is usually not clear. 
In addition to nutrients, specific anti-nutrients are 
also measured that are crop specific, including lectins 
and trypsin inhibitors, toxins such as solanine and 
allergens for highly allergenic crops (e.g. soybean). 
While there are generally accepted limits for many 
anti-nutrients (e.g. solanine at 200 mg per kg fresh 
weight, Friedman, 2006), acceptable limits of variation 
allergens have not be established[92].
3.2  Measuring potential changes in endogenous 
allergen levels 
There is a requirement in the US and a recommendation 
by the EU to consider whether insertion of the 
transgene has increased the expression or accumulation 
of naturally occurring endogenous allergens if the 
gene recipient (host plant) is a common source of 
food allergy.  Regulators recognized that the risk of 
food allergy is not equal from different allergenic 
sources.  Labeling requirements for processed foods 
are meant to be truthful and to protect those at risk. 
In the US and in the EU food labeling regulations 
demand that all ingredients derived from the major 
allergenic sources must be labeled.  That list includes 
the eight common allergenic food in the US: chicken 
eggs, cow’s milk, peanut, many tree nuts, crustacean 
shellfish, fish, soybeans, wheat (http://www.fda.gov/
food/resourcesforyou/consumers/ucm079311.htm). 
In addition in the US foods containing glutens from 
wheat, barley and rye must be labeled, unless the 
gluten content is less than 20 ppm on a mass basis. In 
the EU six more foods are added to the list of eight 
including: cereals containing gluten (wheat, rye, barley, 
oats, spelt, kamut and hybrids of those grains); celery 
(root), mustard seed, sesame seed, lupin and molluscs 
as well as sulphur dioxides)  as be listed all whole, 
relatively unfractionated ingredients must be labeled as 
to source (e.g. wheat, eggs, milk). In both the US and 
EU ingredients derived from the commonly allergenic 
foods must also be labeled unless the processed 
ingredient is exempt (e.g. hexane refined soybean oil). 
Starch from wheat must be labeled as coming from 
wheat, but starch from corn, rice or tapioca may simply 
be labeled as modified starch, without indicating the 
source. Thus in the US and EU a developer must 
evaluate potential changes in endogenous allergens in 
GM peanuts, soybeans and wheat, but not in common 
beans (Phaseolus vulgaris), corn and rice as they are 
not common sources of allergy.  The methods used to 
perform the evaluation have generally been consistent 
with measurements of allergens in diagnostic allergen 
products[93-94]. Pharmaceutical grade allergen extracts 
are expected to show similar qualitative binding using 
immunoblots as well as variation in total IgE binding 
between 50% and 150% of the extract standard mean 
serum IgE binding using pooled allergic sera to 
compare one batch of allergen extract to a previous 
batch[93,95].   The first herbicide tolerant soybean (event 
40-3-2 from Monsanto) was tested for differences in 
IgE binding using western blots of soybean extracts 
separated on SDS-PAGE with sera from three 
individual soybean allergic subjects[96].  Sten et al.[97] 
performed a much more extensive, non-regulatory 
study of IgE binding by in vitro methods using sera 
from 10 soybean sensitized subjects to compare results 
between 10 genetic varieties of the same GM event 
(40-3-2) and 8 genetically similar non-GM varieties 
of soybean. They used RAST-inhibition and basophil 
histamine release and found no significant difference 
between the GM and non-GM soybeans although there 
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were marked individual subject to subject and soybean 
line to soybean line differences.  My laboratory has 
also performed serum IgE binding studies on five 
different soybean events in total from three different 
commercial developers.  The methods used included 
direct IgE binding, ELISA inhibition with pooled 
soybean allergic sera or direct ELISA with individual 
sera and found no significant differences in binding 
except between one or more of the non-GM lines[92,94]. 
Some differences were found in gain or loss of an IgE 
binding band in the qualitative IgE immunoblots in 
some non-GM soybeans. In addition to those standard 
methods for evaluating potential changes in allergen 
abundance, two-dimensional (2D) immunoblots were 
performed using individual sera to compare each GM 
to three non-GM soybean lines due to new regulatory 
demands by the EFSA[51] and EC regulations[52].  Some 
individual serum IgE binding spot differences were 
noted, but not showing specific changes for the GM 
lines[92,94]. Clearly the population of allergic subjects 
included in such studies will influence the outcome. 
It is impractical to include more than a few (10?) 
specifically allergic subjects in a study unless multiple 
large allergy centers are included.  There will always 
be some uncertainties regarding which proteins and 
isoforms might bind IgE from individual allergic 
subjects.  However, the suggestion by the EFSA to use 
proteomics (LC-MSMS) to evaluate the abundance of 
individual “allergens” in soybeans and other commonly 
allergenic food crops is not as valid as serum testing 
because the list of “allergens” that EFSA wants to use 
[e.g. allergenic proteins in the OECD composition 
list for soybeans, includes proteins with little or no 
evidence of allergenicity (Gly m 1, Gly m 2, Gly m 3 
(profilin), P34 Gly m Bd 30 K, Unknown Asn-linked 
glycoprotein, lectin, lipoxygenase, Kunitze trypsin 
inhibitor, unknown 39 and 50 kD proteins and[22-25]. 
The important allergens in soybean that have been 
identified include Gly m 5 (β-conglycinins alpha-, 
alpha’- and beta-) and Gly m 6 (5-glycinins) and 
possibly Gly m 4, also known as SAM22.  Thus the 
EFSA recommendation is not based on evidence of 
risk since there is no gradation of risk in the proteins 
chosen and in fact some have no published evidence 
of allergy, or the protein sequence was not determined. 
In addition, LC-MSMS does not provide 100% 
coverage of any protein and it is therefore unlikely to 
identify isoforms, some of which may not bind IgE. 
Serum IgE binding tests at least compares a biological 
measurement between the GM and other non-GM 
varieties using sera from allergic subjects.   
However, it is important to consider whether there is 
relevance for safety to these measurements. Is there an 
increased risk of allergy if there is a difference?  People 
allergic to soybean should avoid eating any soybean. 
People who are not allergic can eat as much as they 
desire.  In processed foods the amount of total soybean 
protein can vary markedly from product to product and 
the food companies are not choosing lots of soybean 
based on specific varieties.  Instead they buy in bulk 
with the soybeans typically mixed at the silo, during 
shipment, in milling and processing and during food 
manufacture.
An important question that has not been answered 
by any scientific study or any regulatory body is what 
difference would be required in endogenous allergen 
accumulation to have an adverse impact on human 
health for the specifically food allergic subjects who 
are the sensitive, at-risk population?  An informative 
estimate might be made based on the dose-increase 
interval highly trained clinical food allergists use in 
performing double-blind placebo-controlled food 
challenges (DBPCFC).  There are a few publications 
describing protocols for testing high risk patients 
with the intent of establishing thresholds of doses 
for various allergens.  A review of studies by Crevel 
et al.[98] reported protocols with increasing challenge 
doses between 3-fold and 10-fold for peanuts with 
peanut allergic subjects. The experimental design for 
DBPCFC in the EuroPrevall studies began at three 
micrograms of protein from allergenic sources and 
used ten-fold increasing doses to 30 mg of protein, then 
reducing the step increase to three-fold above 30 mg as 
the risk of serious reactions were felt to increase above 
that dose[99]. Therefore it seems logical to conclude that 
at least a three-fold increase might of concern.
3.3  Assessing potential new, unintended proteins
During characterization of each new GM event 
the insertion of DNA is to be analyzed to confirm 
the sequence of the insert as well as the immediate 
surrounding DNA.  Typically a few hundred bases to 
a thousand bases are provided beyond the insert.  The 
sequence of the insert is to ensure that the protein(s) 
intended to be expressed (if any) are correct.  If an 
unexpected change has occurred, that should be 
evaluated in terms of the function of the new protein 
as well as possible risks for allergy and toxicity using 
bioinformatics.  The flanking DNA is considered to 
determine if there is a possibility a new fusion protein 
might be expressed in the plant.  All six potential 
reading frames in the DNA sequence are evaluated 
using computer algorithms to identify potential open 
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reading frames (ORF).  Some regulators are satisfied 
with start (methionine) to stop codons to define a 
potential ORF.  Others want all hypothetical ORFs 
meaning stop to stop.  The potential ORFs are then 
evaluated using bioinformatics to search for matches 
to allergens and toxins.  The critical segment is the 
fusion site. The plant DNA on each side of the insert 
was already there and if it encoded an allergen or toxin, 
those would have been endogenous hazards.  The 
safety assessment is focused on new potential hazards 
and risks. If there were matches to an allergen or a 
toxin, further analysis may be performed to evaluate 
whether and what tissues would transcribe RNA 
from that region of the DNA.  If the specific RNA is 
present, measurements could be made to determine if 
there is translation product (protein) using either LC-
MSMS or antibodies generated against a synthetic 
peptide “encoded” by the ORF in assays.  If there is a 
negligible level of protein, then the risk is minimal. 
Some regulators ask for flanking sequence until 
it is clear that the transgene has not interrupted an 
endogenous plant gene in the coding or intervening 
sequences (introns).  However evaluation of agronomic 
traits of the plants in field trials with geographical 
replicates will help identify any biologically significant 
differences of the GM vs non-GM varieties.  That type 
of evaluation is about performance of the plant, not 
safety.  The US regulators very interested in obtaining 
information relevant to safety of the food and feed 
products.  The GM developer and associated seed 
companies must show data to farmers to convince them 
that the GM plants produce adequately in terms of yield 
and overall composition.  Otherwise farmers will not 
purchase the seeds.
3.4  Assessing unintended effects conclusions
The conclusion of the compositional analysis is 
generally whether the total nutrients and anti-nutrients 
for the specific crop are substantially equivalent to non-
GM comparators or not. These analyses are performed 
using field-trial grown material of the GM and non-
GM varieties in geographical replicates.  Certainly 
there can be some statistically significant differences 
of measuring a number of components in many 
samples over different geographies will often result in 
a few statistically significant differences. Most of the 
variation is due to actual genetic differences that are 
associated with the whole plant genomes and back-
crossing and breeding programs and have nothing to 
do with transgene insertion[82-83].  In addition, recent 
discoveries that DNA methylation patterns can be 
inherited and alter gene expression without any change 
in DNA help us realize that we cannot expect to control 
or understand every measureable difference based on 
DNA sequence information[100].  And it is extremely 
important that we realize that every measurable 
difference does not constitute a risk for consumers, in 
fact very few do.  Humans selected and have improved 
most of the domesticated crops hundreds to thousands 
of years ago. We know that genetic variation is needed 
to be able to grow the same species in a wide variety of 
environmental conditions in order to produce food and 
feed.  
In the US the values from individual measurements 
are compared between the GM event and the near 
genetic relative (near isoline or parental variety) and 
also compared to either a number of commercial lines 
grown in the same field trials or recent historical data 
from real production samples.  If the measures from 
the GM crop fall within the typical range of variation 
as a benchmark for potentially relevant biological 
differences, a difference between the GM and near 
genetic relative is considered acceptable.  The GM 
plant is therefore deemed “substantially equivalent” to 
other varieties of the crop.  Similar inferences are made 
from data obtained by measuring animal responses in 
feeding studies such as the 90-day rat feeding trial that 
some regulators require; 42 day broiler studies or large 
animal feeding trials that are generally used as industry 
acceptance studies in many countries, but are required 
in some (e.g. India).  
3.5  Current status of GMO approvals
How many GM events have been developed and 
gotten regulatory approvals for growing, of use as 
food and feed?  It is hard to find accurate information. 
The Center for Environmental Risk Assessment 
(CERA) GM crop database www.cera-gmc.org/
GmCropDatabase lists 153 total crop-events.  Not all 
of those were developed through GM technology as 
some were developed by mutagenesis or traditional 
breeding.  In addition, not all of those are approved 
anywhere and some are approved but not used.  The 
International Service for the Acquisition of Agri-
Biotech Applications (ISAAA) also maintains a GM 
crop database that lists 353 events (www.isaaa.org/
gmapprovaldatabase).  By quick examination it seems 
ISAAA shows some crop types not listed by CERA 
including beans (Phaseolus vulgaris), eggplant or 
brinjal (Solanum melongea), poplar trees (Populus sp.), 
sugar cane (Saccharum sp.) and pepper (Capsicum 
annuum) that have not been submitted to U.S. or 
Canadian regulators.  It is likely that each of these 
databases misses a few events, but unlikely that either 
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of them miss globally traded GM crops. In addition 
the three US regulatory bodies each have a separate 
database that presents their actions on individual GM 
events.  The USDA website is: http://www.aphis.usda.
gov/biotechnology/petitions_table_pending.shtml. The 
FDA website is: http://www.accessdata.fda.gov/scripts/
fdcc/?set=Biocon. The EPA website is: http://www.epa.
gov/oppbppd1/biopesticides/pips/pip_list.htm. 
Even though many events with different properties 
and in different plants are approved for use, the bulk of 
the GM events are in a few commodity crops (canola, 
cotton, maize, and soybean). The rate of adoption as 
measured in percent of hectares planted in GM crops 
in the U.S. has been extremely rapid, going from zero 
in 1994 to more than 90% of our soybeans and corn 
(maize) in 2014. A significant fraction of the cotton 
production in the U.S. is from GM events while 95% 
of cotton in India and 90% of cotton in China is GM 
cotton. There are now multiple events from different 
developers having similar functions (herbicide 
tolerance or specific insect resistance). At the same 
time a number of previously approved GM crops 
(post-1994) have disappeared from the market. Some 
products were dropped due to consumer or company 
pressures including the viral resistant, Colorado potato 
beetle resistant potatoes developed by Monsanto as 
major potato markets are dominated by French fry 
and fast food restaurants that are very sensitive to 
perceived consumer preferences.  Those products 
that dramatically reduced insecticide use on potatoes 
were withdrawn in about 2002 due to pressure from 
the fast food industry.  Herbicide tolerant wheat was 
submitted by Monsanto to Canada and the US, but 
was withdrawn before approval due to pressure from the 
Canadian Wheat Board because of fears export markets 
to Asia would block trade.   Delayed ripening tomatoes 
were dropped as they were not commercially viable (four 
companies including Zeneca and Monsanto had approved 
GM events) because fresh food qualities were not as good 
as non-GM varieties.  The viral resistant squash that was 
developed by Asgrow is still on the market, though now 
owned by Seminis. Viral resistant papaya was developed 
by researchers at Cornell University and was approved 
for use in the US because the Hawaiian trees were being 
decimated by ring spot virus.  The GM construct blocked 
replication of the virus and the introduction of this trait 
saved the industry in Hawaii.  
4  Summary
Some experts predict an eminent global food crisis 
while others suggest continuation of more regionalized 
crises that may be caused by local draught, disease 
or have artificial political or economic causes[101-102] 
(Butler, 2009a; Butler, 2009b).  Some solutions for 
improving the global sustainable agriculture are 
and can be contributed through biotechnology, with 
current and future GM crops.  Yet progress is being 
stifled by a very focused, well financed vocal minority 
of NGOs and by celebrities who are stirring public 
uncertainty even though they clearly do not have a 
good understanding of agriculture, food production 
and costs.  Can we find common ground in this debate? 
Few who are students of food production, agriculture 
and human health would deny that at some point the 
world’s growing global population will outstrip the 
capacity to maintain food production in in the long-run 
even though the efficiency of production has increased 
markedly in the past century[103]. Yet our ability to 
increase production currently comes through the use of 
adding mined minerals, increased use of fossil fuels for 
fertilizer and tillage and the use of machines to replace 
human labor and draft animals in intensive agricultural 
practices.  Can we maintain our current rate of 
expansion? Experiences in the US agricultural system 
may provide useful examples for the potential benefit 
of GM crops in China and other Asian countries and in 
setting a standard for food safety of newly developed 
products.
In considering the experiences in the US regarding 
the safety evaluation process and regulations of 
genetically modified (GM) crops, it is necessary to 
look also at the global nature of food supplies, the 
concerns of various food safety regulatory bodies as 
well as consideration of the long history of various 
food crops. No country is self-sufficient and most 
foods consumed in any one country originally came 
from, or is dependent to some extent on inputs from 
other countries. The adaptation of wheat, rice, potatoes, 
tomatoes, peppers, various legumes and the specific 
animals we consume today were developed from 
naturally occurring ancestral organisms from very 
different geographical locations than those used for 
production today.  They were selected and improved 
through breeding processes that took hundreds or 
thousands of years.  They were chosen by experience, 
but based on food utility (nutritional and anti-
nutritional) characteristics, ease of production and 
food safety.  Yes there are real risks of foods for those 
with allergies and celiac disease. There are risks for 
those who do not prepare or store food properly to 
suppress microbes and spoilage and to inactivate anti-
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nutrients.  The primary potential risks of new proteins 
are relatively easy to prevent through the current 
assessment scheme.
There are a few uncertainties that US regulators are 
still finding perplexing. Primarily if the protein is stable 
in the pepsin assay, they are concerned that it might 
sensitize and become an allergen. Low abundance 
stable proteins have little risk, and they should find an 
acceptance level.  We also need to continue working 
on a better way of predicting sensitization.  The 
current suggestions of computer programs to predict 
antigenicity are far from perfect and over-predict risk. 
Animal models so far have failed to provide sufficiently 
accurate predictions to be useful.  Cell based assays 
using human antigen presenting cells, T cells and B 
cells have not been validated to demonstrate accurate 
predictions. Therefore additional research is needed for 
difficult proteins where the current Codex guideline[1] 
and US evaluation process do not show results leading 
to a conclusion of unlikely harm.  But most GM 
products today are easily cleared with bioinformatics 
for allergenicity, celiac disease and toxicity.  In a few 
cases serum IgE tests are needed and simple, predictive 
toxicity tests are needed.  
Labeling of foods is a major obstacle around 
the world.  Some countries like China have rules 
demanding labeling at least some foods if they contain 
GMOs.  In the US a few states have passed laws that 
may take effect in the near future and a few states 
will vote on labeling in November, 2014.  Major 
economic and practical food production hurdles make 
this approach untenable. Crops are grown and traded 
across state lines and national boundaries.  Food 
companies often make products for all 50 states and 
for export.  There are many individual ingredients that 
might contain a GMO, but that is not consistent from 
lot to lot.  As an example, figure 2 shows the labeled 
ingredients in a black vegetarian bean burger produced 
in the US.  Each component derived from soybeans, 
corn (maize), canola or cotton may be from a GMO. 
The CERA GM crop database (http://cera-gmc.org/
index.php/GMCropDatabase) lists 12 approved GM 
soybeans representing 8 GM proteins and 57 approved 
maize lines representing at least 15 different proteins. 
Suppliers of commodities, ingredients and final food 
products would have to control and test for all of those 
ingredients if they do not want to list “GMO” on the 
label if these laws pass.  There will be added expense, 
110 Journal of Huazhong Agricultural University Vol. 33
and no safety benefit.  For foods that are already 
cluttered with labeled information, critical safety 
information such as allergen content gets lost.  
The foods humans consume are tremendously 
diverse in composition, nutritional qualities and to 
some extent, risks.  We are omnivores and our ancestors 
adapted to many different climates and conditions 
as they spread across continents and changed from 
migratory hunter-gatherers to migratory pastoralists 
and then to relatively sedentary agriculturalists[104,106]. 
The adaptations seem to have been possible because 
of the ability of humans to cooperate and accept added 
costs of helping to ensure survival of others rather 
than protection of the immediate family, an adaptation 
that was not always beneficial to the immediate 
relatives, but was beneficial for the society[106]. In 
the post-industrial era humans have become highly 
mobile individually.  However, within each society 
the basic food production infrastructure needed to 
maintain the population is slow to change for many 
reasons including the large investment in equipment, 
complexity of the commodity and food processing 
facilities and the relatively restricted genetic pool of 
plants and animals that are used for production.  But 
adaptation occurs and the efficiency of production 
has increased, especially during the last century. 
Increased have occurred even as land is available 
for farming as the population concentrated in cities 
away from the production of food crops[107].  Since 
the world population is now estimated to be over 7.25 
billion people, and with a total biomass exceeding the 
combined total of all other terrestrial vertebrates we 
need to think hard about how to improve food and feed 
production.  It took hundreds or thousands of years to 
learn how to manage and accept many new methods of 
food production. In the past 100 years food production 
has shifted markedly to more industrialized methods to 
meet food demands.  Some people would seek to stop 
the technology, restrict the tools of introducing new 
improvements into food crops because of claims they 
produce unsafe foods.  But as I search for evidence of 
harm from GM crops, it is not there.
It is helpful to consider that none of the plant foods 
that we grow and consume today are completely natural. 
Although they are genetically fairly similar to some 
native plants, the grains (wheat, barley, rye, rice, maize, 
sorghum) have been bred and selected for hundreds of 
years.  Many varieties of tomatoes, potatoes, eggplant 
and peppers are quite safe for consumption after many 
forms of cooking and processing.  But they are closely 
related, in the same plant family (Solanaceae) as toxic 
nightshade, which along with tobacco and petunias 
are really not edible.  The edible solanaceous plants 
have wild relatives in the same species that produce 
sufficient levels of glycoalkaloids (solanine, tomatine 
and others) and lectins that are quite harmful to us and 
to many domestic animals if consumed.  We can only 
consume the current varieties of these crops because 
our ancestors went through a process of breeding and 
selecting varieties with low levels of these toxins and 
anti-nutrients in the edible plant parts.  They did that 
without the complex scientific tests and instruments we 
use today to detect specific substances that cause harm. 
They did that without having standardized animal 
feeding trials. Even though we are omnivores and can 
consume many different plants and animals, we have 
had to learn the limits of what we can consume.  And 
even though the potatoes that we eat today are safe, 
we have learned that some wild relatives produce 
sufficiently high concentrations of a solanine, tomatine 
and other glycoalkaloids to cause harm or even death.
Beyond a historical perspective, it is also important 
to remember that we live in an age of increasing 
information distribution with frequent unintended 
impacts of miss-information. There are many claims of 
real or potential harm from various foods that would 
never have been noticed centuries or event decades 
ago, but often the communicated fears are hypothetical 
risks.  However, instant messaging and the internet 
compress years to seconds.  When European explorers 
brought tomatoes and potatoes from South America to 
Italy and the United Kingdom in the 1500’s they were 
introducing crops that had been grown and consumed 
safely for over a thousand years.  But in Europe people 
did not have full knowledge of how to grow and use 
the plants.  Some who became ill due to improper food 
preparation or eating the green part of the plants and 
after falling ill people suggested that the entire plants 
were poisonous including the fruits and tubers.  Natives 
of South American knew to avoid consuming the green 
plant material.  The rare cases of harm in Europe lead 
to wide spread fear that stifled the introduction of 
these now staple foods into the European diets.  Now 
false claims about GMOs are common and effects 
long lasting.  Recent claims by Dr. Oz, Jeffrey Smith, 
Oprah Winfrey or Cui Yongyuan claim that GM 
crops are unsafe or untested have caused consumers 
to become skeptical of claims by biotechnology 
companies and governments that they are safe. Those 
media personalities however have not read the dossiers 
or performed safety studies that have convinced US 
regulators the products like European Corn Borer 
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resistant MON810 is safe.  How do we present the truth 
to consumers when there are “trusted” personalities 
telling consumers that the government is corrupt and 
that big biotech companies like Monsanto did not do an 
adequate job of testing and evaluating safety? 
5  Conclusions
The US regulatory system for evaluating the safety of 
GM crops involves three federal agencies, the USDA, 
the FDA and EPA. The process for evaluation was 
initiated in the late 1980s and early 1990s through 
consultations that included academics, industry 
scientists and governmental regulatory scientists 
and policy makers. The assessment was refined in 
the late 1990s through 2003 and aligned with the 
Codex Alimentarius Commission Guidelines for the 
safety assessment of GM crops.  Potential risks of 
allergenicity of foods produced from the GM crops 
must be evaluated using scientifically acceptable 
methods.  The process is efficient for identifying 
proteins that are likely to present a significant risk of 
food allergy, which would be the transfer of a known 
allergen or a likely cross-reactive protein. There is 
a bit less certainty trying to predict whether a new 
protein with no obvious risks factors might sensitize 
de novo, but risks are clearly low in those cases where 
the protein is rapidly digested by pepsin in a test-tube 
assay and/or low in abundance in the food component. 
The potential that a transgenic has significantly higher 
expression of endogenous allergens is quite low 
compared to non-GM varieties, but in addition the 
risk is for those consumers who should be avoiding 
consumption of food from the host plant anyway. Thus 
there is no practical increase in risk even if the content 
of endogenous allergens was increased.  Potential 
food toxicity is also evaluated based on criteria 
established for non-GMOs.  Few proteins are toxic 
and the comparison of the sequence of the GM protein 
to those of known toxins along with evaluation of the 
gene source and the mechanism of action of the protein 
will identify high risk proteins.  The US has evaluated 
and approved the commercialization of approximately 
100 new events or varieties of GMO.  There are no 
documented cases where an approved GM crop has 
caused harm to humans or animals who have consumed 
edible parts of the plants.  However, the regulatory 
process is expensive and time consuming. Since most 
food crops are traded on an international market, it is 
unfortunate that there isn’t a single safety evaluation 
process that is standardized and accepted across all 
countries to avoid duplication of studies.   
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